Reproductive Health — MCQs

Q: A 26-year-old woman presents with amenorrhea, galactorrhea, and headaches. Visual field defects are noted. What is the appropriate initial treatment?

Cabergoline. ***Cabergoline***- **Cabergoline** is the preferred first-line treatment for suspected **prolactinomas** (indicated by amenorrhea and galactorrhea), regardless of tumor size, due to its high efficacy in normalizing prolactin levels and shrinking the tumor.- This drug, a **dopamine agonist**, can rapidly reduce tumor volume, often resolving the mass effect symptoms like headaches and **visual field defects**, which are crucial to address immediately.*Transsphenoidal surgery*- Surgery is generally reserved for patients who are intolerant of or unresponsive to maximal **dopamine agonist** therapy, or for specific tumor types (e.g., highly cystic).- Given the typical response rates of prolactinomas to medical therapy, surgery is not the appropriate **initial** treatment.*Radiotherapy*- Radiotherapy is typically reserved as a **tertiary treatment** for aggressive or malignant prolactinomas that have failed to respond to both dopamine agonists and surgical resection.- It carries risks of long-term pituitary dysfunction and damage to surrounding **neural structures**, making it inappropriate for initial management.*Observation*- Observation is only appropriate for asymptomatic patients with **microprolactinomas** (less than 10 mm) without mass effect or desire for fertility.- Since this patient has significant symptoms (galactorrhea, amenorrhea) and signs of mass effect (**visual field defects**), immediate intervention is necessary.*Bromocriptine*- Bromocriptine is also a **dopamine agonist** effective for prolactinomas but is generally considered a second-line option to Cabergoline.- **Cabergoline** is preferred due to its higher efficacy, longer half-life (allowing less frequent dosing), and better patient tolerability (fewer **gastrointestinal side effects**).

Q: A 37-year-old woman presents with recurrent miscarriages (3 in 2 years) and a history of deep vein thrombosis. Blood tests show prolonged APTT that doesn't correct with mixing studies. What is the most likely diagnosis?

Antiphospholipid syndrome. ***Antiphospholipid syndrome*** - The clinical presentation of **recurrent miscarriages** (obstetric morbidity) and a history of **deep vein thrombosis** strongly points to Antiphospholipid Syndrome (APS). - The finding of a **prolonged APTT that doesn't correct with mixing studies** is characteristic of the **lupus anticoagulant**, an antiphospholipid antibody, indicating a prothrombotic state. *Factor V Leiden mutation* - This genetic mutation causes resistance to **activated protein C**, increasing the risk of **venous thrombosis**, but is less typically associated with recurrent miscarriages as the primary cause compared to APS. - Standard coagulation screening tests, including **APTT and PT, are typically normal** as it does not involve an inhibitor that prolongs the APTT in vitro. *Protein C deficiency* - This inherited thrombophilia primarily causes an increased risk of **venous thromboembolism** due to impaired regulation of coagulation, but is less strongly linked to recurrent miscarriages than APS. - Protein C deficiency would generally result in **normal APTT** or, if severely deficient, a prolonged APTT that **corrects** with mixing studies, unlike the uncorrectable APTT seen here. *Prothrombin gene mutation* - The **Prothrombin G20210A mutation** leads to increased plasma levels of **prothrombin (factor II)**, thereby elevating the risk of **venous thrombosis**. - This mutation does not cause an in vitro anticoagulant effect; therefore, routine coagulation tests like **APTT and PT are usually normal**. *Antithrombin deficiency* - Antithrombin is a crucial natural anticoagulant, and its deficiency predisposes patients primarily to **venous thrombosis**. - This inherited condition does not produce an in-vitro inhibitor; thus, it usually does not result in a **prolonged, uncorrectable APTT**.

Q: A 34-year-old woman presents with recurrent miscarriages and a history of DVT. Blood tests show prolonged APTT not correcting with mixing studies, and positive anticardiolipin antibodies. What is the most likely diagnosis?

Antiphospholipid syndrome. ***Antiphospholipid syndrome*** - This syndrome is defined by recurrent **venous or arterial thrombosis** (DVT) and/or **pregnancy morbidity** (recurrent miscarriages), occurring in the presence of specific antiphospholipid antibodies. - The laboratory findings of positive **anticardiolipin antibodies** and a prolonged **APTT** (suggestive of lupus anticoagulant, an inhibitory antibody) that does not correct upon mixing strongly confirm the diagnosis of APS. *Factor V Leiden* - This condition is the most common inherited thrombophilia, characterized by resistance to cleavage by **Activated Protein C (APC)**, leading to increased clot risk. - While it causes thrombosis (like DVT), it does not cause the autoantibody profile (anticardiolipin) or the characteristic uncorrectable **APTT** observed. *Protein C deficiency* - This is an inherited thrombophilia resulting from insufficient levels of the anticoagulant Protein C, leading to uncontrolled coagulation. - It typically causes thrombosis but is not associated with obstetrical complications like **recurrent miscarriages** or the presence of **anticardiolipin antibodies**. *Lupus anticoagulant* - This is one of the specific antiphospholipid antibodies that define APS (causing the prolonged non-correcting **APTT** finding). - While present in this patient, it is a *laboratory criterion* for Antiphospholipid Syndrome (the definitive clinical diagnosis), which encompasses both the antibodies and the clinical events (DVT and miscarriages). *Von Willebrand disease* - This is the most common inherited **bleeding disorder**, caused by deficiency or dysfunction of **von Willebrand factor** (vWF). - It is characterized by mucocutaneous bleeding symptoms and is a disorder of **hemostasis**, not a thrombotic condition associated with DVT or recurrent miscarriages.

Q: A 41-year-old parous woman requests contraception following the birth of her third child 4 weeks ago. She is not breastfeeding and is considering the combined oral contraceptive pill, which she used successfully between her previous pregnancies. She had an uncomplicated vaginal delivery with estimated blood loss of 400ml. She is a non-smoker with BMI of 26 kg/m² and no medical history of note. According to UKMEC criteria, when can she safely commence the combined oral contraceptive pill?

At 6 weeks postpartum. ***At 6 weeks postpartum*** - In non-breastfeeding women without additional risk factors, the **combined oral contraceptive pill (COCP)** is classified as **UKMEC 2** (benefits outweigh risks) or UKMEC 1 only after **6 weeks postpartum**. - The postpartum period is associated with a significantly increased risk of **venous thromboembolism (VTE)**, which remains elevated until 6 weeks; starting COCP earlier carries an **unacceptable health risk**. *At 3 weeks postpartum* - Starting COCP between **21 days and 6 weeks** postpartum in non-breastfeeding women is classified as **UKMEC 3**, meaning the risks generally outweigh the benefits. - Although the absolute risk of VTE begins to decline after 3 weeks, it is still considered too high to routinely recommend **estrogen-containing** methods. *At 2 weeks postpartum* - Prior to **21 days (3 weeks)** postpartum, the use of COCP is classified as **UKMEC 4**, indicating an unacceptable health risk due to the peak in **hypercoagulability**. - Women are advised to use **progestogen-only** methods or barrier methods if contraception is required this early in the puerperium. *Immediately, as she is not breastfeeding* - Immediate initiation is contraindicated because the **prothrombotic state** of pregnancy does not resolve instantly upon delivery, regardless of breastfeeding status. - The classification for using COCP before 21 days is **UKMEC 4**, even in the absence of other risk factors like smoking or high BMI. *At 12 weeks postpartum* - Delaying initiation until **12 weeks** is unnecessary for this patient as she is a **non-smoker** with a normal BMI and no other VTE risk factors. - By 6 weeks, the VTE risk typically returns to baseline, making it safe to prescribe the pill according to **UKMEC guidelines**.

Q: A 35-year-old woman with a history of previous ectopic pregnancy treated by laparoscopic salpingectomy 2 years ago presents requesting long-acting reversible contraception. She is in a new relationship and wishes to avoid pregnancy. She has regular periods, BMI of 25 kg/m², no other medical history, and is a non-smoker. She is particularly concerned about the risk of another ectopic pregnancy. What is the most appropriate contraceptive method to recommend?

Etonogestrel subdermal implant. ***Etonogestrel subdermal implant*** - The **subdermal implant** is the most effective contraceptive method available, with a failure rate of <0.1%, thereby minimizing the **absolute risk** of any pregnancy, including ectopic. - Unlike intrauterine methods, the implant primarily works by **inhibiting ovulation**, meaning if a rare contraceptive failure occurs, it is highly likely to be an **intrauterine pregnancy** rather than an ectopic one. *Copper intrauterine device* - While the **copper IUD** reduces the absolute risk of ectopic pregnancy compared to using no contraception, it mainly prevents **intrauterine implantation** rather than ovulation. - If a pregnancy does occur with a copper IUD in situ, there is a higher **relative risk** that the pregnancy will be ectopic compared to other methods. *52 mg levonorgestrel intrauterine system* - Like the copper IUD, the **LNG-IUS** is a highly effective LARC (UKMEC 1 for history of ectopic pregnancy), but it works largely through **local progestogenic effects** on cervical mucus and the endometrium. - While it significantly reduces the overall pregnancy rate, the risk of a pregnancy being ectopic if the device fails is higher than with the **subdermal implant**. *Combined oral contraceptive pill* - The **combined oral contraceptive pill** is not classified as a **long-acting reversible contraceptive (LARC)**, which is specifically what the patient requested. - Its efficacy is highly dependent on **user compliance**, and typical use failure rates are significantly higher than those of the implant or IUS. *Depot medroxyprogesterone acetate injection* - Although highly effective, the **DMPA injection** is not categorized as a LARC because it requires administration every 12 to 13 weeks. - It effectively inhibits ovulation, but the patient's request for a **long-acting** method makes the implant a more suitable and convenient choice.

Q: A 49-year-old woman commenced on sequential combined HRT (transdermal estradiol 50 mcg patches changed twice weekly plus oral micronised progesterone 200 mg for 14 days each month) 6 months ago for troublesome vasomotor symptoms. She reports good symptom control but has persistent irregular bleeding throughout the month, not just during the expected withdrawal bleed. Her last menstrual period before starting HRT was 14 months ago. Pelvic examination is normal. What is the most appropriate next step in management?

Arrange transvaginal ultrasound to assess endometrial thickness. ***Arrange transvaginal ultrasound to assess endometrial thickness*** - Persistent **unscheduled bleeding** on HRT for more than 6 months, or a new change in bleeding pattern, necessitates investigation to exclude **endometrial hyperplasia** or malignancy. - A **transvaginal ultrasound (TVUS)** is the first-line investigation to assess the **endometrial thickness (ET)**; in postmenopausal women, an ET >4mm typically requires an endometrial biopsy. *Continue current regimen and reassure that irregular bleeding is expected in the first year* - While irregular bleeding is common in the first 3-6 months of HRT, persistence beyond **6 months** requires clinical evaluation and cannot be dismissed as "expected." - This patient is technically **postmenopausal** (LMP was 14 months ago), making any unscheduled bleeding more concerning for **endometrial pathology**. *Switch to continuous combined HRT regimen* - Although **continuous combined HRT** is the standard for postmenopausal women to avoid withdrawal bleeds, switching regimens before investigating irregular bleeding is unsafe. - Initiating a new regimen may mask underlying **endometrial stimulation** or pathology caused by the previous sequential therapy. *Stop HRT for 3 months then restart with a different preparation* - Stopping HRT would likely cause a return of **vasomotor symptoms** without providing a diagnosis for the current irregular bleeding. - This approach delays the necessary **diagnostic workup** (ultrasound/biopsy) required to rule out serious intrauterine issues. *Add tranexamic acid during bleeding episodes* - **Tranexamic acid** is an antifibrinolytic used to reduce heavy menstrual loss but does not address the **underlying etiology** of irregular unscheduled bleeding. - Using it in this context is inappropriate as it treats the symptom while ignoring the risk of **endometrial malignancy**.

A 54-year-old woman who had a total abdominal hysterectomy with conservation of ovaries for fibroid-related menorrhagia 6 years ago presents with a 12-month history of troublesome vasomotor symptoms, mood disturbance, and poor concentration affecting her work as a teacher. She also reports reduced libido which is causing relationship difficulties. She has no other medical history, BMI is 24 kg/m², and she does not smoke. Her blood pressure is 118/76 mmHg. What is the most appropriate HRT regimen to address all her symptoms?

A 41-year-old parous woman requests contraception following the birth of her third child 4 weeks ago. She is not breastfeeding and is considering the combined oral contraceptive pill, which she used successfully between her previous pregnancies. She had an uncomplicated vaginal delivery with estimated blood loss of 400ml. She is a non-smoker with BMI of 26 kg/m² and no medical history of note. According to UKMEC criteria, when can she safely commence the combined oral contraceptive pill?

A 58-year-old woman with type 2 diabetes mellitus and a BMI of 31 kg/m² presents requesting continuation of her HRT. She was diagnosed with premature ovarian insufficiency at age 39 and has been taking continuous combined HRT (oral estradiol 2 mg with dydrogesterone 10 mg) since then. She currently has good glycaemic control (HbA1c 48 mmol/mol) on metformin alone and has no microvascular or macrovascular complications. She has no other cardiovascular risk factors and does not smoke. What is the most appropriate advice regarding HRT continuation?

A 35-year-old woman with a history of previous ectopic pregnancy treated by laparoscopic salpingectomy 2 years ago presents requesting long-acting reversible contraception. She is in a new relationship and wishes to avoid pregnancy. She has regular periods, BMI of 25 kg/m², no other medical history, and is a non-smoker. She is particularly concerned about the risk of another ectopic pregnancy. What is the most appropriate contraceptive method to recommend?

A 49-year-old woman commenced on sequential combined HRT (transdermal estradiol 50 mcg patches changed twice weekly plus oral micronised progesterone 200 mg for 14 days each month) 6 months ago for troublesome vasomotor symptoms. She reports good symptom control but has persistent irregular bleeding throughout the month, not just during the expected withdrawal bleed. Her last menstrual period before starting HRT was 14 months ago. Pelvic examination is normal. What is the most appropriate next step in management?

Q10

A 28-year-old woman with well-controlled ulcerative colitis on mesalazine presents requesting contraception. She was recently started on azathioprine 150 mg daily by her gastroenterologist. She is in a stable relationship and desires highly effective contraception. She has regular menstrual cycles, BMI of 22 kg/m², and is a non-smoker with no other medical history. According to UKMEC criteria, which statement regarding contraceptive options is correct for this patient?

Reproductive Health UK Medical PG Practice Questions and MCQs

Question 1: A 43-year-old woman presents with fatigue, weight gain, and cold intolerance. TSH is 22 mU/L, free T4 is low. Anti-TPO antibodies are positive. She is trying to conceive. What is the TSH target?

A. $< 1.0 \mathrm{mU} / \mathrm{L}$
B. $< 2.5 \mathrm{mU} / \mathrm{L}$ (Correct Answer)
C. $< 4.0 \mathrm{mU} / \mathrm{L}$
D. $< 6.0 \mathrm{mU} / \mathrm{L}$
E. $< 10.0 \mathrm{mU} / \mathrm{L}$

Explanation: ***< 2.5 \mathrm{mU} / \mathrm{L}$*** - For women with **hypothyroidism** who are trying to conceive or are in the first trimester of pregnancy, the recommended TSH target is generally **< 2.5 mU/L** to ensure optimal maternal and fetal outcomes. - Achieving this target helps to reduce the risk of **infertility**, **miscarriage**, and adverse pregnancy complications such as **preterm birth** and **gestational hypertension**, while also supporting proper fetal neurodevelopment. *$< 1.0 \mathrm{mU} / \mathrm{L}$* - This target is generally considered **too stringent** and may lead to **over-treatment** with levothyroxine, potentially inducing iatrogenic hyperthyroidism symptoms. - While very low TSH can be observed, it is not the standard recommendation for preconception in hypothyroidism and could be unnecessarily aggressive. *$< 4.0 \mathrm{mU} / \mathrm{L}$* - While a TSH of < 4.0 mU/L might be acceptable for non-pregnant adults with hypothyroidism, it is **insufficient** for women trying to conceive or in early pregnancy. - Higher TSH levels during the preconception period and early pregnancy are associated with increased risks for both the mother and the fetus, necessitating a tighter TSH control. *$< 6.0 \mathrm{mU} / \mathrm{L}$* - This TSH target is significantly **too high** for a woman attempting to conceive and is typically considered for adults with **subclinical hypothyroidism** (TSH 4-10 mU/L) who are **not pregnant**. - Maintaining TSH at this level during pregnancy substantially increases the risk of **adverse obstetric outcomes** and potential cognitive deficits in the offspring. *$< 10.0 \mathrm{mU} / \mathrm{L}$* - A TSH target of < 10.0 mU/L is far **too liberal** and would mean the patient remains **frankly hypothyroid** in the context of trying to conceive or during pregnancy. - This target would not adequately address the patient's severe hypothyroid symptoms nor mitigate the significant risks to successful conception and healthy pregnancy progression.

Question 2: A 26-year-old woman presents with amenorrhea, galactorrhea, and headaches. Visual field defects are noted. What is the appropriate initial treatment?

A. Transsphenoidal surgery
B. Cabergoline (Correct Answer)
C. Radiotherapy
D. Observation
E. Bromocriptine

Explanation: ***Cabergoline***- **Cabergoline** is the preferred first-line treatment for suspected **prolactinomas** (indicated by amenorrhea and galactorrhea), regardless of tumor size, due to its high efficacy in normalizing prolactin levels and shrinking the tumor.- This drug, a **dopamine agonist**, can rapidly reduce tumor volume, often resolving the mass effect symptoms like headaches and **visual field defects**, which are crucial to address immediately.*Transsphenoidal surgery*- Surgery is generally reserved for patients who are intolerant of or unresponsive to maximal **dopamine agonist** therapy, or for specific tumor types (e.g., highly cystic).- Given the typical response rates of prolactinomas to medical therapy, surgery is not the appropriate **initial** treatment.*Radiotherapy*- Radiotherapy is typically reserved as a **tertiary treatment** for aggressive or malignant prolactinomas that have failed to respond to both dopamine agonists and surgical resection.- It carries risks of long-term pituitary dysfunction and damage to surrounding **neural structures**, making it inappropriate for initial management.*Observation*- Observation is only appropriate for asymptomatic patients with **microprolactinomas** (less than 10 mm) without mass effect or desire for fertility.- Since this patient has significant symptoms (galactorrhea, amenorrhea) and signs of mass effect (**visual field defects**), immediate intervention is necessary.*Bromocriptine*- Bromocriptine is also a **dopamine agonist** effective for prolactinomas but is generally considered a second-line option to Cabergoline.- **Cabergoline** is preferred due to its higher efficacy, longer half-life (allowing less frequent dosing), and better patient tolerability (fewer **gastrointestinal side effects**).

Question 3: A 37-year-old woman presents with recurrent miscarriages (3 in 2 years) and a history of deep vein thrombosis. Blood tests show prolonged APTT that doesn't correct with mixing studies. What is the most likely diagnosis?

A. Factor V Leiden mutation
B. Protein C deficiency
C. Antiphospholipid syndrome (Correct Answer)
D. Prothrombin gene mutation
E. Antithrombin deficiency

Explanation: ***Antiphospholipid syndrome*** - The clinical presentation of **recurrent miscarriages** (obstetric morbidity) and a history of **deep vein thrombosis** strongly points to Antiphospholipid Syndrome (APS). - The finding of a **prolonged APTT that doesn't correct with mixing studies** is characteristic of the **lupus anticoagulant**, an antiphospholipid antibody, indicating a prothrombotic state. *Factor V Leiden mutation* - This genetic mutation causes resistance to **activated protein C**, increasing the risk of **venous thrombosis**, but is less typically associated with recurrent miscarriages as the primary cause compared to APS. - Standard coagulation screening tests, including **APTT and PT, are typically normal** as it does not involve an inhibitor that prolongs the APTT in vitro. *Protein C deficiency* - This inherited thrombophilia primarily causes an increased risk of **venous thromboembolism** due to impaired regulation of coagulation, but is less strongly linked to recurrent miscarriages than APS. - Protein C deficiency would generally result in **normal APTT** or, if severely deficient, a prolonged APTT that **corrects** with mixing studies, unlike the uncorrectable APTT seen here. *Prothrombin gene mutation* - The **Prothrombin G20210A mutation** leads to increased plasma levels of **prothrombin (factor II)**, thereby elevating the risk of **venous thrombosis**. - This mutation does not cause an in vitro anticoagulant effect; therefore, routine coagulation tests like **APTT and PT are usually normal**. *Antithrombin deficiency* - Antithrombin is a crucial natural anticoagulant, and its deficiency predisposes patients primarily to **venous thrombosis**. - This inherited condition does not produce an in-vitro inhibitor; thus, it usually does not result in a **prolonged, uncorrectable APTT**.

Question 4: A 34-year-old woman presents with recurrent miscarriages and a history of DVT. Blood tests show prolonged APTT not correcting with mixing studies, and positive anticardiolipin antibodies. What is the most likely diagnosis?

A. Factor V Leiden
B. Protein C deficiency
C. Antiphospholipid syndrome (Correct Answer)
D. Lupus anticoagulant
E. Von Willebrand disease

Explanation: ***Antiphospholipid syndrome*** - This syndrome is defined by recurrent **venous or arterial thrombosis** (DVT) and/or **pregnancy morbidity** (recurrent miscarriages), occurring in the presence of specific antiphospholipid antibodies. - The laboratory findings of positive **anticardiolipin antibodies** and a prolonged **APTT** (suggestive of lupus anticoagulant, an inhibitory antibody) that does not correct upon mixing strongly confirm the diagnosis of APS. *Factor V Leiden* - This condition is the most common inherited thrombophilia, characterized by resistance to cleavage by **Activated Protein C (APC)**, leading to increased clot risk. - While it causes thrombosis (like DVT), it does not cause the autoantibody profile (anticardiolipin) or the characteristic uncorrectable **APTT** observed. *Protein C deficiency* - This is an inherited thrombophilia resulting from insufficient levels of the anticoagulant Protein C, leading to uncontrolled coagulation. - It typically causes thrombosis but is not associated with obstetrical complications like **recurrent miscarriages** or the presence of **anticardiolipin antibodies**. *Lupus anticoagulant* - This is one of the specific antiphospholipid antibodies that define APS (causing the prolonged non-correcting **APTT** finding). - While present in this patient, it is a *laboratory criterion* for Antiphospholipid Syndrome (the definitive clinical diagnosis), which encompasses both the antibodies and the clinical events (DVT and miscarriages). *Von Willebrand disease* - This is the most common inherited **bleeding disorder**, caused by deficiency or dysfunction of **von Willebrand factor** (vWF). - It is characterized by mucocutaneous bleeding symptoms and is a disorder of **hemostasis**, not a thrombotic condition associated with DVT or recurrent miscarriages.

Question 5: A 54-year-old woman who had a total abdominal hysterectomy with conservation of ovaries for fibroid-related menorrhagia 6 years ago presents with a 12-month history of troublesome vasomotor symptoms, mood disturbance, and poor concentration affecting her work as a teacher. She also reports reduced libido which is causing relationship difficulties. She has no other medical history, BMI is 24 kg/m², and she does not smoke. Her blood pressure is 118/76 mmHg. What is the most appropriate HRT regimen to address all her symptoms?

A. Transdermal estradiol patches 50 mcg twice weekly
B. Oral estradiol 2 mg daily plus testosterone supplementation
C. Transdermal estradiol patches plus oral micronised progesterone
D. Tibolone 2.5 mg daily
E. Transdermal estradiol patches with trial of testosterone supplementation if symptoms persist (Correct Answer)

Explanation: ***Transdermal estradiol patches with trial of testosterone supplementation if symptoms persist*** - **Transdermal estradiol** is the first-line treatment for vasomotor symptoms, mood disturbance, and poor concentration in postmenopausal women, offering a lower **thromboembolic risk** compared to oral therapy by bypassing first-pass metabolism. - For **reduced libido**, guidelines recommend optimizing **estrogen levels** initially. If sexual dysfunction persists after 3-6 months of adequate estrogenization, a trial of **testosterone supplementation** is indicated to address this specific symptom. *Transdermal estradiol patches 50 mcg twice weekly* - While **transdermal estradiol** effectively manages **vasomotor symptoms** and cognitive issues, this option does not explicitly account for the patient's persistent **low libido**. - It overlooks the recommended step of considering **testosterone supplementation** if sexual desire issues are not resolved with estrogen alone. *Oral estradiol 2 mg daily plus testosterone supplementation* - **Oral estrogen** carries a higher risk of **venous thromboembolism (VTE)** and may not be the optimal choice for a low-risk woman when a transdermal option is available. - Initiating **testosterone** concurrently with initial HRT is generally not recommended; it's typically considered only after adequate **estrogenization** has failed to improve libido. *Transdermal estradiol patches plus oral micronised progesterone* - This patient has undergone a **total abdominal hysterectomy**, meaning she no longer has a uterus, and therefore does not require **progesterone** for endometrial protection. - The addition of **progesterone** in a woman without a uterus is unnecessary and can introduce additional side effects without benefit. *Tibolone 2.5 mg daily* - **Tibolone** has estrogenic, progestogenic, and **androgenic properties**, which could potentially address libido; however, it is not typically the first-line HRT, especially for multiple symptoms where a standard estrogen-progestogen (or estrogen-only) regimen is usually preferred. - It is associated with an increased risk of **stroke** in women over 60 years of age, making transdermal estradiol a generally safer initial choice.

Question 6: A 41-year-old parous woman requests contraception following the birth of her third child 4 weeks ago. She is not breastfeeding and is considering the combined oral contraceptive pill, which she used successfully between her previous pregnancies. She had an uncomplicated vaginal delivery with estimated blood loss of 400ml. She is a non-smoker with BMI of 26 kg/m² and no medical history of note. According to UKMEC criteria, when can she safely commence the combined oral contraceptive pill?

A. At 3 weeks postpartum
B. At 2 weeks postpartum
C. Immediately, as she is not breastfeeding
D. At 6 weeks postpartum (Correct Answer)
E. At 12 weeks postpartum

Explanation: ***At 6 weeks postpartum*** - In non-breastfeeding women without additional risk factors, the **combined oral contraceptive pill (COCP)** is classified as **UKMEC 2** (benefits outweigh risks) or UKMEC 1 only after **6 weeks postpartum**. - The postpartum period is associated with a significantly increased risk of **venous thromboembolism (VTE)**, which remains elevated until 6 weeks; starting COCP earlier carries an **unacceptable health risk**. *At 3 weeks postpartum* - Starting COCP between **21 days and 6 weeks** postpartum in non-breastfeeding women is classified as **UKMEC 3**, meaning the risks generally outweigh the benefits. - Although the absolute risk of VTE begins to decline after 3 weeks, it is still considered too high to routinely recommend **estrogen-containing** methods. *At 2 weeks postpartum* - Prior to **21 days (3 weeks)** postpartum, the use of COCP is classified as **UKMEC 4**, indicating an unacceptable health risk due to the peak in **hypercoagulability**. - Women are advised to use **progestogen-only** methods or barrier methods if contraception is required this early in the puerperium. *Immediately, as she is not breastfeeding* - Immediate initiation is contraindicated because the **prothrombotic state** of pregnancy does not resolve instantly upon delivery, regardless of breastfeeding status. - The classification for using COCP before 21 days is **UKMEC 4**, even in the absence of other risk factors like smoking or high BMI. *At 12 weeks postpartum* - Delaying initiation until **12 weeks** is unnecessary for this patient as she is a **non-smoker** with a normal BMI and no other VTE risk factors. - By 6 weeks, the VTE risk typically returns to baseline, making it safe to prescribe the pill according to **UKMEC guidelines**.

Question 7: A 58-year-old woman with type 2 diabetes mellitus and a BMI of 31 kg/m² presents requesting continuation of her HRT. She was diagnosed with premature ovarian insufficiency at age 39 and has been taking continuous combined HRT (oral estradiol 2 mg with dydrogesterone 10 mg) since then. She currently has good glycaemic control (HbA1c 48 mmol/mol) on metformin alone and has no microvascular or macrovascular complications. She has no other cardiovascular risk factors and does not smoke. What is the most appropriate advice regarding HRT continuation?

A. Continue current HRT as benefits outweigh risks given her premature ovarian insufficiency (Correct Answer)
B. Switch to transdermal HRT as oral preparations are contraindicated in diabetes
C. Discontinue HRT immediately as she has now reached the age of natural menopause
D. Continue HRT but add aspirin for cardiovascular protection
E. Reduce to the lowest dose of HRT and plan to stop within 6 months

Explanation: ***Continue current HRT as benefits outweigh risks given her premature ovarian insufficiency*** - In patients with **premature ovarian insufficiency (POI)**, HRT is typically recommended until at least the average age of natural menopause (51 years) and can be continued beyond that based on **individual risk-benefit assessment**. - This patient has **well-controlled type 2 diabetes** (HbA1c 48 mmol/mol) without complications and no other **cardiovascular risk factors**, making the continuation of her current regimen appropriate. *Switch to transdermal HRT as oral preparations are contraindicated in diabetes* - **Type 2 diabetes** itself is not a contraindication to oral HRT; under **UKMEC 2** criteria, the benefits generally outweigh the risks if there are no vascular complications. - While **transdermal HRT** is preferred in patients with a high risk of **Venous Thromboembolism (VTE)** or obesity, it is not mandatory if the patient is stable on an oral preparation. *Discontinue HRT immediately as she has now reached the age of natural menopause* - There is no arbitrary **upper age limit** for HRT; the decision to continue should be based on persistent symptoms and the patient's **overall health profile**. - Women with a history of **POI** may require longer treatment durations to mitigate long-term risks such as **osteoporosis** and cardiovascular disease. *Continue HRT but add aspirin for cardiovascular protection* - **Low-dose aspirin** is not routinely indicated for primary prevention in diabetic patients unless there is a high **10-year cardiovascular risk** or established vascular disease. - HRT is not an independent indication for starting **antiplatelet therapy** in a woman with well-controlled diabetes and no macrovascular complications. *Reduce to the lowest dose of HRT and plan to stop within 6 months* - Tapering or stopping HRT is a personal choice; however, there is no medical requirement to stop within a fixed timeframe if the patient is **asymptomatic** and clinical risks are low. - Abruptly planning to stop within 6 months for a patient who has required therapy since age 39 may lead to a recurrence of **vasomotor symptoms** and a decline in **bone mineral density**.

Question 8: A 35-year-old woman with a history of previous ectopic pregnancy treated by laparoscopic salpingectomy 2 years ago presents requesting long-acting reversible contraception. She is in a new relationship and wishes to avoid pregnancy. She has regular periods, BMI of 25 kg/m², no other medical history, and is a non-smoker. She is particularly concerned about the risk of another ectopic pregnancy. What is the most appropriate contraceptive method to recommend?

A. Copper intrauterine device
B. 52 mg levonorgestrel intrauterine system
C. Etonogestrel subdermal implant (Correct Answer)
D. Combined oral contraceptive pill
E. Depot medroxyprogesterone acetate injection

Explanation: ***Etonogestrel subdermal implant*** - The **subdermal implant** is the most effective contraceptive method available, with a failure rate of <0.1%, thereby minimizing the **absolute risk** of any pregnancy, including ectopic. - Unlike intrauterine methods, the implant primarily works by **inhibiting ovulation**, meaning if a rare contraceptive failure occurs, it is highly likely to be an **intrauterine pregnancy** rather than an ectopic one. *Copper intrauterine device* - While the **copper IUD** reduces the absolute risk of ectopic pregnancy compared to using no contraception, it mainly prevents **intrauterine implantation** rather than ovulation. - If a pregnancy does occur with a copper IUD in situ, there is a higher **relative risk** that the pregnancy will be ectopic compared to other methods. *52 mg levonorgestrel intrauterine system* - Like the copper IUD, the **LNG-IUS** is a highly effective LARC (UKMEC 1 for history of ectopic pregnancy), but it works largely through **local progestogenic effects** on cervical mucus and the endometrium. - While it significantly reduces the overall pregnancy rate, the risk of a pregnancy being ectopic if the device fails is higher than with the **subdermal implant**. *Combined oral contraceptive pill* - The **combined oral contraceptive pill** is not classified as a **long-acting reversible contraceptive (LARC)**, which is specifically what the patient requested. - Its efficacy is highly dependent on **user compliance**, and typical use failure rates are significantly higher than those of the implant or IUS. *Depot medroxyprogesterone acetate injection* - Although highly effective, the **DMPA injection** is not categorized as a LARC because it requires administration every 12 to 13 weeks. - It effectively inhibits ovulation, but the patient's request for a **long-acting** method makes the implant a more suitable and convenient choice.

Question 9: A 49-year-old woman commenced on sequential combined HRT (transdermal estradiol 50 mcg patches changed twice weekly plus oral micronised progesterone 200 mg for 14 days each month) 6 months ago for troublesome vasomotor symptoms. She reports good symptom control but has persistent irregular bleeding throughout the month, not just during the expected withdrawal bleed. Her last menstrual period before starting HRT was 14 months ago. Pelvic examination is normal. What is the most appropriate next step in management?

A. Continue current regimen and reassure that irregular bleeding is expected in the first year
B. Switch to continuous combined HRT regimen
C. Arrange transvaginal ultrasound to assess endometrial thickness (Correct Answer)
D. Stop HRT for 3 months then restart with a different preparation
E. Add tranexamic acid during bleeding episodes

Explanation: ***Arrange transvaginal ultrasound to assess endometrial thickness*** - Persistent **unscheduled bleeding** on HRT for more than 6 months, or a new change in bleeding pattern, necessitates investigation to exclude **endometrial hyperplasia** or malignancy. - A **transvaginal ultrasound (TVUS)** is the first-line investigation to assess the **endometrial thickness (ET)**; in postmenopausal women, an ET >4mm typically requires an endometrial biopsy. *Continue current regimen and reassure that irregular bleeding is expected in the first year* - While irregular bleeding is common in the first 3-6 months of HRT, persistence beyond **6 months** requires clinical evaluation and cannot be dismissed as "expected." - This patient is technically **postmenopausal** (LMP was 14 months ago), making any unscheduled bleeding more concerning for **endometrial pathology**. *Switch to continuous combined HRT regimen* - Although **continuous combined HRT** is the standard for postmenopausal women to avoid withdrawal bleeds, switching regimens before investigating irregular bleeding is unsafe. - Initiating a new regimen may mask underlying **endometrial stimulation** or pathology caused by the previous sequential therapy. *Stop HRT for 3 months then restart with a different preparation* - Stopping HRT would likely cause a return of **vasomotor symptoms** without providing a diagnosis for the current irregular bleeding. - This approach delays the necessary **diagnostic workup** (ultrasound/biopsy) required to rule out serious intrauterine issues. *Add tranexamic acid during bleeding episodes* - **Tranexamic acid** is an antifibrinolytic used to reduce heavy menstrual loss but does not address the **underlying etiology** of irregular unscheduled bleeding. - Using it in this context is inappropriate as it treats the symptom while ignoring the risk of **endometrial malignancy**.

Question 10: A 28-year-old woman with well-controlled ulcerative colitis on mesalazine presents requesting contraception. She was recently started on azathioprine 150 mg daily by her gastroenterologist. She is in a stable relationship and desires highly effective contraception. She has regular menstrual cycles, BMI of 22 kg/m², and is a non-smoker with no other medical history. According to UKMEC criteria, which statement regarding contraceptive options is correct for this patient?

A. The etonogestrel implant is UKMEC 3 due to azathioprine interaction
B. The copper intrauterine device is UKMEC 3 due to immunosuppression
C. The combined oral contraceptive pill is UKMEC 1 with no restrictions (Correct Answer)
D. The levonorgestrel intrauterine system is UKMEC 2 due to increased infection risk
E. The depot medroxyprogesterone acetate injection is UKMEC 3 due to inflammatory bowel disease

Explanation: ***The combined oral contraceptive pill is UKMEC 1 with no restrictions*** - For patients with **Inflammatory Bowel Disease (IBD)** like ulcerative colitis that is uncomplicated and well-controlled, the **Combined Oral Contraceptive (COC)** is classified as **UKMEC 1**, indicating no restriction. - There is no clinically significant **drug interaction** between **azathioprine** and hormonal contraceptives, including the COC, meaning its efficacy is not compromised and its use is safe. *The etonogestrel implant is UKMEC 3 due to azathioprine interaction* - The **etonogestrel implant** (Nexplanon) is a progestogen-only method that is generally classified as **UKMEC 1** for women with well-controlled IBD and no known interaction with **azathioprine**. - UKMEC 3 indicates that risks generally outweigh benefits, which is not applicable to the implant in this context, as it is a highly effective and safe option. *The copper intrauterine device is UKMEC 3 due to immunosuppression* - The **copper intrauterine device (Cu-IUD)** is classified as **UKMEC 1** for women on immunosuppressants like **azathioprine**, as the risk of infection is not significantly increased. - Current evidence does not support a significantly higher risk of **Pelvic Inflammatory Disease (PID)** in immunosuppressed women using IUDs, especially when IBD is stable. *The levonorgestrel intrauterine system is UKMEC 2 due to increased infection risk* - The **levonorgestrel intrauterine system (LNG-IUS)** is classified as **UKMEC 1** for women with well-controlled IBD, even when on immunosuppressive therapy such as **azathioprine**. - Similar to the copper IUD, the theoretical concern for **infection risk** in immunocompromised patients using LNG-IUS is not supported by evidence to warrant a UKMEC 2 classification. *The depot medroxyprogesterone acetate injection is UKMEC 3 due to inflammatory bowel disease* - **Depot medroxyprogesterone acetate (DMPA) injection** is classified as **UKMEC 2** for women with IBD, not UKMEC 3, primarily due to theoretical concerns. - The main concern with DMPA in IBD relates to potential **bone mineral density (BMD) loss**, which could theoretically be exacerbated by malabsorption in severe or uncontrolled IBD, though this patient's UC is well-controlled.

Question 11: A 52-year-old woman presents with troublesome vaginal dryness and dyspareunia. She went through natural menopause 3 years ago. She is reluctant to take systemic HRT as she had a previous venous thromboembolism 4 years ago related to prolonged immobilization following a fractured ankle. She has no other medical problems and takes no regular medications. Examination reveals vaginal atrophy with no other abnormalities. What is the most appropriate initial management?

A. Vaginal oestrogen therapy (estriol pessaries or estradiol tablets) (Correct Answer)
B. Systemic transdermal oestrogen-only HRT
C. Vaginal moisturizers and lubricants only
D. Ospemifene 60 mg daily
E. Systemic continuous combined oral HRT with low-dose oestrogen

Explanation: ***Vaginal oestrogen therapy (estriol pessaries or estradiol tablets)*** - This is the most appropriate initial management for **genitourinary syndrome of menopause (GSM)**, as it directly treats **vaginal atrophy** with minimal systemic absorption. - Due to its localized effect and low systemic absorption, **vaginal oestrogen** is considered safe even in patients with a history of **venous thromboembolism (VTE)**, as it does not significantly increase VTE risk.*Systemic transdermal oestrogen-only HRT* - While transdermal HRT has a lower **VTE risk** compared to oral preparations, any systemic HRT is generally contraindicated (UKMEC 4) in individuals with a past **thromboembolic event**. - Systemic therapy is also not indicated when the symptoms are solely localized to **vaginal atrophy**, as seen in this patient.*Vaginal moisturizers and lubricants only* - These provide symptomatic relief for **vaginal dryness** and **dyspareunia** but do not address or reverse the underlying **atrophic changes** in the vaginal tissue. - They are typically used for mild symptoms, as an adjunct, or when hormonal therapy is absolutely contraindicated or refused.*Ospemifene 60 mg daily* - **Ospemifene** is a **selective oestrogen receptor modulator (SERM)** specifically approved for moderate to severe dyspareunia due to menopause, but it carries a boxed warning regarding an increased risk of **venous thromboembolism**. - Therefore, it is not a suitable option for a patient with a history of **VTE**.*Systemic continuous combined oral HRT with low-dose oestrogen* - **Oral HRT** carries the highest risk of **VTE** due to its first-pass hepatic effects and is strongly contraindicated in patients with a history of **venous thromboembolism**. - Furthermore, systemic combined HRT is used to treat systemic menopausal symptoms and protect the endometrium; this patient's symptoms are localized to the vagina.

Question 12: A 47-year-old woman with regular menstrual cycles presents with worsening premenstrual mood symptoms including irritability, anxiety and low mood for 10 days before each period, which resolve shortly after menstruation begins. She also experiences moderate hot flushes in the week before her period. She requests effective contraception as she remains sexually active. Her BMI is 27 kg/m² and she has no significant medical history. What is the most appropriate management option?

A. Copper intrauterine device for contraception plus sequential HRT
B. 52 mg levonorgestrel intrauterine system for contraception plus cyclical progestogens
C. Combined oral contraceptive pill taken continuously
D. 52 mg levonorgestrel intrauterine system for contraception plus transdermal oestrogen patches (Correct Answer)
E. Progestogen-only pill for contraception plus selective serotonin reuptake inhibitor

Explanation: ***52 mg levonorgestrel intrauterine system for contraception plus transdermal oestrogen patches***- The 52 mg **levonorgestrel intrauterine system (LNG-IUS)** provides highly effective **contraception** and necessary **endometrial protection**, while **transdermal oestrogen** manages perimenopausal vasomotor symptoms and stabilizes hormonal fluctuations associated with PMS.- This combination is ideal for a **perimenopausal** woman over 45 as it avoids its first-pass hepatic metabolism and effectively treats both the mood symptoms and **hot flushes**.*Copper intrauterine device for contraception plus sequential HRT*- While providing contraception, the **Copper IUD** does not assist in hormonal stabilization; **sequential HRT** maintains cyclical bleeding and hormonal peaks/troughs which can exacerbate **premenstrual mood symptoms**.- **Sequential progestogens** in HRT are often linked to the return or worsening of PMS-like symptoms during the progestogen phase.*52 mg levonorgestrel intrauterine system for contraception plus cyclical progestogens*- Using **cyclical progestogens** on top of an **LNG-IUS** is unnecessary and results in an excessive progestogen load without addressing the **oestrogen deficiency** causing her hot flushes.- This regimen fails to provide the **continuous oestrogen** needed to suppress the hypothalamic-pituitary-ovarian axis and stabilize mood symptoms.*Combined oral contraceptive pill taken continuously*- Although continuous **COCP** can suppress the cycle and stabilize mood, oestrogen-containing pills are generally transitioned to **HRT** as patients approach age 50 due to changing metabolic risks.- **Transdermal oestrogen** combined with an **IUS** is often preferred over the COCP in this age group (BMI 27, age 47) to minimize **venous thromboembolism (VTE)** risks.*Progestogen-only pill for contraception plus selective serotonin reuptake inhibitor*- While an **SSRI** can treat premenstrual dysphoria, it does not address the patient's **vasomotor symptoms** (hot flushes) caused by declining oestrogen levels.- The **progestogen-only pill (POP)** provides contraception but does not provide the **ovulation suppression** or hormonal stability as effectively as the LNG-IUS/oestrogen combination in perimenopause.

Question 13: A 56-year-old woman presents for review of her HRT. She has been taking continuous combined HRT (oral estradiol 2 mg with norethisterone acetate 1 mg) for 4 years following surgical menopause from hysterectomy and bilateral salpingo-oophorectomy at age 52 for benign ovarian cysts. She feels well with no menopausal symptoms. She has no other medical history and does not smoke. Her mother had breast cancer diagnosed at age 72. What is the most appropriate management regarding her HRT continuation?

A. Continue HRT until at least age 60 given her premature surgical menopause
B. Discontinue HRT immediately as she has exceeded the recommended duration
C. Switch to oestrogen-only HRT as she has had a hysterectomy (Correct Answer)
D. Reduce the dose of HRT to the lowest available strength
E. Continue current HRT only if she develops recurrent symptoms after a trial of discontinuation

Explanation: ***Switch to oestrogen-only HRT as she has had a hysterectomy***- Women who have had a **hysterectomy** do not require a **progestogen** for **endometrial protection**; therefore, oestrogen-only therapy is the standard of care.- Removing the **norethisterone** (progestogen) is beneficial as progestogens are associated with a slightly higher risk of **breast cancer** compared to oestrogen-only HRT.*Continue HRT until at least age 60 given her premature surgical menopause*- While HRT is recommended until at least the **average age of menopause (51)**, continuing treatment is based on individual symptoms and risk profiles.- The primary issue here is the **incorrect formulation** (combined HRT) rather than just the duration of the therapy.*Discontinue HRT immediately as she has exceeded the recommended duration*- There is no arbitrary **time limit** for HRT; many women continue beyond age 51 to manage symptoms and for **bone protection**.- Sudden discontinuation may trigger the return of **vasomotor symptoms** and increase the risk of **osteoporotic fractures**.*Reduce the dose of HRT to the lowest available strength*- Dose reduction is a strategy for weaning, but it does not address the fundamental issue of unnecessary **progestogen exposure** in a woman without a uterus.- The patient is currently symptom-free, but her management must first be optimized by switching to the **safer oestrogen-only** profile.*Continue current HRT only if she develops recurrent symptoms after a trial of discontinuation*- A trial of discontinuation is not mandatory at age 56, especially since she should have been on a different **therapeutic regimen** (oestrogen-only) throughout.- This approach risks unnecessary exposure to **norethisterone**, which provides no benefit to this patient while increasing potential risks.

Question 14: According to UK Medical Eligibility Criteria for Contraceptive Use (UKMEC), what category is assigned to the use of the combined oral contraceptive pill in a woman who is 6 weeks postpartum, fully breastfeeding, and has no other risk factors?

A. UKMEC 1 - No restriction for use
B. UKMEC 2 - Advantages generally outweigh risks
C. UKMEC 3 - Risks generally outweigh advantages (Correct Answer)
D. UKMEC 4 - Unacceptable health risk
E. UKMEC 1 if breastfeeding established, UKMEC 2 if not

Explanation: ***UKMEC 3 - Risks generally outweigh advantages***- From **6 weeks to 6 months postpartum** in breastfeeding women, the **Combined Oral Contraceptive Pill (COCP)** is categorized as **UKMEC 3** because estrogen may negatively impact **milk volume** and quality.- While the risk of **Venous Thromboembolism (VTE)** has decreased compared to the immediate postpartum period, the potential impact on infant nutrition remains a concern.*UKMEC 1 - No restriction for use*- This category is reserved for methods that have no health restrictions, such as **Progestogen-only pills (POP)** or implants in breastfeeding women at this stage.- The **COCP** is never UKMEC 1 during active breastfeeding before 6 months due to hormonal interference with lactation.*UKMEC 2 - Advantages generally outweigh risks*- The COCP only becomes **UKMEC 2** for breastfeeding women after **6 months postpartum**, when the infant is likely consuming complementary foods.- It is also UKMEC 2 for **non-breastfeeding** women between 3 and 6 weeks postpartum if no other VTE risk factors are present.*UKMEC 4 - Unacceptable health risk*- The COCP is classified as **UKMEC 4** (absolute contraindication) for all women, regardless of breastfeeding status, during the first **21 days postpartum** due to the high risk of **VTE**.- For breastfeeding women specifically, it remains UKMEC 4 until **6 weeks postpartum** because of the combined risks of VTE and suppression of early lactation.*UKMEC 1 if breastfeeding established, UKMEC 2 if not*- This is not a standard UKMEC classification; eligibility is based on the **physiological timeframes** since delivery and the specific hormonal content of the contraceptive.- **Establishment of breastfeeding** does not waive the UKMEC 3 status of estrogen-containing methods between 6 weeks and 6 months.

Question 15: A 33-year-old woman presents requesting emergency contraception. She had unprotected sexual intercourse 36 hours ago and also mentions having unprotected intercourse 6 days ago. She has regular 28-day menstrual cycles and her last period started 11 days ago. Her BMI is 24 kg/m². She takes no regular medications and has no significant medical history. What is the most appropriate form of emergency contraception for this patient?

A. Levonorgestrel 1.5 mg single dose
B. Ulipristal acetate 30 mg single dose
C. Copper intrauterine device (Correct Answer)
D. Combined oral contraceptive (Yuzpe method)
E. Reassure that emergency contraception is not required

Explanation: ***Copper intrauterine device***- The **Copper IUD** is the most effective form of emergency contraception and is indicated here because it can be inserted up to **5 days after the first episode** of unprotected intercourse or up to **5 days after the earliest predicted date of ovulation**.- Given her 28-day cycle and LMP 11 days ago, she is in her **fertile window**, and the IUD covers both the episode 6 days ago and the one 36 hours ago while providing **ongoing contraception**.*Levonorgestrel 1.5 mg single dose*- This hormonal method must be taken within **72 hours** of unprotected intercourse and would not provide protection for the incident that occurred **6 days ago**.- It works primarily by **delaying ovulation** and is significantly less effective than the Copper IUD, especially if LH levels have already started to rise.*Ulipristal acetate 30 mg single dose*- While effective up to **120 hours (5 days)** after intercourse, it would still not cover the episode that occurred **6 days ago**.- It is a **selective progesterone receptor modulator** that is more effective than Levonorgestrel but remains inferior to the **Copper IUD** in terms of failure rates.*Combined oral contraceptive (Yuzpe method)**- This method involves high doses of **estrogen and progestogen** but is now rarely used due to a higher incidence of **side effects** like nausea and vomiting.- It is significantly **less effective** than both modern hormonal emergency contraceptives and the Copper IUD.*Reassure that emergency contraception is not required*- Reassurance is inappropriate because the patient is currently on **day 11 of a 28-day cycle**, placing her directly in the **peri-ovulatory phase**.- Both episodes of unprotected intercourse occurred during her **fertile window**, posing a high risk of pregnancy that necessitates intervention.

Question 16: A 51-year-old woman presents with severe vasomotor symptoms including frequent hot flushes and night sweats that significantly impact her sleep and work performance. Her last menstrual period was 8 months ago. She has no significant medical history except for well-controlled hypothyroidism on levothyroxine. She underwent endometrial ablation 5 years ago for heavy menstrual bleeding. What is the most appropriate initial hormone replacement therapy regimen for this patient?

A. Continuous combined HRT with oral estradiol and dydrogesterone (Correct Answer)
B. Sequential combined HRT with transdermal estradiol and micronised progesterone
C. Oestrogen-only HRT with transdermal estradiol patches
D. Tibolone
E. Vaginal oestrogen only

Explanation: ***Continuous combined HRT with oral estradiol and dydrogesterone*** - Even after **endometrial ablation**, the uterus remains in situ and the basal layer of the endometrium persists, necessitating **progestogen cover** to prevent endometrial hyperplasia and malignancy. - **Continuous combined HRT** is appropriate here as the patient is likely in the late **menopausal transition** (periods ceased for 8 months) or early postmenopause, and it avoids the withdrawal bleeds associated with sequential regimens. *Sequential combined HRT with transdermal estradiol and micronised progesterone* - **Sequential HRT** is typically indicated for perimenopausal women who are still having regular periods, to mimic a natural cycle and induce a monthly bleed. - This patient's last menstrual period was 8 months ago, indicating she is likely **postmenopausal or in late menopausal transition**, making continuous combined HRT more suitable to avoid regular, often unwanted, withdrawal bleeding. *Oestrogen-only HRT with transdermal estradiol patches* - This option is **contraindicated** because the patient has an **intact uterus** (even post-ablation), and unopposed oestrogen increases the risk of **endometrial hyperplasia and cancer**. - Endometrial ablation reduces the lining but does not remove all endometrial tissue, thus the need for progestogen cover remains for uterine protection. *Tibolone* - **Tibolone** is a synthetic steroid with oestrogenic, progestogenic, and androgenic properties, used for vasomotor symptoms in postmenopausal women, but it is typically reserved for women at least **12 months post-menopause**. - While effective, it may not be the **most appropriate initial regimen** when a standard combined HRT is available and suitable for a patient who is 8 months since her LMP. *Vaginal oestrogen only* - **Vaginal oestrogen** therapy is primarily indicated for localised symptoms of **genitourinary syndrome of menopause (GSM)**, such as vaginal dryness, dyspareunia, and recurrent UTIs. - It provides **minimal systemic absorption** and would be ineffective in alleviating the patient's severe systemic **vasomotor symptoms** like hot flushes and night sweats.

Question 17: A 24-year-old woman attends for contraceptive advice. She currently uses condoms inconsistently and requests a reliable method. She has no medical history of note, takes no regular medications, is a non-smoker, and has a BMI of 23 kg/m². Her menstrual cycles are regular every 28 days. She mentions she often forgets to take daily medications and would prefer a method that doesn't require daily attention. What is the most appropriate contraceptive method to recommend?

A. Combined oral contraceptive pill
B. Progestogen-only pill
C. Etonogestrel contraceptive implant (Correct Answer)
D. Natural family planning
E. Barrier methods with spermicide

Explanation: ***Etonogestrel contraceptive implant*** - This is a **Long-Acting Reversible Contraceptive (LARC)** that aligns with the patient's preference for a method requiring no daily attention and provides effective contraception for **three years**. - It boasts a very **high efficacy rate** (failure rate <0.1%) and is suitable for this patient with no contraindications, making it a highly reliable choice given her history of forgetting daily medications. *Combined oral contraceptive pill* - This method requires **daily administration** at a consistent time, which is not suitable for a patient who states she often forgets to take daily medications. - Its effectiveness is highly dependent on **user compliance**, making it less reliable for an individual with a history of inconsistent medication adherence. *Progestogen-only pill* - Similar to the combined pill, it requires **strict daily adherence**, often within a narrow time window (e.g., 3 hours for traditional POPs), which contradicts the patient's preference. - Given her history of **forgetting daily medications**, the risk of contraceptive failure with a progestogen-only pill is significantly increased. *Natural family planning* - This method demands **meticulous daily monitoring** of fertility signs (e.g., basal body temperature, cervical mucus), which is inconsistent with her desire for a method that doesn't require daily attention. - It has a significantly **higher typical-use failure rate** compared to LARC methods, making it a less reliable option for someone seeking a highly effective contraceptive. *Barrier methods with spermicide* - The patient already states she uses **condoms inconsistently**, indicating that methods requiring user action at the time of intercourse are not reliable for her. - While spermicide can increase efficacy slightly, these methods still require consistent and correct use with each act of intercourse and are **less effective** than hormonal options or LARCs.

Question 18: A 50-year-old woman with a history of deep vein thrombosis 10 years ago (unprovoked) presents with severe vasomotor symptoms significantly affecting her quality of life. She has tried lifestyle modifications and cognitive behavioural therapy with minimal benefit. Her thrombophilia screen at the time was negative. Her BMI is 26 kg/m² and she is a non-smoker. What is the most appropriate management of her menopausal symptoms?

A. Prescribe transdermal estradiol with micronised progesterone as transdermal route has lower VTE risk
B. Prescribe venlafaxine 75 mg daily as HRT is absolutely contraindicated (Correct Answer)
C. Prescribe clonidine as a non-hormonal alternative to HRT
D. Refer to haematology for assessment before considering any form of HRT
E. Prescribe tibolone as it has a more favorable effect on coagulation than standard HRT

Explanation: ***Prescribe venlafaxine 75 mg daily as HRT is absolutely contraindicated*** - A history of **unprovoked venous thromboembolism (VTE)** is a **UKMEC 4** (absolute contraindication) for all forms of systemic hormone replacement therapy. - **Venlafaxine**, an SNRI, is an effective non-hormonal treatment that can reduce **vasomotor symptoms** by approximately 50-60%. *Prescribe transdermal estradiol with micronised progesterone as transdermal route has lower VTE risk* - While **transdermal HRT** does not increase VTE risk in the general population, it remains **contraindicated** in patients with a personal history of VTE. - Safety data for transdermal use in patients with prior **unprovoked clots** is insufficient to override the absolute contraindication. *Prescribe clonidine as a non-hormonal alternative to HRT* - **Clonidine** is often less effective than SSRIs or SNRIs for the relief of **vasomotor symptoms** and carries side effects like dry mouth and drowsiness. - It is generally considered a second-line non-hormonal option behind **venlafaxine** or gabapentin. *Refer to haematology for assessment before considering any form of HRT* - A **haematology referral** is unnecessary here because the clinical history of an **unprovoked VTE** already clearly defines the contraindication for HRT. - Guidelines advise against systemic HRT regardless of further **thrombophilia screening**, as previous clotting events are the strongest predictor of future risk. *Prescribe tibolone as it has a more favorable effect on coagulation than standard HRT* - **Tibolone** is a synthetic steroid that still carries a risk of **VTE and stroke**, making it unsuitable for this patient. - Like conventional systemic HRT, it is **contraindicated** in women with a personal history of thromboembolic disease.

Question 19: A 42-year-old woman with menorrhagia has been using a 52 mg levonorgestrel intrauterine system for 4 years with good effect. She now presents requesting early replacement as she has read that the device lasts 5 years for contraception but only 4 years for heavy menstrual bleeding. Her bleeding remains well controlled. What is the most appropriate advice?

A. Replace the device now as it is only licensed for 4 years for heavy menstrual bleeding
B. Replace the device at 5 years as per contraception licensing regardless of indication
C. Reassure her that current evidence supports 5-year use for heavy menstrual bleeding (Correct Answer)
D. Remove the device and trial tranexamic acid to see if it is still needed
E. Add oral progestogen in the luteal phase to extend the device life

Explanation: ***Reassure her that current evidence supports 5-year use for heavy menstrual bleeding*** - Although historical licensing limits were lower, current **FSRH guidelines** and updated product licenses (e.g., **Mirena**) support the use of the **52 mg LNG-IUS** for 5 years for both **contraception** and **heavy menstrual bleeding (HMB)**. - Clinical evidence shows that **levonorgestrel levels** remain sufficient to provide effective **endometrial suppression** and bleeding control for the full 5-year duration. *Replace the device now as it is only licensed for 4 years for heavy menstrual bleeding* - This advice is outdated; while some older formulations had a 4-year license for HMB, modern **52 mg systems** are licensed for **5 years** across all indications. - Replacing the device early when bleeding is **well controlled** exposes the patient to unnecessary procedural risks such as **perforation** or **infection**. *Replace the device at 5 years as per contraception licensing regardless of indication* - While the replacement at 5 years is the correct timeframe, the rationale provided ignores that the **HMB indication** now also carries a 5-year recommendation. - It is important to reassure the patient that the efficacy for her specific condition (**menorrhagia**) matches the **contraceptive longevity**. *Remove the device and trial tranexamic acid to see if it is still needed* - **Tranexamic acid** is generally less effective than the **LNG-IUS** for managing HMB and would be a step down in therapy for a patient currently well-controlled. - Discontinuing a successful treatment without a clinical indication like **side effects** or the desire for pregnancy is not recommended. *Add oral progestogen in the luteal phase to extend the device life* - There is no clinical evidence to support adding **cyclical progestogens** to "extend" the life of an intrauterine system. - If an **LNG-IUS** is failing to control symptoms due to hormone depletion, the standard of care is **device replacement**, not supplementary oral therapy.

Question 20: A 35-year-old woman with a BMI of 38 kg/m² attends for review 6 months after insertion of a 52 mg levonorgestrel intrauterine system for contraception and heavy menstrual bleeding. She reports her bleeding has improved significantly but she has gained 4 kg weight since insertion. She is concerned the IUS is causing weight gain and requests removal. What is the most appropriate advice?

A. Remove the IUS immediately as weight gain is a recognized side effect
B. Explain that while weight gain is commonly reported, evidence does not support the LNG-IUS causing significant weight gain (Correct Answer)
C. Offer to replace with copper IUD as this has no hormonal effects
D. Arrange blood tests including thyroid function before making any changes
E. Reduce dietary calories to 1200 kcal daily and review in 3 months

Explanation: ***Explain that while weight gain is commonly reported, evidence does not support the LNG-IUS causing significant weight gain*** - Clinical trials and systematic reviews consistently show no **causal relationship** between the **52 mg levonorgestrel intrauterine system (LNG-IUS)** and significant weight gain. - The **progestogen** in the LNG-IUS acts primarily **locally on the endometrium**, resulting in very low systemic levels compared to other hormonal contraceptives. *Remove the IUS immediately as weight gain is a recognized side effect* - Immediate removal is inappropriate without first discussing the lack of **clinical evidence** linking the IUS to weight changes. - The patient is benefiting significantly from the device for her **heavy menstrual bleeding**, and removal would lose these therapeutic benefits. *Offer to replace with copper IUD as this has no hormonal effects* - While a **copper IUD** is non-hormonal, it is known to increase **menstrual blood loss** and cramps, which would worsen the patient's primary complaint of heavy bleeding. - The LNG-IUS is the preferred **first-line treatment** for heavy menstrual bleeding, whereas the copper IUD is often contraindicated in such cases. *Arrange blood tests including thyroid function before making any changes* - While excluding **hypothyroidism** is reasonable in a patient with a high **BMI** and recent weight gain, it should not be the primary response to her concern about the IUS. - The main priority is to provide **evidence-based counseling** regarding her specific concern about the contraceptive device itself. *Reduce dietary calories to 1200 kcal daily and review in 3 months* - Recommending a specific, highly restrictive **1200 kcal diet** is often unsustainable and should be managed through structured **metabolic or nutritional services**. - This approach fails to address the patient's concern that the **contraceptive device** is the underlying cause of her physiological changes.

Question 21: A 55-year-old woman presents for follow-up. She started continuous combined HRT (oral estradiol 1 mg with dydrogesterone 10 mg) 4 years ago for severe vasomotor symptoms. Her symptoms are now well controlled and she has no side effects. She has no personal history of breast cancer but her mother was diagnosed with breast cancer at age 68. Her BMI is 24 kg/m² and she is otherwise well. What is the most appropriate advice regarding continuation of HRT?

A. Continue HRT indefinitely as benefits outweigh risks with good symptom control
B. Discontinue HRT immediately as she has exceeded 5 years of recommended use
C. Discuss risks and benefits; consider trial of stopping or reducing dose if symptoms allow (Correct Answer)
D. Switch to transdermal estrogen to reduce breast cancer risk before continuing
E. Discontinue HRT due to family history of breast cancer

Explanation: ***Discuss risks and benefits; consider trial of stopping or reducing dose if symptoms allow*** - She has been on HRT for 4 years. It is crucial to **annually review** the **risk-benefit profile** of HRT, particularly as risks like **breast cancer** and **venous thromboembolism (VTE)** increase with duration of use. - A **trial of dose reduction** or stopping allows assessment of whether **vasomotor symptoms** have resolved, minimizing long-term exposure to potential risks while still managing symptoms if they recur. *Continue HRT indefinitely as benefits outweigh risks with good symptom control* - **Indefinite use** without regular re-evaluation is generally discouraged because the risks of **breast cancer** and **VTE** accumulate over time, even with good symptom control. - HRT should be used for the **shortest duration** necessary and at the **lowest effective dose** to manage symptoms, with periodic reassessment. *Discontinue HRT immediately as she has exceeded 5 years of recommended use* - There is **no arbitrary time limit** for HRT, and immediate cessation can lead to a sudden and severe recurrence of **menopausal symptoms**, negatively impacting quality of life. - Decisions to stop HRT should be a **shared process** between the patient and clinician, considering individual symptoms, risks, and benefits, rather than adherence to a fixed duration. *Switch to transdermal estrogen to reduce breast cancer risk before continuing* - While **transdermal estrogen** reduces the risk of **VTE** and stroke compared to oral forms, it does not significantly alter the **breast cancer risk** associated with combined HRT (estrogen plus progestogen). - The breast cancer risk in combined HRT is primarily linked to the **progestogen component** and duration of use, not solely the route of estrogen administration. *Discontinue HRT due to family history of breast cancer* - A mother diagnosed with breast cancer at age 68 represents only a **slightly increased baseline risk** for the patient and is not an absolute **contraindication** to HRT, especially if symptoms are well controlled. - **Family history** should be thoroughly discussed as part of the overall risk assessment, but it does not automatically mandate the cessation of HRT if the patient's personal risk profile remains acceptable.

Question 22: A 27-year-old woman presents 96 hours after unprotected sexual intercourse requesting emergency contraception. She has a BMI of 29 kg/m² and her last menstrual period was 16 days ago (regular 28-day cycle). She is not on any regular medications. On further questioning, she reveals she also had unprotected intercourse 7 days ago. What is the most appropriate emergency contraception?

A. Levonorgestrel 1.5 mg as she is within 120 hours of most recent intercourse
B. Ulipristal acetate 30 mg as it is more effective than levonorgestrel at this timeframe
C. Copper intrauterine device (Correct Answer)
D. No emergency contraception needed as both episodes were likely after ovulation
E. Ulipristal acetate 30 mg but inform her it may not cover the earlier episode

Explanation: ***Copper intrauterine device*** - The **copper IUD** is the most effective form of emergency contraception and can be inserted up to **5 days (120 hours)** after the first episode of unprotected intercourse or up to **5 days after the earliest likely ovulation**. - Given the patient's cycle (ovulation likely around day 14) and the timing of both unprotected acts (day 9 and day 12), the **copper IUD** is the only method that offers high efficacy for both episodes, particularly the earlier one, and is still within the acceptable timeframe (up to Day 19, which is 5 days post-ovulation). *Levonorgestrel 1.5 mg as she is within 120 hours of most recent intercourse* - **Levonorgestrel** EC is primarily effective when taken within **72 hours** (3 days) of unprotected intercourse, with significantly reduced efficacy up to 120 hours; the patient presented at 96 hours. - Its effectiveness is also reduced in women with a **BMI > 26 kg/m²** (patient's BMI is 29 kg/m²), and it would not cover the earlier episode of intercourse (7 days ago). *Ulipristal acetate 30 mg as it is more effective than levonorgestrel at this timeframe* - **Ulipristal acetate (UPA)** is effective up to **120 hours** (5 days) and has shown better efficacy than levonorgestrel in later timeframes and in women with a higher BMI. - However, UPA works by **delaying ovulation** and would not be effective if fertilization from the earlier intercourse (7 days ago) has already occurred or if ovulation has passed for that specific act. *No emergency contraception needed as both episodes were likely after ovulation* - In a regular 28-day cycle, ovulation typically occurs around day 14. The unprotected intercourse episodes occurred on cycle days 9 and 12. - Both these days fall within the **fertile window**, as sperm can survive in the female reproductive tract for up to **5 days**, making pregnancy a significant risk. *Ulipristal acetate 30 mg but inform her it may not cover the earlier episode* - While this option correctly identifies a limitation of **ulipristal acetate**, it does not propose the most appropriate or effective emergency contraception for this patient. - The **copper IUD** is a superior choice as it covers both episodes of unprotected intercourse and provides ongoing contraception, which is ideal in this scenario.

Question 23: A 49-year-old woman started on sequential combined HRT (transdermal estradiol 50 mcg twice weekly with oral micronised progesterone 200 mg days 15-28) 3 months ago for perimenopausal symptoms. She is still having occasional irregular menstrual periods. She now reports breakthrough bleeding on day 10 of her cycle. What is the most appropriate initial management?

A. Reassure and continue current regimen as irregular bleeding is common in first 3-6 months (Correct Answer)
B. Switch to continuous combined HRT
C. Arrange urgent transvaginal ultrasound and endometrial biopsy
D. Increase the progestogen duration to days 1-14 each month
E. Stop HRT and arrange investigation before restarting

Explanation: ***Reassure and continue current regimen as irregular bleeding is common in first 3-6 months*** - **Irregular bleeding** or breakthrough bleeding is common and expected in up to 80% of women during the **first 3-6 months** of Hormone Replacement Therapy (HRT) as the endometrium adjusts. - Since the patient is only **3 months** into her regimen and is still **perimenopausal**, the most appropriate initial step is to observe for resolution rather than rushing to investigations. *Switch to continuous combined HRT* - **Continuous combined HRT** is only indicated for women who are **postmenopausal** (at least one year since their last period) to avoid heavy and unpredictable bleeding. - Switching a **perimenopausal** woman with ongoing cycles to this regimen would likely worsen the frequency of **breakthrough bleeding**. *Arrange urgent transvaginal ultrasound and endometrial biopsy* - **Urgent investigations** for unscheduled bleeding are generally deferred until the bleeding persists beyond the **6-month adaptation period** or if there are high-risk red flags. - Initial management focuses on **clinical patience** unless the bleeding is unusually heavy or occurs in a postmenopausal woman on long-term therapy. *Increase the progestogen duration to days 1-14 each month* - **Sequential HRT** typically provides progestogen for 12–14 days in the second half of the cycle; changing the timing to days 1–14 does not align with standard **endometrial protection** protocols for perimenopausal women. - Adjusting the **progestogen dose or duration** is a secondary step considered only if bleeding persists or remains heavy after the initial stabilization phase. *Stop HRT and arrange investigation before restarting* - There is no clinical indication to **cease HRT** abruptly for breakthrough bleeding that has occurred for only 3 months in a perimenopausal patient. - Stopping therapy would likely lead to a recurrence of her **vasomotor/perimenopausal symptoms** without providing additional diagnostic clarity at this early stage.

Question 24: A 31-year-old woman with well-controlled epilepsy on lamotrigine 200 mg twice daily requests contraception. She is in a stable relationship and wants highly effective contraception. Her BMI is 23 kg/m² and she has regular 28-day cycles. She has no other medical conditions. Which contraceptive method requires particular caution or adjustment in this patient?

A. Copper intrauterine device
B. Levonorgestrel intrauterine system 52 mg
C. Combined oral contraceptive pill containing ethinylestradiol and levonorgestrel (Correct Answer)
D. Etonogestrel contraceptive implant
E. Progestogen-only pill (desogestrel 75 mcg)

Explanation: ***Combined oral contraceptive pill containing ethinylestradiol and levonorgestrel***- **Ethinylestradiol** in combined oral contraceptives significantly induces the **glucuronidation of lamotrigine**, leading to a substantial decrease in its serum concentration and potentially compromising seizure control.- During the **pill-free interval**, when ethinylestradiol levels drop, **lamotrigine levels can rapidly rise**, increasing the risk of dose-dependent adverse effects such as **ataxia**, **dizziness**, and **nystagmus**.*Copper intrauterine device*- This is a **non-hormonal** contraceptive method, meaning it does not release any hormones into the systemic circulation.- Therefore, it has **no pharmacological interaction** with lamotrigine or its metabolic pathways, making it a safe and highly effective option.*Levonorgestrel intrauterine system 52 mg*- The **levonorgestrel intrauterine system (LNG-IUS)** delivers progestogen primarily locally to the uterus with minimal systemic absorption.- This localized action means it does not significantly induce or inhibit liver enzymes involved in the **metabolism of lamotrigine**, making it a suitable and highly effective choice.*Etonogestrel contraceptive implant*- The etonogestrel implant is a **progestogen-only method** that does not contain estrogen, which is the component responsible for interacting with lamotrigine.- **Lamotrigine is not a potent enzyme inducer** to the extent that it would compromise the efficacy of progestogen-only methods, making the implant a safe and reliable option.*Progestogen-only pill (desogestrel 75 mcg)*- The **progestogen-only pill (POP)**, such as desogestrel, does not contain **ethinylestradiol**, thereby avoiding the interaction that significantly lowers lamotrigine levels.- While some enzyme-inducing antiepileptic drugs can reduce POP efficacy, **lamotrigine is not considered a significant enzyme inducer** for most progestogen-only contraceptives.

Question 25: A 38-year-old woman with premature ovarian insufficiency diagnosed 2 years ago has been taking HRT (transdermal estradiol 100 mcg twice weekly with oral micronised progesterone 200 mg daily). She enquires about when she can discontinue HRT. She is otherwise well with no contraindications to HRT. What is the most appropriate advice regarding continuation of HRT?

A. Continue HRT at least until age 45 years
B. Continue HRT until age 51 years (average age of natural menopause) (Correct Answer)
C. Continue HRT for 5 years from diagnosis then review
D. Continue HRT until age 50 years then switch to lower dose
E. Discontinue HRT now as she has been on it for 2 years

Explanation: ***Continue HRT until age 51 years (average age of natural menopause)***- In women with **premature ovarian insufficiency (POI)**, HRT is recommended until at least the **average age of natural menopause** (51 years) to reduce long-term health risks.- This duration is crucial for maintaining **bone mineral density** and reducing the risk of **cardiovascular disease** and cognitive decline associated with early estrogen deficiency.*Continue HRT at least until age 45 years*- While 45 marks the end of "early menopause," it is still significantly younger than the **average age of natural menopause**.- Discontinuing at 45 would leave the patient with a deficit of **estrogen protection** during years when she would naturally still be premenopausal.*Continue HRT for 5 years from diagnosis then review*- The **five-year review** rule often applied to older postmenopausal women does not apply to POI patients who are replacing a **physiological deficiency**.- Treatment should be viewed as **hormone replacement** to match natural biological timing rather than a short-term symptom management strategy.*Continue HRT until age 50 years then switch to lower dose*- There is no clinical requirement to automatically **switch to a lower dose** at 50, as the goal is to align with the natural transition to menopause.- Management should be individualized at the **age of natural menopause**, but mandated dose reduction before this point is not standard practice for POI.*Discontinue HRT now as she has been on it for 2 years*- Discontinuing after only 2 years would expose a 40-year-old woman to high risks of **osteoporosis** and **urogenital atrophy**.- Short-term use is insufficient for **POI management**, as these patients require hormonal support until they reach the physiological age of menopause.

Question 26: According to the UK Medical Eligibility Criteria for Contraceptive Use (UKMEC), what category is assigned to the copper intrauterine device in a woman with current pelvic inflammatory disease?

A. UKMEC 1 - No restriction for use
B. UKMEC 2 - Advantages generally outweigh risks
C. UKMEC 3 - Risks usually outweigh advantages
D. UKMEC 4 - Unacceptable health risk (Correct Answer)
E. UKMEC 2 for insertion, UKMEC 1 for continuation

Explanation: ***UKMEC 4 - Unacceptable health risk***- For a woman with **current pelvic inflammatory disease (PID)**, the insertion of a copper IUD is classified as **UKMEC 4**, indicating an unacceptable health risk due to the potential for worsening the infection.- The procedure could facilitate the **migration of pathogens** from the lower to the upper genital tract, increasing the risk of complications such as **tubo-ovarian abscesses** and subsequent infertility.*UKMEC 1 - No restriction for use*- This category applies to conditions where there is no restriction for use, such as a **past history of PID** followed by a successful pregnancy.- Current PID represents an active **contraindication** and does not fall into this risk-free category.*UKMEC 2 - Advantages generally outweigh risks*- **UKMEC 2** would apply to a past history of PID without a subsequent pregnancy, but not to an **acute infection**.- For active PID, the risks of **ascending infection** far outweigh any benefits of immediate IUD insertion.*UKMEC 3 - Risks usually outweigh advantages*- This category is reserved for conditions where risks generally outweigh benefits but the method is not strictly prohibited; current PID is more severe, warranting a **complete restriction (Category 4)**.- It is often confused with clinical scenarios like **unexplained vaginal bleeding** before evaluation, which is a Category 3 for copper IUDs.*UKMEC 2 for insertion, UKMEC 1 for continuation*- This distinction is incorrect for current PID; in fact, the classification is **UKMEC 4 for insertion** and **UKMEC 2 for continuation** if the device is already in place and the patient responds to treatment.- If a patient develops PID with an IUD *in situ*, the device does not necessarily need removal if **antibiotic therapy** is initiated and the patient is closely monitored.

Question 27: A 53-year-old woman who underwent total hysterectomy for fibroids 8 years ago presents requesting HRT for severe hot flushes. She has a history of grade 1 endometrial cancer treated with hysterectomy alone 8 years ago, with no evidence of recurrence. She has no other significant medical history and her BMI is 26 kg/m². What is the most appropriate advice regarding HRT?

A. HRT is contraindicated due to her history of endometrial cancer (Correct Answer)
B. Prescribe estrogen-only HRT (transdermal estradiol) as she has had hysterectomy
C. Prescribe continuous combined HRT despite hysterectomy due to cancer history
D. Recommend selective serotonin reuptake inhibitors as first-line treatment
E. Prescribe tibolone as an alternative to standard HRT

Explanation: ***HRT is contraindicated due to her history of endometrial cancer*** - A personal history of **estrogen-sensitive endometrial cancer** is an absolute contraindication to hormone replacement therapy, as exogenous estrogen could stimulate any **residual malignant cells**. - This contraindication applies even after a complete hysterectomy, regardless of the **grade of cancer**, the time elapsed since treatment (8 years), or the absence of current recurrence. *Prescribe estrogen-only HRT (transdermal estradiol) as she has had hysterectomy* - While **estrogen-only HRT** is typically prescribed for women post-hysterectomy, it is unsafe in this patient due to her history of **estrogen-dependent endometrial cancer**. - Providing estrogen, even transdermally, carries a significant risk of stimulating potential **dormant malignant cells** elsewhere in the body. *Prescribe continuous combined HRT despite hysterectomy due to cancer history* - Continuous combined HRT is intended to protect the **endometrium** from estrogenic stimulation by adding a progestogen, which is irrelevant in a patient who has undergone a **total hysterectomy**. - The primary concern remains the history of **estrogen-sensitive cancer**, which contraindicates any form of estrogenic therapy, whether combined or alone. *Recommend selective serotonin reuptake inhibitors as first-line treatment* - While **SSRIs** (e.g., paroxetine, escitalopram) or **SNRIs** (e.g., venlafaxine) are valid non-hormonal alternatives for managing vasomotor symptoms, the most appropriate initial advice is to identify and communicate the absolute **contraindication to HRT**. - Recommending an alternative treatment does not address the fundamental safety issue regarding hormonal therapy in this patient's specific medical history. *Prescribe tibolone as an alternative to standard HRT* - **Tibolone** is a synthetic steroid with estrogenic, progestogenic, and androgenic properties, and it is contraindicated in women with a history of **estrogen-dependent cancers**. - Its estrogenic effects mean it carries the same risk as conventional HRT for stimulating residual or recurrent **endometrial cancer cells**.

Question 28: A 46-year-old woman with perimenopause presents with heavy menstrual bleeding and hot flushes. She has completed her family and requests contraception that will also manage her symptoms. She has a BMI of 32 kg/m², smokes 10 cigarettes daily, and has well-controlled hypertension on amlodipine. Pelvic examination is normal and recent pelvic ultrasound shows a bulky uterus with small fibroids (<3cm) but normal endometrium. What is the most appropriate management?

A. Combined oral contraceptive pill containing 30 mcg ethinylestradiol
B. 52 mg levonorgestrel intrauterine system (Correct Answer)
C. Oral norethisterone 5 mg three times daily days 5-26
D. Progestogen-only pill (desogestrel 75 mcg)
E. Tranexamic acid 1 g three times daily during menstruation

Explanation: ***52 mg levonorgestrel intrauterine system***- The **LNG-IUS** is the first-line treatment for **heavy menstrual bleeding** and provides highly effective **contraception**, which the patient specifically requested.- It is safe for this patient (UKMEC 1) despite her high BMI, **smoking status**, and **hypertension**, and it can later serve as the progestogen component of **HRT** for perimenopausal symptoms.*Combined oral contraceptive pill containing 30 mcg ethinylestradiol*- This option is contraindicated (**UKMEC 3/4**) because the patient is over 35 years old and **smokes**, which significantly increases the risk of **venous thromboembolism** and stroke.- Her **hypertension** further increases the cardiovascular risks associated with ethinylestradiol, making combined hormonal methods unsuitable.*Oral norethisterone 5 mg three times daily days 5-26*- While high-dose oral progestogens can manage bleeding, they are less effective than the **LNG-IUS** and require strict **daily compliance**.- This regimen does not provide reliable **contraception** and often has more systemic side effects compared to local intrauterine delivery.*Progestogen-only pill (desogestrel 75 mcg)*- The **POP** provides effective contraception and is safe for smokers with hypertension, but it is not a primary treatment for **heavy menstrual bleeding** in this context.- It may cause **irregular bleeding** or spotting rather than the significant reduction in menstrual volume needed to manage her symptoms, and does not directly address hot flushes.*Tranexamic acid 1 g three times daily during menstruation*- This is a non-hormonal treatment that effectively reduces **menstrual blood loss**, but it provides no **contraceptive benefit**.- It does not address the patient's **hot flushes** or her specific request for a contraceptive method.

Question 29: A 25-year-old woman presents requesting emergency contraception. She had unprotected sexual intercourse 72 hours ago and again 24 hours ago. She has a regular 28-day menstrual cycle and her last menstrual period started 11 days ago. Her BMI is 24 kg/m². She is not taking any regular medications. What is the most appropriate emergency contraception for this patient?

A. Levonorgestrel 1.5 mg single dose
B. Ulipristal acetate 30 mg single dose
C. Copper intrauterine device (Correct Answer)
D. Levonorgestrel 3 mg single dose (double dose)
E. Combined oral contraceptive (Yuzpe regimen)

Explanation: ***Copper intrauterine device*** - The **copper IUD** is the most effective method of emergency contraception (EC) with over **99% efficacy**, and it can be inserted up to **5 days** after the earliest episode of unprotected sex or 5 days after the earliest predicted **ovulation**. - This patient is on **day 11** of a 28-day cycle, placing her in the high-risk **peri-ovulatory** window; the IUD is the only method that provides **ongoing contraception** and works effectively even after fertilization by preventing implantation. *Levonorgestrel 1.5 mg single dose* - This hormonal method primarily works by **delaying ovulation** and is significantly less effective if the **LH surge** has already begun, which is likely on day 11 of a regular cycle. - It is generally licensed up to **72 hours** after unprotected intercourse, and its efficacy decreases notably the later it is administered compared to the copper IUD. *Ulipristal acetate 30 mg single dose* - While more effective than levonorgestrel and licensed for use up to **120 hours** (5 days), it is still less effective than the **copper IUD** in the crucial peri-ovulatory period. - It works by delaying ovulation even after the **LH surge** has started (but before it peaks), but its efficacy is diminished if ovulation has fully occurred or fertilization has already taken place. *Levonorgestrel 3 mg single dose (double dose)* - A double dose of levonorgestrel (3 mg) is typically recommended only for women with a **BMI >26 kg/m²** or weight >70kg, or those taking **enzyme-inducing** medications. - This patient has a **BMI of 24 kg/m²**, so a double dose is not clinically indicated and would not provide superior efficacy compared to the standard dose or the copper IUD. *Combined oral contraceptive (Yuzpe regimen)* - The **Yuzpe regimen** is an older and significantly **less effective** method of emergency contraception compared to newer hormonal options and the copper IUD. - It is associated with a much higher incidence of **side effects** such as nausea and vomiting due to the high estrogen content, making it a less preferred option.

Question 30: A 54-year-old woman presents for review 9 months after starting continuous combined HRT (oral estradiol 2 mg with dydrogesterone 10 mg). She reports good control of her vasomotor symptoms but has noticed persistent breast tenderness and mild bloating. Her BMI is 27 kg/m² and she has no history of breast disease. What is the most appropriate management to address her side effects while maintaining symptom control?

A. Switch to sequential combined HRT regimen
B. Reduce the estradiol dose to 1 mg daily with the same progestogen
C. Switch to transdermal estradiol with micronised progesterone (Correct Answer)
D. Add evening primrose oil and continue current HRT
E. Switch to estradiol with norethisterone acetate

Explanation: ***Switch to transdermal estradiol with micronised progesterone*** - **Transdermal estradiol** avoids first-pass hepatic metabolism, potentially leading to fewer systemic side effects like **breast tenderness** due to more stable hormone levels. - **Micronised progesterone** is a body-identical progestogen often associated with a lower incidence of typical progestogenic side effects, such as **bloating** and mastalgia, compared to synthetic progestogens like dydrogesterone. *Switch to sequential combined HRT regimen* - Switching to a **sequential regimen** would reintroduce cyclical withdrawal bleeding, which is generally undesirable for a 54-year-old woman already established on continuous combined HRT and likely postmenopausal. - This change would not directly address the specific side effects of **breast tenderness** (often estrogen-related) or **bloating** (often progestogen-related) as effectively as modifying the type or route of hormones. *Reduce the estradiol dose to 1 mg daily with the same progestogen* - The patient reports good control of her **vasomotor symptoms** on the current 2 mg estradiol dose; reducing it risks a return of these symptoms. - This approach would also fail to address the **progestogenic side effects** (bloating) potentially caused by dydrogesterone, which is a significant part of her complaint. *Add evening primrose oil and continue current HRT* - **Evening primrose oil** lacks robust scientific evidence to support its effectiveness in significantly alleviating HRT-induced breast tenderness or systemic bloating. - The most appropriate management involves optimizing the **hormone therapy itself** rather than adding unproven supplements, especially when direct adjustments to HRT can be made. *Switch to estradiol with norethisterone acetate* - **Norethisterone acetate** is a synthetic progestogen that is generally more **androgenic** and can be associated with a higher incidence of progestogenic side effects like **bloating**, mood changes, and breast tenderness. - Therefore, switching to this progestogen is unlikely to resolve her current complaints and may even worsen them, as it is not typically better tolerated than dydrogesterone for these specific side effects.

Question 31: A 30-year-old woman attends for contraceptive counselling. She has a history of cervical intraepithelial neoplasia grade 2 (CIN2) treated successfully with large loop excision of the transformation zone 18 months ago. She is a non-smoker with a BMI of 25 kg/m² and has regular menstrual cycles. She requests long-acting reversible contraception. What is the most appropriate contraceptive method according to UK Medical Eligibility Criteria (UKMEC)?

A. Combined oral contraceptive pill
B. Levonorgestrel intrauterine system
C. Copper intrauterine device
D. Progestogen-only implant (Correct Answer)
E. Depo-medroxyprogesterone acetate injection

Explanation: ***Progestogen-only implant*** - The **progestogen-only implant** is classified as **UKMEC 1** (no restriction) for patients with a history of successfully treated **CIN2**, making it a highly appropriate LARC choice. - It provides the highest contraceptive efficacy (>99%) and does not carry the theoretical local tissue concerns associated with some intrauterine methods in the context of cervical dysplasia. *Combined oral contraceptive pill* - While effective, this is not a **Long-Acting Reversible Contraceptive (LARC)**, which was specifically requested by the patient. - According to **UKMEC** guidelines, combined hormonal methods are categorized as **UKMEC 2** for cervical intraepithelial neoplasia, unlike the implant which is MEC 1. *Levonorgestrel intrauterine system* - The **LNG-IUS** is classified as **UKMEC 2** for women with cervical neoplasia awaiting treatment or with recent treatment, as the theoretical risks of local progestogen on the cervix generally outweigh the benefits. - Although it is a **LARC**, the higher MEC category compared to the implant makes it a less ideal choice in this specific scenario. *Copper intrauterine device* - The **Copper IUD** is classified as **UKMEC 1** and is a valid LARC; however, the implant remains a primary recommendation for its superior efficacy and lack of procedure-related cervical irritation. - Unlike the implant, the Copper IUD may cause **increased menstrual bleeding** or pain, which may not be desirable given her regular cycles. *Depo-medroxyprogesterone acetate injection* - The **DMPA injection** is a **UKMEC 1** method for this patient, but it is often considered a "medium-acting" method rather than a long-term LARC like the implant or IUDs. - It requires administration every **12 weeks**, whereas the implant provides protection for **3 years**, aligning better with the request for LARC.

Question 32: A 50-year-old woman commenced sequential combined HRT (transdermal estradiol 50 mcg twice weekly with cyclical dydrogesterone 10 mg days 15-28) 9 months ago for perimenopausal symptoms. Her periods have been irregular with the last natural period 8 months ago before starting HRT. She now reports that her withdrawal bleeds on HRT are occurring on day 8-9 of progestogen therapy rather than after completion of the progestogen course. The bleeding is light and lasts 3-4 days. What is the most appropriate management?

A. Urgent transvaginal ultrasound and endometrial assessment for early breakthrough bleeding
B. Increase the progestogen dose to dydrogesterone 20 mg to improve endometrial stability
C. Continue current regimen as irregular bleeding patterns can occur in the first year of sequential HRT
D. Switch to continuous combined HRT as she is likely postmenopausal (Correct Answer)
E. Add additional cyclical progestogen in the first half of the cycle

Explanation: ***Switch to continuous combined HRT as she is likely postmenopausal*** - The occurrence of **withdrawal bleeds on day 8-9 of progestogen therapy** (before completion of the course) suggests the patient's own endogenous estrogen levels are waning, indicating a transition towards **postmenopause**. - Given her age (50) and that her last natural period was 8 months ago, she is likely approaching the 12-month **amenorrhea threshold** for postmenopause, making **continuous combined HRT** (which aims for no cyclical bleeding) the most appropriate next step. *Urgent transvaginal ultrasound and endometrial assessment for early breakthrough bleeding* - **Urgent endometrial investigation** is typically indicated for unscheduled bleeding in a patient *established* on HRT for more than 6-12 months, or for new-onset postmenopausal bleeding. - This specific pattern of **early withdrawal bleeding** on sequential HRT, especially with a natural period 8 months ago, is more indicative of a physiological transition rather than immediate **endometrial pathology**. *Increase the progestogen dose to dydrogesterone 20 mg to improve endometrial stability* - Increasing the **progestogen dose** is usually considered when bleeding is **heavy** or occurs *late* in the progestogen phase, indicating insufficient endometrial suppression. - It would not address **early withdrawal bleeding**, which points to a different physiological shift (waning endogenous estrogen and thus an earlier 'withdrawal' from external progestogen due to lack of endogenous estrogen priming). *Continue current regimen as irregular bleeding patterns can occur in the first year of sequential HRT* - While some irregular bleeding can occur, an **early withdrawal bleed** (bleeding while still taking progestogen) is a specific sign that the sequential regimen is no longer synchronized with her changing endogenous hormone levels. - Ignoring this pattern can lead to patient dissatisfaction and may delay appropriate management for her menopausal stage. *Add additional cyclical progestogen in the first half of the cycle* - Adding progestogen in the first half of the cycle (the estrogen-only phase) would fundamentally alter the sequential nature of the HRT, potentially leading to a more continuous progestogen exposure. - This is not a standard or appropriate management strategy for early withdrawal bleeding in sequential HRT and could further complicate bleeding patterns.

Question 33: A 32-year-old nulliparous woman who had a copper IUD inserted 3 years ago for long-term contraception now presents requesting removal as she is planning pregnancy in the next 6 months. She asks about what to expect regarding return to fertility. What is the most accurate information to provide about fertility after copper IUD removal?

A. Fertility returns to baseline immediately after removal with no delay in conception rates (Correct Answer)
B. There is typically a 3-6 month delay in return to normal fertility after IUD removal
C. Copper IUDs may cause permanent reduction in fertility in nulliparous women
D. The duration of IUD use (3 years) will result in at least 3 months of reduced fertility
E. Fertility is reduced for 1-2 cycles after removal due to endometrial changes

Explanation: ***Fertility returns to baseline immediately after removal with no delay in conception rates*** - The **copper IUD** works primarily by preventing fertilization through a **local inflammatory response** that is rapidly reversible upon removal. - Studies consistently show that **conception rates** after copper IUD removal are similar to those of women discontinuing non-hormonal contraception or having no prior contraception. *There is typically a 3-6 month delay in return to normal fertility after IUD removal* - This delay is characteristic of **hormonal methods** like **Depot medroxyprogesterone acetate (DMPA)**, which suppress ovulation and require a washout period. - The **copper IUD** does not affect the **hypothalamic-pituitary-ovarian axis** or ovulation, so no such delay is expected. *Copper IUDs may cause permanent reduction in fertility in nulliparous women* - Modern evidence refutes this misconception; **copper IUDs** do not cause **infertility** or **tubal damage** in women at low risk for sexually transmitted infections. - The historical link to **pelvic inflammatory disease (PID)** and subsequent infertility was largely associated with older IUD designs and STI exposure, not the device itself. *The duration of IUD use (3 years) will result in at least 3 months of reduced fertility* - The **duration of copper IUD use** does not influence the time to return to fertility; its mechanism is local and immediately reversible. - Fertility is not diminished by the length of time the IUD is in place, whether for a few months or several years. *Fertility is reduced for 1-2 cycles after removal due to endometrial changes* - The **endometrial changes** induced by the copper IUD (e.g., sterile inflammation) resolve very quickly after removal. - The uterus becomes receptive to **implantation** almost immediately, with no clinically significant period of reduced fertility due to endometrial recovery.

Question 34: A 55-year-old woman with a BMI of 35 kg/m² presents requesting HRT for moderate vasomotor symptoms. She has a history of well-controlled type 2 diabetes on metformin and hypertension managed with ramipril. Her blood pressure today is 142/88 mmHg. She underwent total abdominal hysterectomy for benign fibroids at age 47. Her mother had a deep vein thrombosis at age 72 following hip replacement surgery. What is the most appropriate HRT regimen to initiate?

A. Transdermal estradiol patches 50 mcg twice weekly without progestogen (Correct Answer)
B. Oral estradiol 2 mg daily with micronized progesterone 200 mg daily
C. Transdermal estradiol patches 25 mcg twice weekly with levonorgestrel IUS for endometrial protection
D. Tibolone 2.5 mg daily as a single agent
E. Oral conjugated equine estrogens 0.625 mg daily without progestogen

Explanation: ***Transdermal estradiol patches 50 mcg twice weekly without progestogen*** - Since the patient has undergone a **total abdominal hysterectomy**, she only requires **estrogen-only HRT**; progestogen for endometrial protection is unnecessary. - The **transdermal route** is safer for patients with **obesity (BMI 35)**, **hypertension**, and **diabetes** because it avoids first-pass hepatic metabolism, minimizing the risk of **venous thromboembolism (VTE)** and metabolic interference. *Oral estradiol 2 mg daily with micronized progesterone 200 mg daily* - Combined HRT containing **progesterone** is not indicated for a woman without a uterus and unnecessarily increases risks such as breast cancer relative to estrogen-only therapy. - **Oral estrogen** confers a higher risk of **VTE** and gallbladder disease compared to transdermal delivery, especially in an obese patient with additional cardiovascular risk factors. *Transdermal estradiol patches 25 mcg twice weekly with levonorgestrel IUS for endometrial protection* - Endometrial protection via a **levonorgestrel IUS** is redundant and inappropriate for a patient who has had a **hysterectomy**. - While the transdermal delivery is correct, the addition of a progestogen adds unnecessary side effects and costs for this specific patient. *Tibolone 2.5 mg daily as a single agent* - **Tibolone** is a synthetic steroid with estrogenic, progestogenic, and androgenic properties; while it can be used in post-hysterectomy women, its **VTE risk profile** makes it a less preferred first-line option compared to transdermal estradiol in a patient with multiple risk factors. - Although it is a single-agent option, **transdermal estradiol** is generally favored in patients with cardiovascular risk factors due to its more favorable VTE and metabolic profile. *Oral conjugated equine estrogens 0.625 mg daily without progestogen* - While this provides estrogen-only therapy, the **oral route** significantly increases the production of clotting factors in the liver, raising **VTE risk**. - **Transdermal patches** are the clinical gold standard for women with co-morbidities like **Type 2 Diabetes** and **hypertension** to maintain stable estrogen levels with minimal metabolic impact.

Question 35: A 24-year-old woman attends for contraceptive advice. She has a history of recurrent cervical intraepithelial neoplasia (CIN), having had two large loop excisions of the transformation zone (LLETZ) procedures in the past 3 years, most recently 4 months ago. Histology from the most recent procedure showed complete excision of CIN 2 with clear margins. She is HPV-positive on recent follow-up testing. She is a non-smoker with a BMI of 24 kg/m². She requests reliable long-acting contraception. What is the most appropriate contraceptive method for this patient?

A. Combined oral contraceptive pill should be avoided as it may increase risk of cervical cancer progression in HPV-positive women
B. Depot medroxyprogesterone acetate injection is the most appropriate as it has protective effects against cervical neoplasia
C. Copper intrauterine device is contraindicated until HPV status is negative
D. Levonorgestrel intrauterine system is appropriate and can be offered as UKMEC 2 (Correct Answer)
E. Etonogestrel subdermal implant should be avoided due to the association between progestogens and cervical neoplasia

Explanation: ***Levonorgestrel intrauterine system is appropriate and can be offered as UKMEC 2*** - According to **UK Medical Eligibility Criteria (UKMEC)**, cervical intraepithelial neoplasia (**CIN**) is classified as **UKMEC 2**, meaning the benefits of using an IUS generally outweigh the theoretical or proven risks. - The patient has had successful treatment of **CIN 2** with **clear margins**, and the presence of **HPV** does not contraindicate the placement of a long-acting reversible contraceptive (LARC) like the **LNG-IUS**. *Combined oral contraceptive pill should be avoided as it may increase risk of cervical cancer progression in HPV-positive women* - While some studies suggest a small increased risk of cervical cancer with **COCP** use over 5 years, it is still classified as **UKMEC 2** for women with **CIN**, not strictly contraindicated. - The patient specifically requested **long-acting contraception**, and the COCP is a daily method, not a LARC. *Depot medroxyprogesterone acetate injection is the most appropriate as it has protective effects against cervical neoplasia* - There is no clinical evidence to support the claim that **DMPA** has protective effects against the development or progression of **cervical neoplasia**. - While it is a reliable method, it requires repeated injections every 12-13 weeks rather than being a single-procedure **long-acting** device. *Copper intrauterine device is contraindicated until HPV status is negative* - A **Copper IUD** is actually classified as **UKMEC 1** or **2** for women with a history of **CIN**, and it is not contraindicated by **HPV-positive** status. - Routine **HPV follow-up** and cervical screening are required post-LLETZ regardless of the contraceptive method chosen, so HPV status does not impact IUD eligibility. *Etonogestrel subdermal implant should be avoided due to the association between progestogens and cervical neoplasia* - Progestogen-only methods like the **subdermal implant** are not associated with an increased risk of **cervical neoplasia** and are considered safe (**UKMEC 1**). - It is a highly effective **long-acting reversible contraceptive**, but the premise for avoiding it in the option is incorrect.

Question 36: A 48-year-old woman presents with troublesome vasomotor symptoms affecting her quality of life and sleep. Her last menstrual period was 3 months ago and prior to that her cycles had been irregular for 8 months. She has a history of unprovoked deep vein thrombosis 6 years ago, for which she completed 6 months of anticoagulation. Thrombophilia screening at the time was negative. Her BMI is 27 kg/m² and blood pressure is 128/82 mmHg. What is the most appropriate management of her menopausal symptoms?

A. Transdermal estradiol with micronized progesterone as transdermal route has lower VTE risk than oral
B. Low-dose combined oral contraceptive pill as she may still be fertile
C. Venlafaxine as a non-hormonal alternative for vasomotor symptoms (Correct Answer)
D. Continuous combined oral HRT as she is more than 6 months post-thrombosis
E. Tibolone as it has a more favorable VTE risk profile

Explanation: ***Venlafaxine as a non-hormonal alternative for vasomotor symptoms*** - A history of **unprovoked deep vein thrombosis (VTE)** is generally considered a contraindication to standard **Hormonal Replacement Therapy (HRT)** because the risk of recurrence remains elevated.- **Venlafaxine**, an SNRI, is an effective **non-hormonal** treatment for moderate to severe **vasomotor symptoms** and provides a safe alternative for patients with VTE risk.*Transdermal estradiol with micronized progesterone as transdermal route has lower VTE risk than oral*- While **transdermal estrogen** does not increase VTE risk in the same way as oral estrogen, an **unprovoked VTE** is still a strong relative contraindication for any estrogen therapy in many clinical guidelines.- HRT should be avoided in this patient until she is reviewed by a **specialist** (Hematologist or Menopause clinic) to weigh risks against benefits.*Low-dose combined oral contraceptive pill as she may still be fertile*- The **Combined Oral Contraceptive Pill (COCP)** is strictly **UKMEC 4** (unacceptable health risk) for any patient with a history of VTE.- Although she is in the **perimenopause** and may be fertile, alternative non-hormonal contraception like a **Copper IUD** should be used instead.*Continuous combined oral HRT as she is more than 6 months post-thrombosis*- **Oral HRT** undergoes **first-pass metabolism** in the liver, which increases the production of clotting factors and significantly raises the risk of recurrent VTE.- The time elapsed since the event (6 years) does not eliminate the risk, especially since the initial event was **unprovoked**.*Tibolone as it has a more favorable VTE risk profile*- **Tibolone** is a synthetic compound with estrogenic, progestogenic, and androgenic properties that still carries an increased risk of **stroke** and **VTE**.- It is generally reserved for postmenopausal women (at least **one year** since the last period) and is not appropriate for someone with a high-risk thrombotic history.

Question 37: A 37-year-old woman presents for contraceptive advice. She has a history of breast cancer diagnosed at age 35, treated with lumpectomy, chemotherapy, and radiotherapy. She completed treatment 18 months ago and is currently taking tamoxifen. Recent scans show no evidence of recurrence. She is in a stable relationship and has two children. Her oncologist has confirmed she should avoid pregnancy. What is the most appropriate contraceptive recommendation?

A. Levonorgestrel intrauterine system as it provides local rather than systemic hormone exposure
B. Copper intrauterine device as it provides effective non-hormonal contraception (Correct Answer)
C. Etonogestrel subdermal implant as progestogen-only methods are safe in breast cancer
D. Barrier methods only due to absolute contraindication to all hormonal contraception
E. Female sterilization as she has completed her family

Explanation: ***Copper intrauterine device as it provides effective non-hormonal contraception*** - The **Copper IUD** is the most appropriate choice because it is categorized as **UKMEC 1**, meaning there are no restrictions on its use in patients with a history of **breast cancer**. - It provides highly effective, **long-acting, reversible contraception (LARC)** without the risk of **hormonal stimulation** of potentially residual cancer cells. *Levonorgestrel intrauterine system as it provides local rather than systemic hormone exposure* - Any hormonal method, including the **LNG-IUS**, is classified as **UKMEC 4** (unacceptable health risk) for patients with current or recent (within 5 years) **breast cancer**. - Despite primarily local action, some **systemic absorption** occurs, which is contraindicated due to the risk of stimulating **hormone-sensitive malignant cells**. *Etonogestrel subdermal implant as progestogen-only methods are safe in breast cancer* - Progestogen-only methods are not considered safe in this context; they are strictly **contraindicated** (UKMEC 4) in the setting of active or recent **breast cancer**. - The implant releases **systemic hormones** that could interfere with the patient's recovery or interact with the management of **hormone-receptor-positive** disease. *Barrier methods only due to absolute contraindication to all hormonal contraception* - While barrier methods are non-hormonal, they have a higher **typical-use failure rate** (~18%), which is risky given the oncological advice to strictly avoid pregnancy. - This recommendation is incorrect because the **Copper IUD** is a far more reliable non-hormonal alternative available to this patient. *Female sterilization as she has completed her family* - **Sterilization** is an invasive surgical procedure that carries unnecessary risks compared to the highly effective and non-invasive **Copper IUD**. - At age 37, a reversible method is often preferred over a permanent one in case the patient's clinical situation or **life goals change** in the future.

Question 38: A 54-year-old woman presents with recurrent urogenital symptoms including vaginal dryness, dyspareunia, and urinary frequency. She experienced natural menopause at age 51. She tried vaginal estrogen pessaries (estradiol 10 mcg) for 6 weeks but found them inconvenient and poorly tolerated. She has no significant past medical history and specifically wishes to avoid systemic hormone therapy. What is the most appropriate alternative management?

A. Vaginal estrogen cream (estriol 0.1%)
B. Vaginal dehydroepiandrosterone (prasterone) pessaries (Correct Answer)
C. Oral ospemifene
D. Systemic continuous combined HRT with monitoring
E. Vaginal moisturizers and lubricants alone

Explanation: ***Vaginal dehydroepiandrosterone (prasterone) pessaries*** - **Prasterone** is a synthetic **DHEA** that is converted intracellularly into **estrogens and androgens**, effectively treating **genitourinary syndrome of menopause (GSM)** without significant systemic absorption. - It is a suitable alternative for patients who find standard **estradiol pessaries** intolerable or ineffective and provides localized relief for both vaginal and **urinary symptoms**. *Vaginal estrogen cream (estriol 0.1%)* - While this is a **localized estrogen** therapy, the patient has already demonstrated intolerance to **estradiol pessaries**, making another form of vaginal estrogen less likely to be tolerated or preferred. - Creams are often perceived as **messier** and less convenient than other localized options, which may conflict with the patient's request for convenience. *Oral ospemifene* - Although **ospemifene** is a **selective estrogen receptor modulator (SERM)** specifically licensed for **dyspareunia**, it is an **oral medication** with systemic distribution. - The patient explicitly wishes to **avoid systemic therapy**, and this drug carries risks similar to HRT, such as an increased risk of **venous thromboembolism (VTE)**. *Systemic continuous combined HRT with monitoring* - This option contradicts the patient's specific preference to **avoid systemic hormone therapy** for her localized urogenital symptoms. - **Systemic HRT** is generally reserved for patients who also have vasomotor symptoms like **hot flashes**, which are not reported in this case. *Vaginal moisturizers and lubricants alone* - These are **non-hormonal** options that provide temporary relief for **dryness and dyspareunia** but do not treat the underlying **atrophy** of the vaginal and urethral tissues. - They are often insufficient for moderate-to-severe symptoms or **urinary frequency** associated with **vulvovaginal atrophy**.

Question 39: A 29-year-old woman with inflammatory bowel disease (Crohn's disease) predominantly affecting the terminal ileum and colon presents for contraceptive counselling. She underwent an ileocaecal resection 18 months ago and is currently in remission on azathioprine. She has no history of thromboembolism. Her BMI is 21 kg/m². She would like a highly effective contraceptive method. According to UKMEC criteria, which statement about contraceptive options is most accurate for this patient?

A. Combined oral contraceptive pill may have reduced efficacy due to malabsorption from bowel disease and should be avoided
B. The etonogestrel subdermal implant efficacy is unaffected by Crohn's disease and azathioprine therapy (Correct Answer)
C. Depot medroxyprogesterone acetate is contraindicated due to concerns about bone density in inflammatory bowel disease
D. The levonorgestrel intrauterine system is relatively contraindicated due to immunosuppression from azathioprine
E. Progesterone-only pills are less effective in patients with inflammatory bowel disease affecting the small bowel

Explanation: ***The etonogestrel subdermal implant efficacy is unaffected by Crohn's disease and azathioprine therapy*** - The **etonogestrel implant** is a Long-Acting Reversible Contraceptive (LARC) that bypasses the gastrointestinal tract, ensuring efficacy is maintained despite **malabsorption** or **small bowel resection**. - It is classified as **UKMEC 1** for patients with inflammatory bowel disease (IBD) and its metabolism is not impacted by **azathioprine**. *Combined oral contraceptive pill may have reduced efficacy due to malabsorption from bowel disease and should be avoided* - While absorption can be a concern in severe disease or significant malabsorption, the **UKMEC** classifies combined oral contraceptives as **Category 2** (benefits outweigh risks) for IBD patients in remission without major malabsorption. - The primary concern for **COCP** in IBD is the potentially increased risk of **venous thromboembolism (VTE)** during active flares, not solely reduced efficacy from malabsorption, and they are not completely avoided in remission. *Depot medroxyprogesterone acetate is contraindicated due to concerns about bone density in inflammatory bowel disease* - Injectable progestogens like **Depot medroxyprogesterone acetate (DMPA)** are **UKMEC 2** (benefits generally outweigh risks), not contraindicated. While they can cause a reversible reduction in **bone mineral density**, they are not forbidden unless the patient has specific high-risk factors for **osteoporosis** that are not present here. - In this patient (young, in remission, normal BMI), DMPA is an acceptable choice, although not the most highly effective LARC. *The levonorgestrel intrauterine system is relatively contraindicated due to immunosuppression from azathioprine* - The **levonorgestrel intrauterine system (LNG-IUS)** is classified as **UKMEC 2** for patients on immunosuppression; there is a theoretical, slight increase in the risk of infection, but the clinical benefits generally outweigh this risk, making it an acceptable option. - Immunosuppressive therapy like **azathioprine** does not represent a contraindication to the use of intrauterine devices or systems, which are highly effective LARCs. *Progesterone-only pills are less effective in patients with inflammatory bowel disease affecting the small bowel* - Although there are theoretical concerns regarding absorption in severe **malabsorption syndromes** or significant small bowel disease, the **UKMEC** still classifies **progesterone-only pills (POPs)** as **Category 2** for IBD. - POPs are considered a safe option, but due to potential absorption variability and the need for strict adherence, LARCs like the implant or IUS are often preferred for higher efficacy and reliability in patients with previous **bowel resections** or IBD.

Question 40: A 51-year-old woman commenced on continuous combined HRT (oral estradiol 1 mg with dydrogesterone 10 mg daily) 5 months ago for vasomotor symptoms. She presents with an episode of vaginal bleeding lasting 4 days which occurred 2 weeks ago and has now stopped. She has had no further bleeding since. Her last natural menstrual period was 16 months ago. She has no pain or other symptoms. What is the most appropriate initial management?

A. Reassure her that irregular bleeding is expected in the first 6 months of continuous combined HRT and review if bleeding persists beyond 6 months (Correct Answer)
B. Arrange urgent transvaginal ultrasound scan to assess endometrial thickness
C. Switch to sequential combined HRT regimen
D. Arrange outpatient hysteroscopy and endometrial biopsy
E. Stop HRT immediately and repeat assessment in 3 months

Explanation: ***Reassure her that irregular bleeding is expected in the first 6 months of continuous combined HRT and review if bleeding persists beyond 6 months*** - **Unscheduled bleeding** is a common and expected side effect in the initial **six months** of continuous combined HRT as the endometrium adapts to the constant hormone levels. - Given this is a single, self-limiting episode at 5 months into treatment and she is otherwise asymptomatic, **reassurance and observation** are the appropriate initial steps. *Arrange urgent transvaginal ultrasound scan to assess endometrial thickness* - While **transvaginal ultrasound (TVUS)** is a key investigation for **postmenopausal bleeding (PMB)**, it is generally not indicated for expected breakthrough bleeding within the first 6 months of HRT initiation. - An urgent scan would be considered if the bleeding was heavy, prolonged, or persisted beyond the initial adjustment period, none of which apply here. *Switch to sequential combined HRT regimen* - **Sequential combined HRT** is typically prescribed for **perimenopausal** women who have had a menstrual period within the last year, allowing for regular withdrawal bleeding. - This patient is 16 months post-menopause, making **continuous combined HRT** the appropriate regimen to avoid regular bleeds, and switching would likely reintroduce them. *Arrange outpatient hysteroscopy and endometrial biopsy* - **Hysteroscopy and endometrial biopsy** are invasive diagnostic procedures usually reserved for cases with persistent or abnormal bleeding, or when **TVUS** findings suggest endometrial pathology (e.g., endometrial thickness >4mm). - Performing these investigations for an isolated, self-limiting episode of bleeding within the expected adjustment phase of HRT is **premature and excessive**. *Stop HRT immediately and repeat assessment in 3 months* - Stopping HRT is unwarranted as the bleeding is likely a normal adjustment response, and she is benefiting from the treatment for her **vasomotor symptoms**. - Immediate cessation would lead to a likely return of her menopausal symptoms and does not align with current guidelines for managing initial HRT-related bleeding.

Question 41: A 46-year-old woman presents with worsening heavy menstrual bleeding and pelvic pain. She has a history of multiple uterine fibroids documented on ultrasound 2 years ago, the largest measuring 6 cm. She has completed her family and requests effective contraception that might also help with her bleeding. Her BMI is 32 kg/m². She has no history of thromboembolism and her blood pressure is 132/78 mmHg. Pelvic examination reveals a bulky uterus consistent with fibroids. What is the most appropriate contraceptive method for this patient?

A. Etonogestrel subdermal implant
B. Progesterone-only pill
C. Combined oral contraceptive pill
D. 52 mg levonorgestrel intrauterine system (Correct Answer)
E. Copper intrauterine device

Explanation: ***52 mg levonorgestrel intrauterine system*** - The **levonorgestrel intrauterine system (LNG-IUS)** is highly effective for managing **heavy menstrual bleeding (HMB)**, often reducing blood loss by 90% or more and can induce **amenorrhea**. - It provides reliable, long-term contraception and can alleviate pelvic pain associated with fibroids, provided the **uterine cavity** is not significantly distorted by the fibroids. *Combined oral contraceptive pill* - While combined oral contraceptives (COCs) can reduce menstrual bleeding and regulate cycles, they are generally less effective than the **LNG-IUS** for severe **HMB** and do not directly address the mass effect of fibroids. - The patient's **BMI of 32 kg/m²** slightly increases potential cardiovascular risks with COCs, though her blood pressure is currently well-controlled. *Copper intrauterine device* - The **copper IUD** is contraindicated in patients with **heavy menstrual bleeding** as it is known to increase both menstrual blood loss and **dysmenorrhea**, which would worsen the patient's symptoms. - It offers only contraception and provides no therapeutic benefit for **fibroid-related bleeding** or pelvic pain. *Etonogestrel subdermal implant* - The implant offers effective contraception but its effect on **heavy menstrual bleeding** is variable; it can cause irregular bleeding or amenorrhea, but is less predictable than the **LNG-IUS** for significant flow reduction. - It does not exert the same localized **endometrial suppression** that is key to managing fibroid-related **menorrhagia** effectively. *Progesterone-only pill* - The **progesterone-only pill (POP)** provides contraception and may reduce bleeding for some, but it is less efficacious than the **LNG-IUS** for treating severe **HMB** associated with uterine fibroids. - It requires strict daily adherence and its impact on **pelvic pain** and fibroid growth is not as significant or consistent compared to the localized effect of the LNG-IUS.

Question 42: What is the recommended approach to progestogen therapy in women using estrogen-only hormone replacement therapy who have an intact uterus?

A. Progestogen should be given for at least 10 days per month if using cyclical combined HRT (Correct Answer)
B. Progestogen protection is not required if using transdermal estrogen
C. Progestogen can be omitted if using low-dose estrogen therapy
D. Progestogen is only required in the first year of HRT therapy
E. Progestogen should be given continuously if more than 5 years post-menopause

Explanation: ***Progestogen should be given for at least 10 days per month if using cyclical combined HRT*** - In women with an **intact uterus**, systemic estrogen therapy without progestogen leads to **unopposed endometrial stimulation**, significantly increasing the risk of **endometrial hyperplasia** and **carcinoma**. - Guidelines recommend progestogen for at least **12-14 days** (with a minimum of **10 days**) per cycle to ensure effective shedding of the endometrial lining and minimize cancer risk. *Progestogen protection is not required if using transdermal estrogen* - Regardless of whether estrogen is administered **transdermally** or **orally**, the systemic levels reach the uterus and cause endometrial proliferation. - Progestogen remains mandatory for all forms of **systemic HRT** when the uterus is intact to prevent malignant transformation. *Progestogen can be omitted if using low-dose estrogen therapy* - Even **low-dose estrogen** can stimulate the endometrium enough to cause hyperplasia over time, making omission unsafe. - Only **vaginal low-dose estrogen** used for local atrophy symptoms typically does not require a progestogen; all **systemic doses** do. *Progestogen is only required in the first year of HRT therapy* - Endometrial protection must be maintained for the **entire duration** of systemic estrogen use, as the risk of hyperplasia persists as long as estrogen is taken. - Discontinuing progestogen while continuing estrogen at any point would leave the endometrium **unopposed** and vulnerable. *Progestogen should be given continuously if more than 5 years post-menopause* - While **continuous combined HRT** is often preferred in post-menopausal women to avoid withdrawal bleeds, it is not a requirement based strictly on a 5-year timeline. - The choice between **cyclical** and **continuous** regimens depends on the woman's preference and menopausal status, but progestogen is required in both for endometrial safety.

Question 43: A 33-year-old woman presents 84 hours after unprotected sexual intercourse requesting emergency contraception. She has a regular 28-day menstrual cycle and estimates she is on day 14 of her cycle. She weighs 72 kg with a BMI of 26 kg/m². She takes no regular medications and has no contraindications to hormonal contraception. She has no previous history of ectopic pregnancy. What is the most appropriate emergency contraception to offer?

A. Ulipristal acetate 30 mg as a single dose
B. Copper intrauterine device insertion (Correct Answer)
C. Combined oral contraceptive (Yuzpe method)
D. Levonorgestrel 1.5 mg as a single dose
E. Levonorgestrel 3 mg (double dose) as a single dose

Explanation: ***Copper intrauterine device insertion***- The **copper IUD** is the most effective method of emergency contraception and can be inserted up to **120 hours (5 days)** after unprotected intercourse, or within 5 days of the earliest predicted **ovulation**.- Given the patient is at **84 hours** post-intercourse and likely in the **periovulatory period** (day 14), the IUD offers superior efficacy compared to hormonal methods that primarily delay ovulation.*Ulipristal acetate 30 mg as a single dose*- While effective for up to **120 hours**, its efficacy can be reduced if **ovulation** is already imminent or has occurred, which is a strong possibility on day 14 of a regular cycle.- It is generally less effective than the **copper IUD** and should not be offered as a first-line alternative when an IUD can be fitted.*Combined oral contraceptive (Yuzpe method)*- This method involves high doses of **estrogen and progestin**, and is significantly less effective and associated with a higher incidence of **nausea and vomiting** compared to newer options.- It is generally **outdated** and not recommended as a primary emergency contraception choice when more effective and better-tolerated methods are available.*Levonorgestrel 1.5 mg as a single dose*- This hormonal emergency contraceptive is licensed and most effective when taken within **72 hours (3 days)** of unprotected intercourse.- The patient has presented at **84 hours**, falling outside the recommended and most effective time window for **levonorgestrel**.*Levonorgestrel 3 mg (double dose) as a single dose*- A double dose of **levonorgestrel** (3 mg) is considered for women with a **BMI >26 kg/m²** or weight **>70 kg** due to potential reduced efficacy at standard doses, which applies to this patient (72kg, BMI 26).- However, similar to the standard dose, its efficacy is time-dependent and significantly reduced or absent when taken **84 hours** after intercourse, well past the **72-hour** window.

Question 44: A 58-year-old woman presents for review of her hormone replacement therapy. She had a total hysterectomy for stage 1 endometrial carcinoma at age 55, treated with surgery alone. She has been taking estrogen-only HRT (transdermal estradiol 50 mcg patches) for 2 years for troublesome vasomotor symptoms which have now completely resolved. She is concerned about continuing HRT given her history. What is the most appropriate management?

A. Switch to continuous combined HRT for endometrial protection
B. Discuss discontinuation of HRT given cancer history and symptom resolution (Correct Answer)
C. Continue current HRT indefinitely as she has had a hysterectomy
D. Add cyclical progesterone to current estrogen therapy
E. Increase estradiol dose to 75 mcg patches for better symptom control

Explanation: ***Discuss discontinuation of HRT given cancer history and symptom resolution*** - This patient's **vasomotor symptoms** have completely resolved, eliminating the primary indication for HRT, which should always be used at the **lowest effective dose** for the shortest duration. - Given her history of **stage 1 endometrial carcinoma**, an **estrogen-sensitive malignancy**, continuing HRT introduces an unnecessary risk of recurrence that outweighs any benefit, making discontinuation the most appropriate management. *Switch to continuous combined HRT for endometrial protection* - The patient has undergone a **total hysterectomy**, meaning she no longer has a uterus or **endometrium**, so there is no need for progesterone to provide endometrial protection. - Adding progesterone would expose her to unnecessary medication and potential **side effects** without providing any therapeutic or protective benefit in this context. *Continue current HRT indefinitely as she has had a hysterectomy* - HRT, even estrogen-only, is associated with long-term risks such as **venous thromboembolism (VTE)** and possibly breast cancer, and should not be continued indefinitely without clear indication. - Indefinite HRT use is particularly cautioned in individuals with a history of **estrogen-dependent cancers**, regardless of hysterectomy status, due to increased risk. *Add cyclical progesterone to current estrogen therapy* - **Cyclical progesterone** is used to induce withdrawal bleeds and protect the endometrium in women with an intact uterus; it serves no purpose after a **total hysterectomy**. - Introducing progesterone would add potential **side effects** (e.g., bloating, mood changes) without offering any clinical benefit for this patient. *Increase estradiol dose to 75 mcg patches for better symptom control* - Increasing the dose is inappropriate as the patient's **vasomotor symptoms** have already completely resolved, indicating that the current dose is sufficient. - A higher dose of **transdermal estradiol** would unnecessarily increase systemic estrogen exposure, which is particularly concerning given her prior **estrogen-dependent endometrial carcinoma**.

Question 45: A 40-year-old woman with well-controlled hypertension on amlodipine presents requesting contraception. She has a BMI of 28 kg/m², smokes 12 cigarettes daily, and is in a stable relationship. Her blood pressure today is 138/86 mmHg. She prefers a method that does not require daily compliance. On examination, cardiovascular and abdominal examinations are unremarkable. What is the most appropriate contraceptive method to recommend?

A. Progesterone-only pill
B. Combined transdermal patch
C. Depot medroxyprogesterone acetate injection
D. Combined oral contraceptive pill
E. Copper intrauterine device (Correct Answer)

Explanation: ***Copper intrauterine device*** - This method is a **long-acting reversible contraceptive (LARC)**, directly addressing the patient's preference for a method that does not require **daily compliance**. - As a **non-hormonal** option, it is ideal for women with **cardiovascular risk factors** such as hypertension and smoking, as it avoids the risks associated with estrogen. *Progesterone-only pill* - While generally safe for patients with **hypertension** and **smoking history**, this method requires **daily adherence**. - It does not meet the patient's specific request for a contraceptive method that does not require **daily compliance**. *Combined transdermal patch* - This method contains **estrogen**, which is generally contraindicated in women over **35 years old** who **smoke** due to increased **cardiovascular risks**. - The combination of age (40), smoking (12 cigarettes daily), and hypertension significantly elevates the risk of **thrombotic events** like VTE, stroke, and MI. *Depot medroxyprogesterone acetate injection* - Although it's a long-acting method, it can cause **delayed return to fertility** after discontinuation, which may be a consideration for some women. - Long-term use of DMPA is associated with a potential decrease in **bone mineral density**, though it usually recovers after cessation. *Combined oral contraceptive pill* - This option contains **estrogen** and is **contraindicated** in women over **35 years old** who **smoke**, particularly with **hypertension**. - The elevated risk of **venous thromboembolism**, myocardial infarction, and **ischemic stroke** makes this an unsafe choice for this patient.

Question 46: A 52-year-old woman who has been taking sequential combined HRT for 11 months reports that her withdrawal bleeds have become very heavy over the past 3 cycles, lasting 7-8 days with passage of clots. She started HRT for vasomotor symptoms and her last spontaneous period was 14 months ago. Pelvic examination is normal and she has no intermenstrual bleeding or postcoital bleeding. What is the most appropriate next step?

A. Switch to continuous combined HRT as she is >12 months post-menopause
B. Reassure that heavy withdrawal bleeds are normal with sequential HRT and continue current regimen
C. Arrange transvaginal ultrasound and consider endometrial sampling before changing HRT (Correct Answer)
D. Add tranexamic acid during withdrawal bleeds to reduce heaviness
E. Increase the duration of progestogen phase to 21 days per cycle

Explanation: ***Arrange transvaginal ultrasound and consider endometrial sampling before changing HRT*** - The patient's report of **progressively heavy withdrawal bleeds** lasting longer with clots, after 11 months on sequential HRT, constitutes an **abnormal bleeding pattern** requiring prompt investigation. - This change necessitates ruling out **endometrial pathology** such as **hyperplasia** or **carcinoma**, which is best achieved through a **transvaginal ultrasound** to assess endometrial thickness and potentially **endometrial sampling** to obtain tissue for histological evaluation. *Switch to continuous combined HRT as she is >12 months post-menopause* - While she is technically post-menopausal (last spontaneous period 14 months ago), switching to continuous combined HRT without investigating the **new-onset heavy bleeding** could mask an underlying serious pathology. - Any **unexplained or new-onset abnormal uterine bleeding (AUB)** in a post-menopausal woman, even one on HRT, warrants a thorough **diagnostic workup** before making changes to the treatment regimen. *Reassure that heavy withdrawal bleeds are normal with sequential HRT and continue current regimen* - While sequential HRT causes withdrawal bleeds, they should be **predictable and generally stable**; heavy bleeding with clots that has become worse over recent cycles is not considered normal and requires investigation. - Reassurance without investigation risks missing significant **endometrial pathology**, which is a crucial consideration in a 52-year-old woman presenting with abnormal bleeding. *Add tranexamic acid during withdrawal bleeds to reduce heaviness* - **Tranexamic acid** is a symptomatic treatment for heavy menstrual bleeding; however, it does not address the underlying cause of the **abnormal bleeding pattern** observed in this patient. - Providing symptomatic relief without a **diagnostic workup** would be inappropriate, as it could delay the diagnosis of a serious underlying condition such as **endometrial cancer**. *Increase the duration of progestogen phase to 21 days per cycle* - Increasing the **progestogen phase duration** is sometimes considered to provide better endometrial protection or manage unscheduled bleeding, but it is not the initial diagnostic step for **new-onset heavy withdrawal bleeding**. - The priority is to **diagnose the cause** of the abnormal bleeding through appropriate investigations before making empirical adjustments to the HRT regimen.

Question 47: A 35-year-old woman with a BMI of 41 kg/m² presents 50 hours after unprotected sexual intercourse requesting emergency contraception. She has a regular 28-day cycle and her last period started 11 days ago. She has no contraindications to any form of emergency contraception and is keen for the most effective option. What is the most appropriate management?

A. Prescribe ulipristal acetate 30 mg as a single dose
B. Prescribe levonorgestrel 3 mg as a double dose
C. Insert copper intrauterine device immediately (Correct Answer)
D. Prescribe ulipristal acetate 60 mg as a double dose
E. Advise she is outside the window for emergency contraception

Explanation: ***Insert copper intrauterine device immediately***- The **copper intrauterine device (Cu-IUD)** is the **most effective form of emergency contraception** (failure rate <0.1%) and its efficacy is **not affected by body weight or BMI**.- It can be inserted up to **5 days (120 hours) after unprotected intercourse**, or up to 5 days after the earliest estimated date of **ovulation**, making it ideal for this patient on day 11 of her cycle and 50 hours post-coitus.*Prescribe ulipristal acetate 30 mg as a single dose*- While **ulipristal acetate (UPA)** is more effective than levonorgestrel, its efficacy is significantly **reduced in women with a BMI >30 kg/m²**.- It acts by **delaying ovulation**, but since the patient is keen for the **most effective option**, the Cu-IUD takes priority over oral methods, especially given her BMI.*Prescribe levonorgestrel 3 mg as a double dose*- **Levonorgestrel (LNG)** is significantly **less effective** than UPA or the copper IUD, especially when administered after **72 hours** (this patient is at 50 hours) and in patients with high BMI.- Although a **double dose** (3 mg) is sometimes used for women taking enzyme-inducing drugs, it is not the primary recommendation for **obesity** when more effective options like the Cu-IUD are available.*Prescribe ulipristal acetate 60 mg as a double dose*- There is currently **no clinical evidence or guideline** supporting a **double dose of ulipristal acetate** for patients with a high BMI.- Recommending an unproven higher dose is inappropriate when the **gold standard (Cu-IUD)** is a viable and available option, offering superior and proven efficacy.*Advise she is outside the window for emergency contraception*- This is incorrect as the patient is only **50 hours** post-intercourse; oral options are licensed for at least **72 to 120 hours**.- The **Cu-IUD** can be inserted up to **120 hours** (5 days) after the event, meaning she is well within the effective window for all available emergency contraception methods.

Question 48: A 47-year-old woman with regular menstrual cycles presents with troublesome vasomotor symptoms affecting her work and sleep. She requests HRT. Her mother had breast cancer diagnosed at age 72. She has a BMI of 28 kg/m², blood pressure 132/84 mmHg, and no other medical history. How should her family history of breast cancer influence prescribing HRT?

A. HRT can be prescribed but duration should be limited to maximum 2 years
B. Genetic testing for BRCA mutations is mandatory before prescribing HRT
C. HRT is absolutely contraindicated due to family history
D. HRT can be prescribed but should be oestrogen-only to reduce breast cancer risk
E. Family history increases baseline risk but HRT can be prescribed with informed consent after discussion of risks and benefits (Correct Answer)

Explanation: ***Family history increases baseline risk but HRT can be prescribed with informed consent after discussion of risks and benefits***- A single first-degree relative diagnosed with **breast cancer after age 70** indicates a moderate increase in baseline risk, but this is **not an absolute contraindication** to Hormone Replacement Therapy (HRT).- Prescribing decisions should be individualized, focusing on **informed consent** and balancing **vasomotor symptom relief** against the duration-dependent increase in breast cancer risk associated with combined HRT.*HRT can be prescribed but duration should be limited to maximum 2 years*- There is no evidence-based **arbitrary time limit** for HRT; duration should be determined by the persistence of symptoms and regular **risk-benefit reassessment**.- While risk increases with duration, setting a strict 2-year cutoff may lead to under-treatment of **vasomotor symptoms** and return of morbidity.*Genetic testing for BRCA mutations is mandatory before prescribing HRT*- **Genetic testing** is only indicated if the family history suggests a **hereditary syndrome**, such as multiple relatives affected, bilateral disease, or diagnosis at an **age <50**.- A single relative diagnosed at age 72 does not meet the clinical criteria for **BRCA mutation** screening or mandatory pre-HRT testing.*HRT is absolutely contraindicated due to family history*- Family history is a risk factor, not an **absolute contraindication**; a personal history of breast cancer would be a contraindication.- According to **NICE guidelines**, women with a family history can still access HRT if the impact on **quality of life** outweighs the risks after thorough counseling.*HRT can be prescribed but should be oestrogen-only to reduce breast cancer risk*- **Oestrogen-only HRT** is only appropriate for women who have had a **hysterectomy**; this patient has regular menstrual cycles and requires the addition of a **progestogen** for endometrial protection.- Using oestrogen-only therapy in a woman with an **intact uterus** significantly increases the risk of **endometrial hyperplasia** and carcinoma.

Question 49: A 39-year-old nulliparous woman requests contraception. She had a pulmonary embolism 5 years ago during long-haul air travel and completed 6 months of anticoagulation. Thrombophilia screening at the time was negative. She is not currently on any anticoagulation. Her BMI is 25 kg/m² and blood pressure is 122/78 mmHg. What is the classification of combined hormonal contraception for this woman according to UK Medical Eligibility Criteria?

A. UKMEC 1 - no restriction on use
B. Cannot be classified without repeat thrombophilia screening
C. UKMEC 2 - benefits generally outweigh risks
D. UKMEC 3 - risks usually outweigh benefits
E. UKMEC 4 - unacceptable health risk (Correct Answer)

Explanation: ***UKMEC 4 - unacceptable health risk*** - A personal history of **venous thromboembolism (VTE)**, specifically a **pulmonary embolism**, regardless of being provoked or having negative thrombophilia screening, is classified as **UKMEC 4** for combined hormonal contraception (CHC). - The **oestrogen** component in CHC significantly increases the risk of recurrent thrombosis, making its use an unacceptable health risk for this woman. *UKMEC 1 - no restriction on use* - This category is for individuals with no medical conditions that pose a risk with the contraceptive method. - A history of **pulmonary embolism** is a severe contraindication for oestrogen-containing contraception, directly contradicting UKMEC 1 classification. *Cannot be classified without repeat thrombophilia screening* - The UKMEC classification for combined hormonal contraception in individuals with a history of VTE is primarily based on the **clinical event** itself. - A negative **thrombophilia screen**, either prior or repeated, does not alter the **UKMEC 4** classification due to the inherent risk associated with a past VTE event and oestrogen. *UKMEC 2 - benefits generally outweigh risks* - This category applies to conditions where the advantages of using the method generally outweigh the theoretical or proven risks. - While other contraceptive methods, such as **progestogen-only pills**, might be UKMEC 2 for this patient, combined hormonal contraception carries a much higher, unacceptable risk for those with a history of VTE. *UKMEC 3 - risks usually outweigh benefits* - This classification is for conditions where the theoretical or proven risks usually outweigh the advantages of using the method. - A personal history of **pulmonary embolism** elevates the risk for combined hormonal contraception to the highest category of **UKMEC 4**, indicating an unacceptable health risk, rather than just risks usually outweighing benefits.

Question 50: A 56-year-old woman with primary ovarian insufficiency diagnosed at age 35 has been taking HRT continuously. She is currently on transdermal oestradiol 100 mcg patches and micronised progesterone 100 mg daily. She asks when she can stop HRT. What is the most appropriate advice regarding duration of HRT in this context?

A. Stop immediately as she has passed the average age of natural menopause
B. Continue at least until age 51-52 (average age of natural menopause) and then review (Correct Answer)
C. Continue lifelong due to early menopause
D. Continue until age 60 and then reassess
E. Reduce dose by 50% now and stop completely at age 60

Explanation: ***Continue at least until age 51-52 (average age of natural menopause) and then review***- Women with **Primary Ovarian Insufficiency (POI)** should be advised to take **HRT** until the average age of natural menopause to replace physiological hormone levels.- This duration is crucial for the **prevention of osteoporosis**, **cardiovascular protection**, and maintaining cognitive function, as benefits significantly outweigh risks in this demographic.*Stop immediately as she has passed the average age of natural menopause*- The patient is currently **56 years old**, meaning she has already reached the average age of natural menopause; however, stopping should be a shared decision based on a **risk-benefit review** rather than an immediate mandate.- Abruptly stopping without review can lead to a return of **vasomotor symptoms** and a rapid decline in **bone mineral density**.*Continue lifelong due to early menopause*- While some women choose to continue HRT longer, **lifelong therapy** is not a universal requirement and must be balanced against individual risks like **breast cancer** or thromboembolism as the patient ages.- Current guidelines recommend a **reassessment** at the age of natural menopause rather than committing to lifelong treatment from the outset.*Continue until age 60 and then reassess*- Age 60 is a common milestone for reassessing HRT in standard menopause, but it is not the standard clinical benchmark for defining the **minimum duration** for POI patients.- Clinical practice focuses on the **age of natural menopause (51-52)** as the primary target for physiological replacement before moving to symptom-based management.*Reduce dose by 50% now and stop completely at age 60*- There is no clinical evidence supporting a mandatory **tapering protocol** specifically at age 56 for women who experienced POI.- Dose reduction should be based on **symptom control** and patient preference rather than an arbitrary age-based percentage cut.

Question 51: A 28-year-old woman with well-controlled focal epilepsy on lamotrigine 200 mg daily presents requesting contraception. She is in a stable relationship and does not wish to conceive for at least 3 years. She has no other medical conditions and has a BMI of 23 kg/m². Which contraceptive method requires the most careful consideration due to potential drug interactions?

A. Copper intrauterine device
B. Desogestrel progestogen-only pill
C. Levonorgestrel intrauterine system
D. Etonogestrel subdermal implant
E. Combined oral contraceptive pill (Correct Answer)

Explanation: ***Combined oral contraceptive pill*** - Use of **ethinylestradiol** induces the **glucuronidation** of **lamotrigine**, which can significantly decrease lamotrigine serum concentrations by up to 50%, risking a loss of **seizure control**. - This interaction is **bidirectional** and complex; during the **pill-free interval**, lamotrigine levels can rise rapidly, potentially leading to **toxicity** (e.g., ataxia, diplopia). *Copper intrauterine device* - This is a **non-hormonal** method and does not interact with any **anti-epileptic drugs**, including lamotrigine. - It is classified as **UKMEC 1** for patients with epilepsy, making it a safe and highly effective long-term option. *Desogestrel progestogen-only pill* - Unlike estrogen, **progestogens** do not significantly induce the metabolism of **lamotrigine**, so they do not lower the seizure threshold. - As lamotrigine is not a **liver enzyme inducer**, it does not decrease the efficacy of the **progestogen-only pill**. *Levonorgestrel intrauterine system* - The **LNG-IUS** acts primarily locally and does not have a clinically significant interaction with **lamotrigine** metabolism. - It is a preferred **Long-Acting Reversible Contraceptive (LARC)** for women on lamotrigine due to its high efficacy and safety profile (**UKMEC 1**). *Etonogestrel subdermal implant* - The **subdermal implant** efficacy is not affected by **lamotrigine** because lamotrigine does not induce **cytochrome P450 enzymes**. - There is no evidence that the etonogestrel implant significantly reduces **lamotrigine plasma levels**, unlike estrogen-containing methods.

Question 52: A 54-year-old woman who has been taking continuous combined HRT (transdermal oestradiol 50 mcg and micronised progesterone 100 mg) for 14 months presents with a single episode of vaginal bleeding lasting 2 days. Her last menstrual period was 3 years ago. She has no abdominal pain or other symptoms. What is the most appropriate initial management?

A. Reassure and continue current HRT regimen with review in 3 months
B. Switch to sequential combined HRT to regulate bleeding
C. Refer for urgent transvaginal ultrasound and consider endometrial sampling (Correct Answer)
D. Stop HRT immediately and review in 6 weeks
E. Increase progesterone dose to 200 mg daily

Explanation: ***Refer for urgent transvaginal ultrasound and consider endometrial sampling***- Any unscheduled vaginal bleeding occurring after the initial **6 months** of **continuous combined HRT** must be investigated as **postmenopausal bleeding (PMB)** due to the risk of endometrial pathology.- An **urgent transvaginal ultrasound** is the first-line investigation to assess **endometrial thickness**, and **endometrial sampling** may be needed to exclude **endometrial hyperplasia** or **malignancy**.*Reassure and continue current HRT regimen with review in 3 months*- Bleeding is only considered normal or expected during the initial **3 to 6-month settling-in period** of starting HRT.- Delaying investigation for a patient on HRT for **14 months** with unscheduled bleeding carries a risk of missing a significant diagnosis such as **endometrial cancer**.*Switch to sequential combined HRT to regulate bleeding*- Sequential HRT is typically used in **perimenopausal** women, whereas this patient is **3 years post-menopause**.- Changing the HRT regimen would mask symptoms and delay the necessary investigation of the **endometrial lining** for any underlying pathology.*Stop HRT immediately and review in 6 weeks*- Stopping HRT does not provide a diagnosis and neglects the critical need to visualize the **uterus** and **endometrium**.- Clinical guidelines prioritize **timely investigation** (often a 2-week wait referral) rather than observing if the bleeding resolves spontaneously.*Increase progesterone dose to 200 mg daily*- While insufficient progesterone can sometimes cause breakthrough bleeding, **endometrial pathology** must be ruled out first in a patient with unscheduled bleeding on long-term HRT.- Increasing the progesterone dose without a prior **transvaginal ultrasound** or biopsy would be inappropriate management for potential **postmenopausal bleeding**.

Question 53: A 32-year-old woman presents 72 hours after unprotected sexual intercourse requesting emergency contraception. She has a BMI of 34 kg/m² and a regular 28-day menstrual cycle. Her last menstrual period started 12 days ago. She takes no regular medications. Which emergency contraception option provides the highest efficacy for her?

A. Ulipristal acetate 30 mg combined with levonorgestrel 1.5 mg
B. Levonorgestrel 1.5 mg single dose
C. Ulipristal acetate 30 mg single dose
D. Copper intrauterine device insertion (Correct Answer)
E. Levonorgestrel 3 mg double dose due to high BMI

Explanation: ***Copper intrauterine device insertion***- The **copper IUD** is the most effective form of emergency contraception, with a failure rate of **less than 0.1%**, and its efficacy is not affected by a high **BMI**.- It can be inserted up to **5 days** after unprotected sexual intercourse or up to 5 days after the **earliest estimated date of ovulation**, making it the superior choice in this scenario.*Ulipristal acetate 30 mg combined with levonorgestrel 1.5 mg*- Combining these two hormonal methods is **not evidence-based** and is clinically contraindicated because they can **antagonize** each other's effects.- Progestogens (like levonorgestrel) can reduce the effectiveness of **ulipristal acetate**, which is a selective progesterone receptor modulator.*Levonorgestrel 1.5 mg single dose*- This method has significantly **reduced efficacy** in women with a **BMI over 26 kg/m²** or weight over 70kg; this patient has a BMI of 34 kg/m².- It is generally most effective when taken within **72 hours**, but it is less effective than ulipristal or the IUD even within that window.*Ulipristal acetate 30 mg single dose*- While more effective than oral levonorgestrel up to **120 hours** post-intercourse, its efficacy is likely **diminished** in women with a **BMI ≥30 kg/m²**.- It works by delaying ovulation, but since this patient is on **day 12** of a 28-day cycle, she may be in the **LH surge** phase where ulipristal is no longer effective.*Levonorgestrel 3 mg double dose due to high BMI*- Although some guidelines suggest doubling the dose for a high BMI if an IUD is unavailable, it is still **less effective** than the **copper IUD**.- Research indicates that even a double dose of levonorgestrel does not achieve the same efficacy in **obese women** as a standard dose does in women with a normal BMI.

Question 54: What is the recommended window for starting progestogen-only contraception postpartum in a non-breastfeeding woman to ensure immediate contraceptive protection without requiring additional precautions?

A. Within 24 hours of delivery
B. Within 48 hours of delivery
C. On day 21 postpartum (Correct Answer)
D. On day 28 postpartum
E. Within 6 weeks postpartum

Explanation: ***On day 21 postpartum*** - Starting **progestogen-only contraception** up to and including **day 21** after delivery provides immediate contraceptive protection because ovulation is unlikely to occur before this time. - This window applies to both breastfeeding and non-breastfeeding women, serving as the standard threshold for requiring **additional precautions** (such as condoms) if started later. *Within 24 hours of delivery* - While **progestogen-only methods** can be safely started immediately after birth, they are not strictly required this early as the risk of **conception** is negligible before day 21. - Starting at this time is safe but is not the specific "limit" for ensuring **immediate protection** without additional backup methods. *Within 48 hours of delivery* - Similar to the 24-hour mark, starting within **48 hours** is medically safe (UKMEC 1 or 2) but does not represent the end of the window for **immediate coverage**. - It is often recommended for convenience before discharge, but the **21-day rule** remains the physiological cutoff for immediate efficacy. *On day 28 postpartum* - If progestogen-only contraception is started after **day 21**, immediate protection is no longer guaranteed, and **barrier methods** are required for a short period. - For **progestogen-only pills (POP)**, additional precautions are needed for **2 days**, whereas for the **injectable**, they are needed for **7 days** if started at this stage. *Within 6 weeks postpartum* - The **6-week** mark is relevant for **combined hormonal contraception (CHC)** to reduce the risk of **venous thromboembolism (VTE)**, but it is not the threshold for progestogen-only methods. - Waiting until **6 weeks** would leave the patient at risk of pregnancy if they have already resumed sexual activity after **day 21 postpartum**.

Question 55: A 44-year-old woman with menorrhagia has been using a 52 mg levonorgestrel IUS for 18 months with good symptom control. She now presents with a 4-week history of persistent intermenstrual bleeding. Examination reveals the IUS threads are visible and the cervix appears normal. A high vaginal swab shows no evidence of infection. What is the most appropriate next step in management?

A. Remove and replace the levonorgestrel IUS
B. Reassure and review in 3 months
C. Perform transvaginal ultrasound scan to check device position and exclude structural pathology (Correct Answer)
D. Remove the device and commence combined oral contraceptive pill
E. Add oral tranexamic acid to reduce bleeding

Explanation: ***Perform transvaginal ultrasound scan to check device position and exclude structural pathology*** - In a patient who previously had good symptom control, a new onset of **persistent intermenstrual bleeding** after 18 months warrants investigation to exclude **structural pathology** (e.g., polyps, fibroids, endometrial hyperplasia) or **device displacement**. - **Transvaginal ultrasound (TVUS)** is the most appropriate initial investigation as it can confirm the **IUS position** and effectively screen for any **uterine or endometrial abnormalities**. *Remove and replace the levonorgestrel IUS* - Replacing the device without first identifying the cause of the new bleeding change risks recurrence of symptoms if an underlying **pathological cause** is present, rather than just device malfunction or age. - This step should only be considered if the current IUS is confirmed to be **malpositioned** or when its lifespan primarily expires after 5–8 years. *Reassure and review in 3 months* - While irregular spotting is common in the first **3-6 months** of IUS use, new onset **persistent intermenstrual bleeding** after long-term stability is atypical and requires active investigation. - Delaying evaluation of new onset bleeding in a 44-year-old woman carries the risk of missing significant **structural abnormalities** or endometrial changes that require prompt attention. *Remove the device and commence combined oral contraceptive pill* - The IUS was providing effective control for **menorrhagia**; removing it prematurely without a diagnosis may lead to a recurrence of heavy menstrual bleeding. - The **combined oral contraceptive pill** may manage bleeding, but it does not replace the need to exclude secondary causes via **ultrasound** and could mask important diagnostic clues. *Add oral tranexamic acid to reduce bleeding* - **Tranexamic acid** is primarily used for **heavy menstrual bleeding** rather than **intermenstrual bleeding**, and it does not facilitate a diagnosis for the change in bleeding pattern. - Using it here would only mask symptoms without addressing potential **structural causes** or **IUS malposition**, which could delay appropriate management.

Question 56: A 50-year-old woman presents requesting HRT for moderate vasomotor symptoms. Her last menstrual period was 8 months ago. She has a BMI of 24 kg/m², blood pressure 118/76 mmHg, and no significant medical history. She still has her uterus and both ovaries. What is the most appropriate initial HRT regimen?

A. Continuous combined oestrogen and progestogen HRT
B. Oestrogen-only HRT
C. Sequential combined HRT with 10 days of progestogen per month
D. Sequential combined HRT with 14 days of progestogen per month (Correct Answer)
E. Tibolone 2.5 mg daily

Explanation: ***Sequential combined HRT with 14 days of progestogen per month*** - This patient is **perimenopausal** (last period 8 months ago) and has an **intact uterus**, requiring a sequential regimen to prevent irregular bleeding and ensure **endometrial protection**. - A minimum of **12 to 14 days** of progestogen per month is necessary in sequential regimens to adequately reduce the risk of **endometrial hyperplasia**. *Continuous combined oestrogen and progestogen HRT* - This regimen is indicated only for women who are **postmenopausal**, defined as at least **12 months** since their last menstrual period. - Starting this too early in the perimenopausal transition often leads to problematic and unpredictable **breakthrough bleeding**. *Oestrogen-only HRT* - This is strictly reserved for women who have undergone a **hysterectomy** (no uterus). - Using unopposed oestrogen in a woman with a uterus significantly increases the risk of **endometrial carcinoma**. *Sequential combined HRT with 10 days of progestogen per month* - Clinical guidelines recommend a minimum of **12 days** of progestogen exposure to effectively transform the endometrium. - Using only **10 days** provides suboptimal protection against the development of **endometrial hyperplasia**. *Tibolone 2.5 mg daily* - Tibolone is a synthetic steroid with oestrogenic, progestogenic, and androgenic properties indicated for **postmenopausal** women. - Like continuous combined HRT, it should only be started at least **one year after** the last menstrual period to avoid irregular bleeding.

Question 57: A 41-year-old woman attends for review 6 months after insertion of a levonorgestrel intrauterine system for contraception and heavy menstrual bleeding. She reports absent periods for the last 3 months and is very concerned about pregnancy. She has not experienced any other symptoms. A urine pregnancy test is negative. What is the most appropriate advice?

A. Remove the device immediately and perform ultrasound scan to exclude pregnancy
B. Arrange urgent blood test for serum beta-hCG
C. Reassure that amenorrhoea is a common and expected effect of the levonorgestrel IUS (Correct Answer)
D. Arrange pelvic ultrasound to check device position
E. Advise additional barrier contraception for the next 3 months

Explanation: ***Reassure that amenorrhoea is a common and expected effect of the levonorgestrel IUS*** - **Amenorrhoea** is a common side effect of the **levonorgestrel intrauterine system (LNG-IUS)**, occurring in approximately 20% of users as the local progestogen suppresses and thins the **endometrium**. - Given the **negative pregnancy test** and lack of other symptoms, no further investigation is needed as the device is highly effective with a failure rate of <0.2%.*Remove the device immediately and perform ultrasound scan to exclude pregnancy* - **Device removal** is unnecessary and contraindicated here, as it would leave the patient without contraception and lose the therapeutic benefit for her **heavy menstrual bleeding**. - A **urine pregnancy test** is highly sensitive 3 months after missed periods, making a routine ultrasound to exclude pregnancy redundant.*Arrange urgent blood test for serum beta-hCG* - There is no clinical indication for an **urgent serum beta-hCG** when a urine pregnancy test is negative and the patient is asymptomatic. - This intervention would cause unnecessary anxiety and utilize healthcare resources for an expected side effect of the **progestogen**.*Arrange pelvic ultrasound to check device position* - An **ultrasound** for position check is only indicated if the **threads are not visible**, there is persistent pain, or abnormal bleeding patterns occur. - **Amenorrhoea** is a hormonal effect on the uterine lining and does not suggest that the device has displaced or failed.*Advise additional barrier contraception for the next 3 months* - The **LNG-IUS** is one of the most effective forms of contraception, and its efficacy is not compromised by the development of **amenorrhoea**. - Additional **barrier methods** are not required if the device was inserted correctly and there are no signs of expulsion or failure.

Question 58: A 53-year-old woman presents with vasomotor symptoms 18 months after her last menstrual period. She has a history of oestrogen receptor-positive breast cancer treated with wide local excision and radiotherapy 3 years ago. She is currently taking tamoxifen. Her hot flushes are significantly affecting her quality of life. What is the most appropriate management?

A. Transdermal oestrogen-only HRT
B. Continuous combined HRT
C. Venlafaxine 75 mg daily (Correct Answer)
D. Black cohosh herbal supplement
E. Tibolone 2.5 mg daily

Explanation: ***Venlafaxine 75 mg daily***- **Venlafaxine**, an SNRI, is a recommended non-hormonal treatment for **vasomotor symptoms** in breast cancer survivors as it effectively reduces hot flushes.- It is preferred over certain SSRIs (like paroxetine) because it does not significantly interfere with the metabolism of **tamoxifen** via the CYP2D6 pathway, thus preserving its efficacy.*Transdermal oestrogen-only HRT*- **Systemic Hormone Replacement Therapy (HRT)** is strictly contraindicated in patients with a history of **oestrogen receptor-positive breast cancer** due to the risk of recurrence.- Additionally, **oestrogen-only therapy** would be inappropriate as this patient has an intact uterus (implied), which would require progesterone to prevent endometrial hyperplasia.*Continuous combined HRT*- **Combined HRT** increases the risk of **breast cancer recurrence** and is therefore contraindicated in patients with a history of oestrogen receptor-positive breast cancer, regardless of symptom severity.- Clinical guidelines strongly recommend focusing on **non-hormonal alternatives** for managing vasomotor symptoms in these high-risk patients.*Black cohosh herbal supplement*- **Black cohosh** lacks robust clinical evidence for efficacy and its safety profile regarding **oestrogen-sensitive tissues** in breast cancer survivors is not well-established.- Patients are generally advised against herbal remedies because they are not regulated with the same rigor as pharmaceuticals and may interact with **tamoxifen**.*Tibolone 2.5 mg daily*- **Tibolone** is a synthetic compound with oestrogenic, progestogenic, and androgenic activity that is contraindicated in breast cancer survivors.- Studies, such as the **LIBERATE trial**, have shown that tibolone significantly increases the risk of **breast cancer recurrence**.

Question 59: A 37-year-old woman with known antiphospholipid syndrome presents requesting contraception. She had a provoked deep vein thrombosis 3 years ago following a long-haul flight and is currently on warfarin. She does not wish to become pregnant. Her blood pressure is 128/82 mmHg and BMI is 27 kg/m². Which contraceptive method is most appropriate?

A. Combined oral contraceptive pill
B. Progestogen-only pill
C. Etonogestrel implant
D. Copper intrauterine device (Correct Answer)
E. Combined transdermal patch

Explanation: ***Copper intrauterine device*** - The **copper IUD** is a non-hormonal method that does not increase the risk of **venous thromboembolism (VTE)**, making it a **UKMEC 1** (no restriction) choice for patients with **antiphospholipid syndrome** and previous VTE. - It provides highly effective long-acting reversible contraception while avoiding the metabolic and pro-thrombotic effects associated with estrogen-containing methods. *Combined oral contraceptive pill* - Ethinylestradiol increases the synthesis of **clotting factors**, significantly raising the risk of recurrent **thrombosis** in patients with a history of VTE or thrombophilia. - In patients with **antiphospholipid syndrome**, it is classified as **UKMEC 4** (unacceptable health risk) and is strictly contraindicated. *Progestogen-only pill* - While progestogen-only methods are generally considered **UKMEC 2** (advantages outweigh risks) for patients with a history of VTE, they are less effective than long-acting methods. - It does not carry the same high risk as combined pills, but the **copper IUD** remains the superior non-hormonal choice for minimizing all thrombotic risks. *Etonogestrel implant* - The **implant** is a highly effective long-acting progestogen-only method, but it is typically categorized as **UKMEC 2** in the context of known thrombogenic mutations. - Unlike the **copper IUD**, it is hormonal and may not be the first choice if a completely **hormone-free** alternative is available for a patient with a high thrombotic profile. *Combined transdermal patch* - Similar to the combined pill, the **patch** delivers **estrogen** and carries a significantly increased risk of **thromboembolic events**. - It is classified as **UKMEC 4** for this patient due to the synergistic risk of **antiphospholipid antibodies** and hormonal estrogen exposure.

Question 60: A 57-year-old woman attends for review of her oestrogen-only HRT, which she has been taking for 7 years following total hysterectomy for cervical cancer at age 50. She remains asymptomatic and wishes to continue HRT. She has no other significant medical history, maintains a healthy weight, and does not smoke. Recent mammography was normal. In counselling her about continuing HRT, which of the following statements about breast cancer risk with oestrogen-only HRT is most accurate?

A. Oestrogen-only HRT carries the same breast cancer risk as combined HRT
B. Oestrogen-only HRT is associated with reduced breast cancer risk compared to no HRT use
C. Oestrogen-only HRT carries lower breast cancer risk than combined HRT, with little or no increased risk for at least 7 years of use (Correct Answer)
D. All forms of HRT double the risk of breast cancer within 5 years
E. Breast cancer risk with oestrogen-only HRT is highest in the first 2 years of use

Explanation: ***Oestrogen-only HRT carries lower breast cancer risk than combined HRT, with little or no increased risk for at least 7 years of use***- Extensive evidence from the **WHI** and **Million Women Study** indicates that the addition of **progestogen** is the primary driver of increased breast cancer risk, making oestrogen-only therapy significantly safer.- For women who have had a **hysterectomy**, oestrogen-only HRT is associated with **little or no change** in breast cancer risk for approximately the first 7 to 10 years of treatment.*Oestrogen-only HRT carries the same breast cancer risk as combined HRT*- **Combined HRT** (oestrogen and progestogen) carries a consistently higher and more immediate risk of breast cancer compared to oestrogen-only regimens.- **Progestogens** are known to increase the proliferation of mammary epithelial cells more than oestrogen alone.*Oestrogen-only HRT is associated with reduced breast cancer risk compared to no HRT use*- While some subgroups in the **WHI trial** showed a potential decrease in risk, most clinical guidelines state there is **no significant reduction** compared to the general population.- It is more medically accurate to counsel patients that the risk remains **neutral** or only minimally elevated, rather than protective.*All forms of HRT double the risk of breast cancer within 5 years*- The absolute risk of HRT is low; for example, **combined HRT** adds only about 4 to 8 extra cases per 1000 women over 5 years of use, which is far from **doubling** the baseline risk.- The risk profile varies significantly between **oestrogen-only** and **combined** preparations, making a blanket statement about all HRT incorrect.*Breast cancer risk with oestrogen-only HRT is highest in the first 2 years of use*- Breast cancer risk associated with HRT is **duration-dependent**, meaning the risk typically increases with the **cumulative years** of exposure rather than being highest at the start.- Early use (less than 5 years) of oestrogen-only HRT shows **minimal impact** on breast cancer statistics.

Question 61: A 48-year-old woman with a history of uterine fibroids and adenomyosis presents with irregular heavy menstrual bleeding and symptoms of perimenopause. She has a levonorgestrel intrauterine system in situ that was inserted 4 years ago for menorrhagia management. She now requests HRT for vasomotor symptoms. Examination reveals a 14-week-size uterus. What is the most appropriate HRT regimen for this patient?

A. Remove the LNG-IUS and start continuous combined oral HRT
B. Add transdermal oestrogen only, utilising the LNG-IUS for endometrial protection (Correct Answer)
C. Start sequential combined HRT without removing the LNG-IUS
D. Start tibolone and remove the LNG-IUS
E. Oestrogen therapy is contraindicated due to her fibroids

Explanation: ***Add transdermal oestrogen only, utilising the LNG-IUS for endometrial protection***- The **LNG-IUS (Mirena)** is licensed for 5 years as the **progestogenic component** of Hormone Replacement Therapy (HRT), providing excellent **endometrial protection** while managing the patient's existing menorrhagia.- **Transdermal oestrogen** is the preferred route as it bypasses first-pass metabolism and carries a lower risk of **venous thromboembolism** compared to oral preparations, especially in patients with bulky fibroids.*Remove the LNG-IUS and start continuous combined oral HRT*- Removing the device is unnecessary and subjects the patient to the discomfort of **reinsertion** when she already has an effective system for **menorrhagia** and contraception.- **Continuous combined oral HRT** may result in inferior bleeding control compared to the **LNG-IUS** in a patient with significant **adenomyosis** and uterine fibroids.*Start sequential combined HRT without removing the LNG-IUS*- **Sequential combined HRT** includes a progestogen phase which is redundant because the **LNG-IUS** already achieves continuous **local endometrial suppression**.- Adding extra systemic progestogen increases the risk of **progestogenic side effects** (mood swings, bloating) without providing additional clinical benefit.*Start tibolone and remove the LNG-IUS*- **Tibolone** is a synthetic compound with oestrogenic, progestogenic, and androgenic properties, but it would require removing the **LNG-IUS**, which is currently managing her **heavy menstrual bleeding**.- Without the local delivery of levonorgestrel, the patient's **adenomyosis** and **uterine fibroids** are likely to cause a recurrence of severe menorrhagia.*Oestrogen therapy is contraindicated due to her fibroids*- **Uterine fibroids** are not a contraindication to HRT, although **oestrogen** can occasionally cause them to increase in size; the benefits for **vasomotor symptoms** typically outweigh this risk.- Clinical management involves **monitoring fibroid size** via examination or ultrasound rather than withholding effective symptom relief for perimenopause.

Question 62: A 36-year-old woman presents requesting contraception. She has a history of stroke 3 years ago, which was attributed to a patent foramen ovale (PFO) that has since been surgically closed. She has made a full recovery with no residual neurological deficit and is not on any regular medications. She is a non-smoker with a BMI of 24 kg/m². Her blood pressure is 122/80 mmHg. According to UKMEC, what is the classification for combined hormonal contraception in this patient?

A. UKMEC 1 - no restriction on use
B. UKMEC 2 - advantages generally outweigh risks
C. UKMEC 3 - risks generally outweigh advantages (Correct Answer)
D. UKMEC 4 - unacceptable health risk
E. UKMEC classification depends on whether she had ischaemic or haemorrhagic stroke

Explanation: ***UKMEC 3 - risks generally outweigh advantages*** - A **history of stroke** (ischaemic or haemorrhagic), even with full recovery and PFO closure, typically classifies combined hormonal contraception (CHC) as **UKMEC 3** for patients without current active symptoms or additional major unmanaged risk factors. - **Combined hormonal contraception (CHC)** increases the risk of **venous thromboembolism (VTE)** and **arterial thrombotic events**; a previous cerebrovascular incident indicates a predisposition, making the risks generally outweigh the benefits. *UKMEC 1 - no restriction on use* - This category is reserved for patients with **no medical contraindications** that increase the risk of CHC use, such as healthy non-smokers with no vascular history. - A **prior stroke**, regardless of recovery or cause, represents a significant medical history that precludes a UKMEC 1 classification for CHC. *UKMEC 2 - advantages generally outweigh risks* - While the patient is otherwise healthy (non-smoker, normal BMI, controlled BP) and has recovered, a **history of stroke** is a too serious a risk factor for a UKMEC 2 rating with **estrogen-containing** contraception. - UKMEC 2 usually applies to conditions where minor risks are outweighed by advantages, but a **cerebrovascular event** is a major vascular risk. *UKMEC 4 - unacceptable health risk* - **UKMEC 4** is typically assigned to patients with **current** cerebrovascular disease, active symptoms, or very recent stroke events (e.g., within the last 6 months). - Since the stroke occurred 3 years ago and she has made a **full recovery** with no residual neurological deficit and PFO closure, the risk is significant but not considered an

Question 63: A 55-year-old woman has been taking continuous combined HRT for 5 years for menopausal symptoms. She now feels well and wishes to stop HRT. She asks about the best way to discontinue treatment. What is the most appropriate advice regarding stopping HRT?

A. Gradually taper the dose over 6-12 months before stopping completely
B. Stop abruptly and monitor symptoms (Correct Answer)
C. Continue HRT indefinitely as stopping will cause severe symptoms
D. Switch to oestrogen-only HRT first, then gradually stop
E. Reduce to alternate day dosing for 3 months before stopping

Explanation: ***Stop abruptly and monitor symptoms*** - Guidelines from bodies like **NICE** and the **British Menopause Society** state that **Hormone Replacement Therapy (HRT)** can be stopped abruptly without clinical harm. - There is no evidence that **tapering** reduces the long-term recurrence of menopausal symptoms compared to **immediate cessation**. *Gradually taper the dose over 6-12 months before stopping completely* - While some women prefer this for personal comfort, it is not medically superior and may **prolong exposure** to HRT risks unnecessarily. - Clinical evidence does not demonstrate that a prolonged **weaning process** prevents the eventual return of symptoms. *Continue HRT indefinitely as stopping will cause severe symptoms* - Indefinite use is generally avoided due to the increased risk of **breast cancer** and **venous thromboembolism (VTE)** with long-term therapy. - The decision to continue should be based on an **individualized balance** of benefits and risks rather than the assumption that symptoms will always be severe. *Switch to oestrogen-only HRT first, then gradually stop* - Switching to **estrogen-only** therapy is contraindicated in women with an **intact uterus** due to the risk of **endometrial hyperplasia**. - There is no clinical rationale for changing the **hormonal formulation** as a step toward discontinuation. *Reduce to alternate day dosing for 3 months before stopping* - **Alternate day dosing** is not a recommended evidence-based strategy and can lead to **hormonal fluctuations**. - Similar to other tapering methods, it does not offer a clear advantage over **abrupt cessation** in preventing symptom recurrence.

Question 64: A 29-year-old woman attends for emergency contraception. She had unprotected sexual intercourse 72 hours ago and also 5 days ago. She has a regular 28-day menstrual cycle and her last menstrual period started 12 days ago. She has a BMI of 29 kg/m² and takes no regular medications. What is the most appropriate emergency contraception for this patient?

A. Levonorgestrel 1.5 mg single dose
B. Ulipristal acetate 30 mg single dose
C. Copper intrauterine device (Correct Answer)
D. Levonorgestrel 3 mg as a double dose due to her BMI
E. Emergency contraception is not required as she is not in her fertile window

Explanation: ***Copper intrauterine device*** - The **copper IUD** is the most effective form of emergency contraception (>99% efficacy) and can be inserted up to **5 days (120 hours)** after the earliest episode of unprotected intercourse, or up to 5 days after the **earliest calculated ovulation**. - Given the patient had unprotected sex 5 days ago and is on day 12 of her cycle (around ovulation), the **copper IUD** is the most appropriate and effective choice for preventing pregnancy from both incidents. *Levonorgestrel 1.5 mg single dose* - This hormonal method is primarily effective when taken within **72 hours** (3 days) of unprotected intercourse; thus, it would not cover the incident 5 days ago. - Its efficacy can be reduced in women with a **BMI of 29 kg/m²**, making it a less reliable option compared to the IUD. *Ulipristal acetate 30 mg single dose* - While effective up to **120 hours** (5 days) post-intercourse, making it potentially suitable for both incidents, it is still less effective than the **copper IUD**. - Its efficacy may also be reduced in women with a **BMI >30 kg/m²**, although the evidence for BMI 29 kg/m² is less clear, the IUD remains superior. *Levonorgestrel 3 mg as a double dose due to her BMI* - Even a double dose of **levonorgestrel** does not extend its therapeutic window beyond 72 hours for maximal efficacy, and therefore would not effectively cover the intercourse that occurred 5 days ago. - Although a higher dose might mitigate some concerns regarding efficacy in women with **higher BMI**, the **copper IUD** remains the gold standard for its superior efficacy and longer time window. *Emergency contraception is not required as she is not in her fertile window* - The patient's last menstrual period started 12 days ago, placing her on day 12 of a 28-day cycle, which is well within her **fertile window** (ovulation typically occurs around day 14). - **Sperm can survive in the female reproductive tract for up to 5 days**, meaning both instances of unprotected intercourse carry a significant risk of pregnancy.

Question 65: A 43-year-old woman with body mass index of 44 kg/m² presents with symptoms of perimenopause including irregular periods, night sweats, and mood changes. She requests HRT for symptom management. She has no other significant medical history, does not smoke, and her blood pressure is 138/88 mmHg. What is the most appropriate HRT formulation for this patient?

A. Oral combined HRT (oestrogen and progestogen)
B. Transdermal oestrogen patch with oral micronised progesterone (Correct Answer)
C. Oestrogen-only HRT as obesity provides endogenous progestogen
D. Tibolone
E. HRT is contraindicated due to her BMI being over 40 kg/m²

Explanation: ***Transdermal oestrogen patch with oral micronised progesterone*** - **Transdermal oestrogen** is the preferred delivery method for women with a **BMI >30 kg/m²** because it bypasses **first-pass hepatic metabolism** and does not increase the risk of **venous thromboembolism (VTE)**. - This patient has an intact uterus (as evidenced by irregular periods), so she requires a **progestogen** for **endometrial protection**; **micronised progesterone** is considered a "body-identical" option with an excellent safety profile. *Oral combined HRT (oestrogen and progestogen)* - **Oral oestrogen** significantly increases the risk of **VTE** and **stroke**, which is particularly dangerous in patients with **obesity** (BMI 44 kg/m²). - Transdermal routes are safer for metabolic health and managing blood pressure in high-BMI individuals. *Oestrogen-only HRT as obesity provides endogenous progestogen* - **Oestrogen-only HRT** is never appropriate for women with an **intact uterus** because it leads to **unopposed oestrogen** and a high risk of **endometrial hyperplasia** and **cancer**. - While adipose tissue produces endogenous oestrogen (oestrone), it does not provide **progestogen**, making exogenous progestogen essential. *Tibolone* - **Tibolone** is a synthetic steroid that carries a higher risk of **stroke** in older women and would not be the first-choice safe delivery method in a woman with a **high BMI**. - It is generally recommended for **postmenopausal** women (12 months amenorrhea) rather than those in the **perimenopausal** phase with irregular cycles. *HRT is contraindicated due to her BMI being over 40 kg/m²* - **Obesity** is not an absolute contraindication to HRT, though it is a factor that dictates the **route of administration**. - Managing perimenopausal symptoms can improve quality of life and potentially help with lifestyle modifications in women with high BMIs.

Question 66: According to current UK guidance, what is the Pearl Index (number of pregnancies per 100 woman-years of use) for the copper intrauterine device with typical use?

A. Less than 1 (Correct Answer)
B. 2-3
C. 6-8
D. 9-12
E. 15-20

Explanation: ***Less than 1*** - The **copper intrauterine device (Cu-IUD)** is classified as a **Long-Acting Reversible Contraceptive (LARC)**, known for its high efficacy. - According to **UK guidance (e.g., FSRH)**, its **Pearl Index** for **typical use** is consistently **less than 1**, reflecting its excellent effectiveness and minimal user dependence. *2-3* - A Pearl Index of 2-3 indicates a higher failure rate than what is observed with the **Cu-IUD**, which is among the most effective contraceptive methods available. - This range is not consistent with the documented efficacy of **intrauterine contraception** but might reflect some other contraceptive methods or perfect use rates of less effective ones. *6-8* - A Pearl Index of 6-8 signifies a considerably lower efficacy, typically associated with **user-dependent methods** that have a greater potential for human error. - Examples include the **progestogen-only pill (POP)** or **male condoms** when considering typical use failure rates. *9-12* - This range represents a moderate to high failure rate, often seen with methods like the **combined oral contraceptive pill (COCP)** or the **diaphragm** under typical use conditions. - The **Cu-IUD** significantly outperforms these methods due to its mechanism and non-reliance on daily user adherence. *15-20* - A Pearl Index of 15-20 suggests a very high failure rate, characteristic of **less effective contraceptive methods** or those with significant user dependency and improper use. - This range is much higher than any accepted efficacy for modern, reliable contraceptive methods like the **Cu-IUD**.

Question 67: A 52-year-old woman presents with vulvovaginal atrophy symptoms including severe dyspareunia and vaginal dryness. She experienced natural menopause 3 years ago. She has a history of oestrogen receptor-positive breast cancer treated with wide local excision and radiotherapy 18 months ago. She is currently taking tamoxifen and will continue this for at least 3 more years. Her oncologist has cleared her to seek gynaecological advice for her symptoms. What is the most appropriate initial management?

A. Vaginal oestrogen therapy is contraindicated and non-hormonal lubricants should be recommended
B. Systemic HRT at the lowest dose for shortest duration
C. Vaginal oestrogen therapy can be offered after discussion with oncologist, as systemic absorption is minimal (Correct Answer)
D. Intravaginal testosterone therapy
E. Vaginal dehydroepiandrosterone (DHEA)

Explanation: ***Vaginal oestrogen therapy can be offered after discussion with oncologist, as systemic absorption is minimal*** - For women with a history of **oestrogen receptor-positive breast cancer**, local vaginal oestrogen is considered an option when non-hormonal treatments fail, as **systemic absorption** remains within the normal postmenopausal range. - **Guidelines (BMS/NICE)** advocate for a shared decision-making process involving the patient and her **oncologist** to balance quality of life against potential recurrence risks. *Vaginal oestrogen therapy is contraindicated and non-hormonal lubricants should be recommended* - While **non-hormonal lubricants** are usually first-line, vaginal oestrogens are not strictly contraindicated in breast cancer survivors if symptoms are resistant and severe. - This approach is too restrictive for a patient with **severe dyspareunia** who has already received oncological clearance for specialist gynaecological advice. *Systemic HRT at the lowest dose for shortest duration* - **Systemic HRT** is generally avoided in patients with a history of **ER-positive breast cancer** due to the significantly higher risk of stimulating micrometastases. - Local therapy is preferred over systemic therapy for managing isolated **genitourinary syndrome of menopause** (GSM) in cancer survivors. *Intravaginal testosterone therapy* - **Intravaginal testosterone** is not a standard licensed treatment for **vulvovaginal atrophy** in the UK and lacks robust long-term safety data in breast cancer patients. - It is generally reserved for **libido issues** (HSDD) in a systemic form rather than as a primary treatment for vaginal dryness. *Vaginal dehydroepiandrosterone (DHEA)* - Although **Prasterone (DHEA)** is an effective treatment for vulvovaginal atrophy, **vaginal oestrogen** is usually preferred initially as it has much more established evidence and wider availability. - Like oestrogen, its use in breast cancer requires **oncological consultation**, making vaginal oestrogen the more conventional starting point for hormonal management.

Question 68: A 30-year-old woman with a history of superficial venous thrombosis in her left leg during pregnancy 2 years ago presents requesting contraception. She completed 6 weeks of anticoagulation at the time. She is not currently breastfeeding, has a BMI of 25 kg/m², and does not smoke. Thrombophilia screening performed after the event showed no abnormalities. Which contraceptive method would be most appropriate according to UKMEC?

A. Combined oral contraceptive pill
B. Progestogen-only implant (Correct Answer)
C. Depot medroxyprogesterone acetate injection
D. Combined contraceptive vaginal ring
E. No hormonal contraception can be used due to history of thrombosis

Explanation: ***Progestogen-only implant***- For women with a history of **venous thromboembolism** or superficial venous thrombosis, progestogen-only methods are classified as **UKMEC 1**, meaning there are no restrictions on use.- These methods do not increase the risk of **VTE**, making them safe and highly effective **Long-Acting Reversible Contraception (LARC)** options in patients with a history of thrombosis.*Combined oral contraceptive pill*- The **Combined oral contraceptive pill** contains estrogen, which increases the liver's production of clotting factors and is generally avoided or used with caution (**UKMEC 2/3**) in patients with a history of thrombosis.- Although a single episode of **superficial venous thrombosis** in pregnancy is a lower risk, estrogen-containing methods are less ideal than progestogen-only alternatives in this context.*Depot medroxyprogesterone acetate injection*- While this is also a **UKMEC 1** option for history of VTE, it is often considered secondary to the implant or IUS because it is not as easily **reversible** and may impact **bone mineral density** over long-term use.- It is a safe alternative, but the **progestogen-only implant** is generally preferred as a first-line LARC due to its higher efficacy and superior side-effect profile.*Combined contraceptive vaginal ring*- This is a **combined hormonal contraceptive** that delivers estrogen systemically, carrying the same increased risk of **thromboembolism** as the combined pill.- It is classified similarly to other combined methods and is less appropriate than **progestogen-only** methods in patients with a history of vascular events.*No hormonal contraception can be used due to history of thrombosis*- This is incorrect because **progestogen-only contraceptives** (pills, implants, injections) do not carry the same clotting risks as estrogen-based methods.- Only **combined hormonal contraception** is restricted; patients with a history of thrombosis can safely use all forms of progestogen-only or **non-hormonal** (copper IUD) methods.

Question 69: A 56-year-old woman who underwent total hysterectomy with bilateral salpingo-oophorectomy at age 42 for endometriosis has been taking continuous oestrogen-only HRT (transdermal estradiol 50 mcg twice weekly) since her surgery. She is now concerned about long-term HRT use after reading about risks online. She continues to experience joint pains and low mood when she has tried to stop HRT previously. What is the most appropriate advice regarding continuation of her HRT?

A. HRT must be stopped immediately as she has exceeded the maximum recommended duration of 5 years
B. Continue HRT until age 60, then gradually reduce and stop
C. HRT can be continued for symptom control as she had premature ovarian insufficiency, with benefits likely outweighing risks until at least the average age of natural menopause (Correct Answer)
D. Switch to the lowest dose of HRT and plan to stop within 6 months
E. Continue current dose but add cyclical progestogen to reduce endometrial cancer risk

Explanation: ***HRT can be continued for symptom control as she had premature ovarian insufficiency, with benefits likely outweighing risks until at least the average age of natural menopause*** - This patient underwent **surgical menopause at age 42**, classifying as **early menopause** (age 40–45); guidelines recommend HRT until at least the average age of natural menopause (51 years) to mitigate cardiovascular and bone risks. - There is no **arbitrary time limit** for HRT; as her symptoms (joint pain, low mood) recur upon stopping, continuation is appropriate based on an **individualized benefit-risk assessment**. *HRT must be stopped immediately as she has exceeded the maximum recommended duration of 5 years* - The "5-year rule" is an outdated concept; duration should be based on **individual clinical need** and severity of symptoms rather than a fixed cutoff. - **Abrupt cessation** is not advised here as the patient has demonstrated significant **vasomotor or psychological symptoms** when previously attempting to stop. *Continue HRT until age 60, then gradually reduce and stop* - Setting a specific age like 60 is **too rigid**; decisions regarding HRT should be reviewed annually based on the patient's **evolving health profile** and symptom management. - While gradual reduction help identify the return of symptoms, the goal should be **lowest effective dose** rather than a pre-determined stopping date. *Switch to the lowest dose of HRT and plan to stop within 6 months* - While using the **lowest effective dose** is a core principle, forcing a stop within 6 months is inappropriate for a patient whose **quality of life** is significantly impacted by recurrence. - Rapid withdrawal can lead to a **rebound of menopausal symptoms**, particularly joint pain and mood instability noted in her history. *Continue current dose but add cyclical progestogen to reduce endometrial cancer risk* - **Progestogen** is only required for women with an **intact uterus** to prevent endometrial hyperplasia; this patient had a **total hysterectomy**. - Adding progestogen unnecessarily would increase the risk of **breast cancer** and side effects without providing any clinical benefit in this case.

Question 70: A 47-year-old woman presents with a 4-month history of irregular menstrual cycles, hot flushes, and mood changes. She uses condoms for contraception and wishes to continue with effective contraception. Her FSH level measured on day 2 of her cycle is 42 IU/L. She asks how long she needs to continue contraception. What is the most appropriate advice?

A. Contraception can be stopped immediately as the elevated FSH confirms menopause
B. Continue contraception for 1 year after the last menstrual period (Correct Answer)
C. Continue contraception for 2 years after the last menstrual period
D. Repeat FSH in 6 weeks and stop contraception if it remains elevated
E. Continue contraception until age 55 regardless of symptoms or FSH levels

Explanation: ***Continue contraception for 1 year after the last menstrual period***- For women **over the age of 50**, it is recommended to continue contraception for **12 months** (1 year) after their last menstrual period (LMP) to ensure no unplanned pregnancies.- The patient is 47 and likely to be over 50 by the time she reaches **menopause** (defined as 12 consecutive months of amenorrhea), making this the appropriate duration.*Contraception can be stopped immediately as the elevated FSH confirms menopause*- A single **FSH level** is not sufficient to confirm menopause, especially in perimenopausal women, as levels can fluctuate significantly.- Fertility, while decreased, is not entirely absent during **perimenopause**, and contraception is still necessary.*Continue contraception for 2 years after the last menstrual period*- This recommendation applies to women who experience menopause **under the age of 50**, as they are considered to have a longer potential window of fertility.- Given the patient's age of 47 and current symptoms, she will most likely be over 50 when she reaches menopause, making the 1-year rule more applicable.*Repeat FSH in 6 weeks and stop contraception if it remains elevated*- **FSH levels** alone do not reliably indicate the permanent cessation of fertility, and repeated measurements are not recommended for guiding contraceptive cessation in women over 45 with typical symptoms.- Relying solely on FSH could lead to an early cessation of contraception and an increased risk of **unintended pregnancy**.*Continue contraception until age 55 regardless of symptoms or FSH levels*- While contraception is generally recommended until at least age 50-52 for most women, continuing until age **55** is often a safe upper limit to ensure fertility has ceased for all women, irrespective of symptoms.- However, specific guidelines based on the **last menstrual period** (LMP) are more precise for determining the actual cessation point.

Question 71: A 34-year-old nulliparous woman with von Willebrand disease type 1 presents requesting contraception. She experiences regular menstrual cycles but has menorrhagia requiring tranexamic acid. She is in a stable relationship and wishes to avoid pregnancy for at least 5 years. Her BMI is 26 kg/m², blood pressure is 120/78 mmHg, and she does not smoke. Which contraceptive method would be most appropriate for this patient?

A. Combined oral contraceptive pill
B. Copper intrauterine device
C. Levonorgestrel intrauterine system (Correct Answer)
D. Progestogen-only pill
E. Barrier methods only due to bleeding disorder contraindication

Explanation: ***Levonorgestrel intrauterine system*** - This is the ideal choice as it provides **long-acting reversible contraception (LARC)** for up to 5 years and significantly reduces **menstrual blood loss** by causing endometrial atrophy. - It is classified as **UKMEC 1** for patients with bleeding disorders like **von Willebrand disease**, effectively managing her **menorrhagia** better than other methods. *Combined oral contraceptive pill* - While it can manage **menstrual flow**, it requires **daily compliance** and may be less effective in preventing pregnancy compared to the **LNG-IUS** over a 5-year period. - The **LNG-IUS** is preferred here because it provides superior **heavy menstrual bleeding (HMB)** control while meeting the patient's request for long-term contraception. *Copper intrauterine device* - The **copper IUD** is contraindicated in this patient as it typically **increases menstrual blood loss** and could worsen her existing **menorrhagia**. - It has no therapeutic benefit for a patient already requiring **tranexamic acid** for bleeding control. *Progestogen-only pill* - This method requires **strict daily timing** to maintain efficacy and often causes **irregular spotting** rather than the predictable reduction in bleeding desired. - It does not offer the same high level of **menstrual suppression** or the "fit and forget" convenience of a **5-year LARC**. *Barrier methods only due to bleeding disorder contraindication* - Bleeding disorders are not a **contraindication** to hormonal contraception; in fact, hormonal methods are often **therapeutic** for managing bleeding symptoms. - **Barrier methods** have a higher **failure rate** and do not address the patient's clinical need to manage her **von Willebrand-related menorrhagia**.

Question 72: A 51-year-old woman presents with severe hot flushes and night sweats affecting her quality of life. Her last menstrual period was 8 months ago. She is keen to start hormone replacement therapy but is concerned about cardiovascular risks. She has a BMI of 27 kg/m², does not smoke, and her blood pressure is 134/84 mmHg. She has no personal or family history of cardiovascular disease or breast cancer. She had a normal cervical screening test 18 months ago and normal mammography 6 months ago. What is the most appropriate initial advice regarding HRT and cardiovascular risk in this patient?

A. HRT is contraindicated due to her age being over 50 years
B. She should commence low-dose aspirin before starting HRT to reduce cardiovascular risk
C. Starting HRT within 10 years of menopause in women under 60 years is not associated with increased cardiovascular risk (Correct Answer)
D. Oral HRT carries lower cardiovascular risk than transdermal preparations in this patient
E. She requires cardiology assessment before HRT can be prescribed

Explanation: ***Starting HRT within 10 years of menopause in women under 60 years is not associated with increased cardiovascular risk*** - This patient, at 51 years old and 8 months post-menopause, falls within the **'window of opportunity'**, where initiating HRT is generally considered safe regarding **cardiovascular risk**. - For healthy women under 60 years or within 10 years of menopause, HRT is not associated with an increased risk of **coronary heart disease** and may even offer **cardioprotective benefits**. *HRT is contraindicated due to her age being over 50 years* - Age over 50 is not a **contraindication** for HRT; in fact, most women start HRT in their 50s to manage **menopausal symptoms**. - The critical factor for cardiovascular risk is the **timing of initiation** relative to menopause, rather than chronological age alone, with a preference for starting close to menopause onset. *She should commence low-dose aspirin before starting HRT to reduce cardiovascular risk* - There is no clinical guideline recommending **routine low-dose aspirin** prophylaxis prior to HRT initiation in healthy women without established cardiovascular disease or high-risk factors. - Aspirin is prescribed for primary or secondary prevention of **cardiovascular events** based on individual risk assessment, not as a blanket recommendation for HRT users. *Oral HRT carries lower cardiovascular risk than transdermal preparations in this patient* - **Transdermal HRT** (patches, gels) generally carries a lower risk of **venous thromboembolism (VTE)** and stroke compared to oral HRT because it avoids **first-pass hepatic metabolism** through the liver. - This makes transdermal routes often preferable, especially for women with a higher BMI (though hers is only slightly elevated) or other risk factors for VTE. *She requires cardiology assessment before HRT can be prescribed* - A **cardiology assessment** is unnecessary for this patient, as she presents with no symptoms or significant risk factors for **cardiovascular disease** (e.g., no personal or family history, non-smoker, normal BP). - Standard primary care evaluation, including a detailed medical history and physical examination, is sufficient before prescribing HRT for this healthy woman.

Question 73: A 23-year-old woman attends for contraceptive counselling. She requests the combined oral contraceptive pill. Her mother was diagnosed with venous thromboembolism at age 55 during prolonged immobilisation following a fractured femur. The patient has no personal history of thrombosis, does not smoke, and has a BMI of 24 kg/m². Her blood pressure is 118/76 mmHg. According to the UK Medical Eligibility Criteria for Contraceptive Use (UKMEC), what is the classification for combined hormonal contraception in this patient?

A. UKMEC 1 - no restriction on use
B. UKMEC 2 - advantages generally outweigh risks (Correct Answer)
C. UKMEC 3 - risks generally outweigh advantages
D. UKMEC 4 - unacceptable health risk
E. Thrombophilia screening required before classification

Explanation: ***UKMEC 2 - advantages generally outweigh risks***- According to **UKMEC guidelines**, a family history of **venous thromboembolism (VTE)** in a first-degree relative aged **45 or older** is classified as **UKMEC 2**.- This patient's mother had a clear **provoking factor** (immobilization and fracture) and was older than 45, meaning the patient can safely use the pill as medical benefits outweigh the risks.*UKMEC 1 - no restriction on use*- **UKMEC 1** is reserved for patients with no risk factors at all; a family history of VTE, even if late-onset, increases risk enough to move to category 2.- Since there is a **first-degree relative** with a thrombotic event, it cannot be classified as a completely unrestricted state.*UKMEC 3 - risks generally outweigh advantages*- **UKMEC 3** would apply if the first-degree relative had suffered a VTE at an age **younger than 45**.- Because the mother's event occurred at **age 55**, the risk profile is lower, avoiding this more restrictive classification.*UKMEC 4 - unacceptable health risk*- **UKMEC 4** is assigned to patients with a **personal history of VTE** or known **thrombogenic mutations** (e.g., Factor V Leiden).- This patient has no personal history and has normal **blood pressure/BMI**, so combined hormonal contraception is not contraindicated.*Thrombophilia screening required before classification*- Routine **thrombophilia screening** is not recommended by UKMEC before starting contraception, even with a family history of VTE.- Testing is only considered if the family history suggests an **inherited disorder** (multiple early-onset events), which is not the case here.

Question 74: A 55-year-old woman presents for review of her HRT. She commenced transdermal oestradiol patches and oral micronised progesterone 2 years ago for menopausal symptoms. Her vasomotor symptoms are now well controlled. She underwent total abdominal hysterectomy for fibroids at age 44. She asks whether she needs to continue taking the progesterone. What is the most appropriate advice?

A. Continue the progesterone as she has been taking it for 2 years and stopping may cause symptom recurrence
B. Reduce the progesterone dose gradually over 3 months before stopping
C. Stop the progesterone immediately as it is not required after hysterectomy (Correct Answer)
D. Continue progesterone for another year then review
E. Continue progesterone to reduce cardiovascular risk

Explanation: ***Stop the progesterone immediately as it is not required after hysterectomy*** - In Hormone Replacement Therapy (HRT), **progesterone** is used solely to provide **endometrial protection** by preventing hyperplasia caused by unopposed estrogen. - Since this patient has undergone a **total abdominal hysterectomy**, she has no uterus and therefore no risk of endometrial cancer, making progesterone unnecessary. *Continue the progesterone as she has been taking it for 2 years and stopping may cause symptom recurrence* - **Vasomotor symptoms** (hot flashes, night sweats) are managed by **estrogen**, not progesterone, so stopping progesterone will not cause these symptoms to return. - Long-term unnecessary use of progesterone increases the risk of **breast cancer** compared to estrogen-only regimens. *Reduce the progesterone dose gradually over 3 months before stopping* - There is no clinical requirement for a **tapered withdrawal** of progesterone as it does not cause physiological withdrawal symptoms in this context. - Immediate cessation is preferred to reduce the risk of side effects like **breast tenderness**, bloating, and mood changes. *Continue progesterone for another year then review* - There is no medical indication to continue a drug that provides **zero benefit** while increasing potential risks. - Standard guidelines dictate that **estrogen-only HRT** is the gold standard for women without a uterus. *Continue progesterone to reduce cardiovascular risk* - Progesterone does not provide **cardiovascular protection** and can sometimes have a negative impact on **lipid profiles**. - Routine use of combined HRT is generally associated with a slightly higher risk profile than **estrogen-only therapy** in postmenopausal women.

Question 75: What is the recommended duration for continuation of contraception after permanent cessation of menses in a woman who experiences menopause at age 48?

A. 1 year after the last menstrual period
B. 2 years after the last menstrual period (Correct Answer)
C. Until age 50
D. Until age 55
E. 6 months after the last menstrual period

Explanation: ***2 years after the last menstrual period***- For women who experience **menopause before age 50**, the recommended duration for continuing contraception is **two years** after the last menstrual period to ensure complete cessation of ovulation.- This precautionary period is longer for younger women because **perimenopause** tends to be more unpredictable and spontaneous ovulation is more likely than in women over 50.*1 year after the last menstrual period*- This duration is recommended for women who reach **menopause at or after age 50**, as their fertility declines more rapidly.- Using this cutoff for a 48-year-old would carry a higher risk of **unplanned pregnancy**.*Until age 50*- Contraceptive advice is based on the **time elapsed since the last menstrual period (amenorrhea)**, not strictly on reaching a specific chronological age.- Reaching age 50 does not guarantee that she has been amenorrheic for the required **two-year safety margin**.*Until age 55*- While the risk of natural conception is considered negligible after **age 55**, this is a general biological marker rather than the specific recommendation for clinical menopause management.- Recommendations focusing on the **last menstrual period** provide more tailored guidance for women experiencing earlier menopause.*6 months after the last menstrual period*- This duration is insufficient to confirm the permanent cessation of **ovarian activity** regardless of the patient's age.- Following this advice would lead to a significant risk of **ovulation and conception** during the late perimenopausal transition.

Question 76: A 26-year-old woman presents for review of her contraception. She has been using the etonogestrel implant for 2 years and experiences frequent irregular bleeding approximately 15 days per month, which is affecting her quality of life. She wishes to continue with the implant if possible as she finds it very convenient. What is the most appropriate management?

A. Remove the implant and insert a levonorgestrel intrauterine system
B. Prescribe a 3-month trial of the combined oral contraceptive pill alongside the implant (Correct Answer)
C. Reassure that bleeding will settle and review in 6 months
D. Prescribe tranexamic acid to take during bleeding episodes
E. Remove and replace the implant with a new one

Explanation: ***Prescribe a 3-month trial of the combined oral contraceptive pill alongside the implant***- FSRH guidance recommends a 3-month trial of a **combined oral contraceptive (COC)** to stabilize the endometrium and regulate the bleeding pattern for women on the implant.- This approach is ideal for this patient because it allows her to maintain her preferred, **highly effective** method of contraception while effectively managing the most common side effect.*Remove the implant and insert a levonorgestrel intrauterine system*- While a **LNG-IUS** provides excellent cycle control, removing the implant should be a last resort given the patient explicitly stated a desire to keep it for its **convenience**.- This step should only be considered if medical management of the bleeding fails or if the patient requests a **change of method**.*Reassure that bleeding will settle and review in 6 months*- **Expectant management** is typically only useful in the first few months, as bleeding patterns with the etonogestrel implant usually **stabilize within the first year**.- Since she has had the implant for 2 years, the irregular bleeding is unlikely to spontaneously resolve, and failing to act may lead to **discontinuation** of an effective method.*Prescribe tranexamic acid to take during bleeding episodes*- **Tranexamic acid** is indicated for the reduction of heavy menstrual loss (menorrhagia) rather than for managing the **frequency or unpredictability** of breakthrough bleeding.- Evidence suggests it is less effective than **hormonal manipulation** (like the COC) for managing progestogen-only related unscheduled bleeding.*Remove and replace the implant with a new one*- The **etonogestrel implant** is licensed for 3 years; replacing it early at 2 years will not change the hormonal profile or improve the side effect profile.- Irregular bleeding is a systemic response to **progestogen-only** delivery on the lining of the womb, not a result of a faulty device or declining hormone levels at this stage.

Question 77: A 49-year-old woman presents with increasingly frequent hot flushes. She has a history of oestrogen receptor-positive breast cancer treated with wide local excision and radiotherapy 4 years ago. She is currently taking tamoxifen. Her vasomotor symptoms are significantly affecting her quality of life and sleep. What is the most appropriate management for her menopausal symptoms?

A. Stop tamoxifen and commence oestrogen-only HRT
B. Prescribe venlafaxine (Correct Answer)
C. Prescribe black cohosh and evening primrose oil
D. Commence continuous combined HRT at the lowest dose
E. Prescribe clonidine

Explanation: ***Prescribe venlafaxine*** - **Venlafaxine** is a Serotonin-Norepinephrine Reuptake Inhibitor (**SNRI**) that is highly effective for treating **vasomotor symptoms** in patients where hormone therapy is contraindicated. - It is preferred over certain SSRIs like paroxetine because it does not inhibit **CYP2D6**, meaning it will not interfere with the metabolic activation of **tamoxifen**. *Stop tamoxifen and commence oestrogen-only HRT* - **Tamoxifen** is essential for reducing the risk of recurrence in **oestrogen receptor-positive** breast cancer and should not be discontinued prematurely. - Any form of **Hormone Replacement Therapy (HRT)** is strictly contraindicated in patients with a history of oestrogen-sensitive breast cancer due to the risk of **disease recurrence**. *Prescribe black cohosh and evening primrose oil* - These **herbal preparations** lack robust clinical evidence for efficacy and their long-term safety in **breast cancer survivors** is not well-established. - NICE guidelines suggest that many herbal products carry a risk of **unpredictable interactions** with breast cancer treatments like tamoxifen. *Commence continuous combined HRT at the lowest dose* - Systemic **oestrogen** is strongly avoided in patients with a history of breast cancer, regardless of the dose or the addition of a **progestogen**. - Combined HRT would significantly increase the **risk of recurrence** and is not an appropriate clinical choice for this patient. *Prescribe clonidine* - **Clonidine** has limited efficacy for hot flushes compared to SNRIs and is associated with significant side effects such as **dry mouth**, drowsiness, and **constipation**. - It is generally considered a second-line non-hormonal option behind **venlafaxine** or gabapentinoids.

Question 78: A 33-year-old woman attends for insertion of a levonorgestrel intrauterine system for contraception and management of heavy menstrual bleeding. She has no history of pelvic infection and is in a stable relationship. During insertion, she experiences significant pain and the procedure is abandoned. What is the most appropriate next step in management?

A. Prescribe mefenamic acid and attempt insertion again immediately
B. Arrange insertion under general anaesthesia
C. Prescribe misoprostol and reattempt insertion in one week
D. Offer cervical priming with misoprostol and insertion under local anaesthetic in 2-4 hours (Correct Answer)
E. Refer for hysteroscopic insertion

Explanation: ***Offer cervical priming with misoprostol and insertion under local anaesthetic in 2-4 hours*** - **Cervical priming** with **misoprostol** softens and dilates the cervix, which is highly effective in managing difficult or painful insertions by facilitating easier passage through the **cervical canal**. - Combining this with a **local anaesthetic** (e.g., paracervical block) significantly reduces the pain associated with the procedure, allowing for a successful second attempt in a clinical setting after the optimal 2-4 hours for misoprostol action. *Prescribe mefenamic acid and attempt insertion again immediately* - Reattempting the procedure immediately after a failed, painful attempt is likely to cause further **patient distress** and has a high probability of failure without addressing the physical barrier of a tight cervix. - While **NSAIDs** like **mefenamic acid** may help with cramping, they do not provide sufficient **cervical relaxation** or acute analgesia needed to overcome severe pain during the procedure. *Arrange insertion under general anaesthesia* - **General anaesthesia** carries significantly higher clinical risks and costs, and should only be considered after less invasive methods like **cervical priming** and **local anaesthesia** have failed. - Current guidelines recommend utilizing **office-based interventions** first to minimize the surgical burden on the patient. *Prescribe misoprostol and reattempt insertion in one week* - While **misoprostol** is useful for ripening the cervix, a delay of one week is unnecessary and may result in the patient losing confidence in the procedure or missing their **contraceptive window**. - The optimal effect of misoprostol for cervical priming typically occurs within **2-4 hours** after administration, making a same-day reattempt more efficient and appropriate. *Refer for hysteroscopic insertion* - **Hysteroscopy** is an invasive surgical procedure that is not indicated for a first-time failed insertion due to simple pain or **cervical resistance**. - This approach is typically reserved for complex cases where there is suspected **intrauterine pathology** or known anatomical abnormalities that prevent standard placement.

Question 79: A 56-year-old woman with a BMI of 38 kg/m² presents with moderate vasomotor symptoms and requests HRT. She had her last menstrual period 3 years ago. She has a history of non-alcoholic fatty liver disease and impaired glucose tolerance. Her blood pressure is 128/82 mmHg. She has never had venous thromboembolism. What is the most appropriate form of HRT to prescribe?

A. Continuous combined oral HRT
B. Continuous combined transdermal HRT (Correct Answer)
C. Tibolone
D. Oestrogen-only transdermal patch
E. No HRT - recommend lifestyle measures and non-hormonal treatments only

Explanation: ***Continuous combined transdermal HRT***- **Continuous combined** therapy is necessary because the patient is postmenopausal (3 years since her last period) and has an **intact uterus**, requiring progesterone to prevent **endometrial hyperplasia**.- The **transdermal route** is preferred as it bypasses **first-pass hepatic metabolism**, making it safer for her **non-alcoholic fatty liver disease (NAFLD)** and reducing the elevated **venous thromboembolism (VTE) risk** associated with her **obesity (BMI 38)**.*Continuous combined oral HRT*- **Oral HRT** increases the risk of **venous thromboembolism (VTE)** by triggering the hepatic production of clotting factors, which is a significant concern in an **obese** patient.- Oral preparations can potentially worsen **non-alcoholic fatty liver disease (NAFLD)** and have a more negative impact on the **metabolic profile** compared to transdermal delivery.*Tibolone*- **Tibolone** is a synthetic steroid that undergoes **hepatic metabolism**, making it less ideal than transdermal options given the patient's **liver disease**.- While it has progestogenic and oestrogenic effects, it is generally not the first-line choice for patients with multiple metabolic risk factors like **impaired glucose tolerance** and obesity.*Oestrogen-only transdermal patch*- **Unopposed oestrogen** is contraindicated in women with an **intact uterus** as it significantly increases the risk of **endometrial carcinoma**.- A **progestogen** must be added to provide essential **endometrial protection** when prescribing HRT to a woman with a uterus.*No HRT - recommend lifestyle measures and non-hormonal treatments only*- **Obesity** and **impaired glucose tolerance** are not absolute contraindications to HRT; the benefits for alleviating **vasomotor symptoms** often outweigh the risks when the correct route and type are chosen.- While lifestyle modifications are beneficial, **hormone replacement therapy** remains the most effective treatment for moderate to severe **menopausal symptoms**, which the patient is experiencing.

Question 80: A 42-year-old woman with a history of migraine without aura has been using the combined oral contraceptive pill for 8 years. She now reports that over the past 6 months her migraines have changed character and she is experiencing visual disturbances with zigzag lines lasting about 20 minutes before the headache starts. She has had 3 such episodes. She smokes 5 cigarettes daily. What is the most appropriate management of her contraception?

A. Continue the combined oral contraceptive pill as current migraine is still infrequent
B. Stop the combined oral contraceptive pill immediately and arrange alternative contraception (Correct Answer)
C. Switch to a progestogen-only pill and review in 3 months
D. Reduce the dose of ethinylestradiol in her combined pill
E. Continue current pill but add prophylactic aspirin

Explanation: ***Stop the combined oral contraceptive pill immediately and arrange alternative contraception*** - The patient has developed **migraine with aura**, characterized by **visual disturbances** like zigzag lines, which is an absolute contraindication (**UKMEC 4**) for combined oral contraceptive pills (COCPs). - The combination of **migraine with aura**, age **over 35**, and **smoking** significantly increases the risk of **ischemic stroke** with COCP use, necessitating immediate cessation. *Continue the combined oral contraceptive pill as current migraine is still infrequent* - The **frequency** of migraine attacks is not the primary concern; the **presence of aura** itself establishes the contraindication for COCPs, regardless of how often it occurs. - Continuing COCPs despite the development of **migraine with aura** significantly elevates the patient's risk of **thromboembolic events**, particularly **stroke**. *Switch to a progestogen-only pill and review in 3 months* - While a **progestogen-only pill (POP)** is a safe alternative (UKMEC 1 or 2), the immediate priority is to **stop the combined pill** due to the high-risk profile. - Reviewing in 3 months is insufficient; the patient requires **immediate counseling** on alternative contraception and the importance of avoiding the combined pill. *Reduce the dose of ethinylestradiol in her combined pill* - Reducing the dose of **ethinylestradiol** does not eliminate the increased risk of **ischemic stroke** associated with any estrogen-containing contraception in the presence of **migraine with aura**. - The **estrogen component** of the COCP, even at lower doses, remains the problematic factor and a **UKMEC 4** contraindication. *Continue current pill but add prophylactic aspirin* - Adding **prophylactic aspirin** does not sufficiently mitigate the significantly elevated risk of **ischemic stroke** caused by the interaction of **estrogen**, **migraine with aura**, and **smoking**. - The recommended management for a **UKMEC 4** contraindication is the **cessation** of the contraindicated medication, not attempting to counteract its risks with other drugs.

Question 81: A 53-year-old woman who has been taking continuous combined HRT for 6 months presents with a 4-day episode of vaginal bleeding. Her last menstrual period was 18 months ago. She has no abdominal pain or other symptoms. On examination, her abdomen is soft and non-tender. She is otherwise well with no significant medical history. What is the most appropriate initial investigation?

A. Transvaginal ultrasound scan to measure endometrial thickness (Correct Answer)
B. Outpatient hysteroscopy and endometrial biopsy
C. Cervical smear test
D. Serum FSH and LH levels
E. Repeat examination in 4 weeks if bleeding has settled

Explanation: ***Transvaginal ultrasound scan to measure endometrial thickness*** - In a postmenopausal woman, any **unscheduled bleeding** after the first 6 months of continuous combined **HRT** must be investigated to rule out **endometrial cancer**. - **Transvaginal ultrasound (TVUS)** is the first-line investigation; an endometrial thickness of **≤4 mm** has a high negative predictive value for malignancy. *Outpatient hysteroscopy and endometrial biopsy* - This is an invasive procedure typically reserved for cases where the **TVUS** shows an endometrial thickness **>4 mm** or is inconclusive. - While it provides a definitive histological diagnosis, it is not the **initial** imaging modality recommended for first-line screening. *Cervical smear test* - This is a screening tool for **cervical intraepithelial neoplasia** and is not the primary investigation for suspected **endometrial pathology**. - Although a speculum exam is necessary to rule out cervical causes, the priority in postmenopausal bleeding is the **endometrium**. *Serum FSH and LH levels* - These levels are not clinically useful here as the patient is already confirmed to be **postmenopausal** and established on HRT treatment. - Hormonal testing does not help diagnose the cause of **bleeding** or rule out structural uterine abnormalities. *Repeat examination in 4 weeks if bleeding has settled* - Delaying investigation is inappropriate; unscheduled bleeding at the **6-month mark** of HRT requires prompt evaluation to exclude hyperplasia or malignancy. - Clinical guidelines mandate that persistent or new-onset bleeding after 6 months of HRT cannot be ignored as mere **breakthrough bleeding**.

Question 82: A 28-year-old woman presents 110 hours after unprotected sexual intercourse requesting emergency contraception. She is on day 18 of a regular 28-day menstrual cycle. She has no significant medical history and is not taking any regular medications. Her BMI is 24 kg/m². She had another episode of unprotected intercourse 8 days ago. What is the most appropriate management?

A. Prescribe ulipristal acetate 30 mg as a single dose
B. Insert a copper intrauterine device (Correct Answer)
C. Prescribe levonorgestrel 1.5 mg as a single dose
D. Prescribe double-dose ulipristal acetate due to the time elapsed
E. Advise that emergency contraception is no longer effective and arrange pregnancy test

Explanation: ***Insert a copper intrauterine device***- The **copper intrauterine device (Cu-IUD)** is the most effective form of emergency contraception and can be inserted up to **120 hours (5 days)** after unprotected intercourse or up to 5 days after the **earliest estimated ovulation**.- Given the patient had intercourse 8 days ago (Day 10 of her cycle) and is now on Day 18 (likely 4 days post-ovulation), the Cu-IUD can prevent both fertilization and implantation from both episodes, including the earlier one. *Prescribe ulipristal acetate 30 mg as a single dose*- While **ulipristal acetate (UPA)** is licensed for use up to 120 hours, its primary mechanism is **delaying ovulation**, making it less effective or ineffective if ovulation has already occurred (which is likely by Day 18).- UPA would not be effective for the unprotected intercourse that occurred **8 days ago** as that falls outside its effective window and mechanism of action. *Prescribe levonorgestrel 1.5 mg as a single dose*- **Levonorgestrel (LNG)** emergency contraception is generally only effective if taken within **72 hours** after unprotected intercourse, making it unsuitable for a presentation at 110 hours.- Like UPA, LNG primarily works by **inhibiting ovulation** and is less effective once ovulation has taken place, or for earlier episodes of intercourse. *Prescribe double-dose ulipristal acetate due to the time elapsed*- There is no clinical evidence or licensed recommendation for a **double dose** of ulipristal acetate based on time elapsed since intercourse.- Double-dosing for oral emergency contraception is typically only considered for **levonorgestrel** in patients with a high **BMI (>26 kg/m²)**, which is not the case here (BMI 24 kg/m²). *Advise that emergency contraception is no longer effective and arrange pregnancy test*- This advice is incorrect because the **copper IUD** remains a highly effective option within the 120-hour window and up to 5 days post-ovulation, covering both episodes of unprotected intercourse.- While a pregnancy test would eventually be needed, it would be **too early** to reliably detect a pregnancy from the intercourse 8 days ago (now Day 18 of the cycle), and effective emergency contraception can still be offered.

Question 83: According to the UK Medical Eligibility Criteria (UKMEC), which of the following clinical scenarios represents a UKMEC 4 (unacceptable health risk) for the copper intrauterine device?

A. Current pelvic inflammatory disease (Correct Answer)
B. History of ectopic pregnancy
C. Endometrial cancer awaiting treatment
D. Unexplained vaginal bleeding
E. Severe thrombocytopenia with platelet count of 30 × 10⁹/L

Explanation: ***Current pelvic inflammatory disease*** - Insertion of a **Copper IUD** in the presence of an active infection can facilitate **ascending infection**, significantly increasing the risk of worsening the condition. - It is classified as **UKMEC 4** because the absolute medical risk to the patient outweighs any contraceptive benefit until the infection is fully resolved. *History of ectopic pregnancy* - This scenario is classified as **UKMEC 1**, meaning there is no restriction on the use of the copper intrauterine device. - While an IUD does not protect against ectopic pregnancy as effectively as it protects against intrauterine pregnancy, a **prior history** is not a contraindication. *Endometrial cancer awaiting treatment* - This is typically classified as **UKMEC 4 for initiation**, but the management usually focuses on oncology protocols rather than standard family planning. - While it represents a contraindication, **active infection** like PID is often considered a more immediate and classic clinical risk for IUD insertion in primary care exams. *Unexplained vaginal bleeding* - **Unexplained vaginal bleeding** (suspicious for serious pathology) is categorized as **UKMEC 4** for initiation of a copper IUD. - However, in many clinical frameworks, **current PID** is considered the more definitive and immediate physiological contraindication compared to symptoms awaiting investigation. *Severe thrombocytopenia with platelet count of 30 × 10⁹/L* - Severe **thrombocytopenia** is classified as **UKMEC 3** for the copper IUD, meaning the risks generally outweigh the benefits. - This is due to the potential for increased **menstrual blood loss** and heavy bleeding, but it does not reach the absolute contraindication level of UKMEC 4.

Question 84: A 47-year-old woman presents with a 9-month history of hot flushes, night sweats, and mood changes. Her periods have become irregular, with the last one occurring 8 weeks ago. She requests HRT but is concerned about side effects. Her mother had a deep vein thrombosis at age 72 following hip replacement surgery. The patient's BMI is 27 kg/m² and blood pressure is 118/76 mmHg. What is the most appropriate initial HRT regimen?

A. Sequential combined oral HRT
B. Continuous combined oral HRT
C. Sequential combined transdermal HRT (Correct Answer)
D. Oestrogen-only transdermal HRT
E. Tibolone

Explanation: ***Sequential combined transdermal HRT*** - This patient is **perimenopausal** (irregular periods with the last one 8 weeks ago); therefore, she requires a **sequential (cyclical)** regimen to provide endometrial protection and regular withdrawal bleeds. - **Transdermal HRT** is the preferred route as it avoids first-pass hepatic metabolism and does not increase the risk of **venous thromboembolism (VTE)**, which is ideal given her concern and family history. *Sequential combined oral HRT* - While the sequential component is correct for a perimenopausal woman, the **oral route** is associated with a higher risk of **VTE** compared to the transdermal route. - Oral oestrogen increases the production of clotting factors in the liver, making it less suitable for patients concerned about thrombosis. *Continuous combined oral HRT* - **Continuous combined HRT** is only indicated for **postmenopausal** women (at least 12 months after the last menstrual period). - Using this in a perimenopausal woman often lead to heavy, **unscheduled breakthrough bleeding** due to the patient's own endogenous oestrogen production. *Oestrogen-only transdermal HRT* - Oestrogen-only HRT is strictly contraindicated in women with an **intact uterus**. - Without a progestogen to oppose the oestrogen, there is a significant risk of **endometrial hyperplasia** and **endometrial cancer**. *Tibolone* - Tibolone is a synthetic compound with oestrogenic, progestogenic, and androgenic properties but is intended for **postmenopausal** use only. - If used in the perimenopausal period, it causes poor cycle control and a high incidence of **irregular vaginal bleeding**.

Question 85: A 35-year-old woman attends for review 3 years after copper IUD insertion for long-term contraception. She has no complaints and examination reveals the threads are visible. Her last menstrual period was 2 weeks ago. She plans to start trying for pregnancy in 6 months. What is the most appropriate management?

A. Replace the IUD with a new copper IUD
B. Remove the IUD now as she wishes to conceive soon
C. Reassure and arrange review when she wishes to conceive (Correct Answer)
D. Arrange hysteroscopy to check IUD position
E. Advise changing to the levonorgestrel intrauterine system

Explanation: ***Reassure and arrange review when she wishes to conceive*** - Modern **Copper IUDs** are licensed for **5 to 10 years**; since this device was inserted 3 years ago and the patient is asymptomatic, it remains effective and safe to use.- Removing the IUD 6 months prior to the desired conception date is unnecessary and would leave the patient at risk of **unplanned pregnancy**, as fertility returns to baseline **immediately upon removal**.*Replace the IUD with a new copper IUD*- Replacing a functioning IUD after only 3 years is incorrect because the device has not reached the end of its **licensed lifespan**.- Routine replacement is not indicated unless the device is expired, displaced, or causing **refractory clinical issues**.*Remove the IUD now as she wishes to conceive soon*- Early removal is contraindicated because she explicitly stated she wants to start trying in **6 months**, not immediately.- Removing it now would necessitate the use of an alternative **short-acting contraceptive** method, which is less efficient than keeping the current IUD in situ.*Arrange hysteroscopy to check IUD position*- **Hysteroscopy** is an invasive procedure and is not indicated when **IUD threads are visible** during a speculum examination.- IUD position is generally confirmed via **ultrasound** only if the threads are missing or clinical symptoms like pelvic pain suggest displacement.*Advise changing to the levonorgestrel intrauterine system*- There is no clinical indication to switch to the **LNG-IUS** as the patient is happy with her current method and has no complaints like **heavy menstrual bleeding**.- Switching methods 6 months before planned conception is impractical and may cause side effects during the **hormonal adjustment** period.

Question 86: A 50-year-old woman presents with vasomotor symptoms and requests HRT. She has a history of stage 1 endometrial cancer treated with total abdominal hysterectomy and bilateral salpingo-oophorectomy 18 months ago. Histology showed grade 1 endometrioid adenocarcinoma confined to the endometrium with no myometrial invasion. She has been discharged from oncology follow-up. What is the most appropriate management regarding HRT?

A. Prescribe continuous combined HRT as she has had a hysterectomy
B. Prescribe oestrogen-only HRT as the risk of recurrence is very low (Correct Answer)
C. Prescribe vaginal oestrogen only for symptom management
D. Prescribe tibolone as an alternative to conventional HRT
E. Advise that HRT is absolutely contraindicated due to her cancer history

Explanation: ***Prescribe oestrogen-only HRT as the risk of recurrence is very low*** - In patients with **stage 1, grade 1 endometrioid adenocarcinoma** and no myometrial invasion, the risk of recurrence is extremely low, making HRT a viable option for **vasomotor symptoms**. - Since the patient has undergone a **total abdominal hysterectomy**, progesterone is not required, and **oestrogen-only HRT** is the standard approach to avoid unnecessary side effects. *Prescribe continuous combined HRT as she has had a hysterectomy* - **Continuous combined HRT** includes progestogen, which is primarily used to protect the **endometrium** from hyperplasia or malignancy in women who still have a uterus. - In a patient who has had a **hysterectomy**, adding progestogen is unnecessary and may slightly increase the risk of **breast cancer** compared to oestrogen alone. *Prescribe vaginal oestrogen only for symptom management* - **Vaginal oestrogen** is effective only for **genitourinary syndrome of menopause** (atrophic vaginitis) and does not provide systemic relief for **vasomotor symptoms** like hot flushes. - This patient specifically requests management for vasomotor symptoms, which require **systemic HRT** for adequate control. *Prescribe tibolone as an alternative to conventional HRT* - **Tibolone** is a synthetic steroid with oestrogenic, progestogenic, and androgenic properties, but it is typically not the first-line choice in post-cancer patients unless specifically indicated. - Standard **oestrogen-only therapy** has more robust evidence for safety and efficacy in low-risk, early-stage endometrial cancer survivors compared to tibolone. *Advise that HRT is absolutely contraindicated due to her cancer history* - While endometrial cancer is oestrogen-dependent, HRT is **not absolutely contraindicated** in patients with successfully treated, **low-grade, early-stage primary disease**. - Evidence suggests that systemic HRT does not significantly increase the risk of recurrence or mortality in women with **Stage 1 disease** after appropriate surgical treatment.

Question 87: A 31-year-old woman with polycystic ovary syndrome presents requesting contraception. She has a BMI of 34 kg/m² and oligomenorrhoea. Her blood pressure is 132/84 mmHg on two separate occasions. She is a non-smoker with no personal or family history of venous thromboembolism. She prefers not to have a coil fitted. What is the most appropriate contraceptive option for this patient?

A. Combined oral contraceptive pill
B. Progestogen-only pill
C. Depot medroxyprogesterone acetate injection
D. Etonogestrel contraceptive implant (Correct Answer)
E. Progesterone-only emergency contraception until blood pressure controlled

Explanation: ***Etonogestrel contraceptive implant*** - This is a **Long-Acting Reversible Contraceptive (LARC)** and is categorized as **UKMEC 1** for this patient, meaning there are no restrictions on its use despite her BMI and blood pressure. - It provides highly effective contraception for 3 years without the **user-dependence** associated with oral pills, which is beneficial for managing her PCOS symptoms. *Combined oral contraceptive pill* - Although often used in PCOS to regulate cycles, her **BMI of 34 kg/m²** and **borderline hypertension** (132/84 mmHg) increase the risks associated with estrogen-containing methods. - The **Combined Hormonal Contraceptive (CHC)** is generally avoided or used with caution (UKMEC 2/3) when multiple cardiovascular risk factors like obesity and elevated BP are present. *Progestogen-only pill* - This is a safe option (**UKMEC 1**), but it is considered less ideal than a LARC because its efficacy depends on **consistent daily administration**. - It does not offer the same high level of long-term contraceptive security as the **subdermal implant** for a patient seeking reliable protection. *Depot medroxyprogesterone acetate injection* - While effective, the **Depot injection** is frequently associated with **weight gain**, which is undesirable in a patient who is already obese (**BMI 34 kg/m²**). - There are also concerns regarding a reduction in **bone mineral density** with long-term use, making it a second-line choice compared to the implant. *Progesterone-only emergency contraception until blood pressure controlled* - Emergency contraception is only indicated after **unprotected sexual intercourse**, which is not the primary presentation here. - Her blood pressure (132/84 mmHg) is not high enough to contraindicate the immediate initiation of a **progestogen-only** maintenance contraceptive.

Question 88: A 35-year-old woman with BMI 31 kg/m² presents 96 hours after unprotected sexual intercourse requesting emergency contraception. She has regular 28-day cycles and calculates she is on day 16 of her cycle. She has no other relevant medical history and takes no regular medications. She has not had any other episodes of unprotected intercourse this cycle. What is the most appropriate management?

A. Prescribe ulipristal acetate 30 mg single dose
B. Prescribe levonorgestrel 1.5 mg single dose
C. Prescribe double-dose levonorgestrel 3 mg due to elevated BMI
D. Arrange copper IUD insertion (Correct Answer)
E. Advise that emergency contraception is not effective beyond 72 hours

Explanation: ***Arrange copper IUD insertion*** - The **copper IUD** is the most effective method of emergency contraception, offering over **99% efficacy**, and can be inserted up to **120 hours (5 days)** after unprotected sexual intercourse or within **5 days of predicted ovulation**. - It is the gold standard choice regardless of the patient's **BMI** and provides immediate and ongoing contraception, making it ideal for this patient presenting at 96 hours with an elevated BMI. *Prescribe ulipristal acetate 30 mg single dose* - While licensed for use up to **120 hours**, it is less effective than the **copper IUD**, particularly when intercourse occurs near the predicted **ovulation window** (day 16). - Its efficacy is significantly reduced in women with a **BMI >30 kg/m²**, making it a secondary choice compared to the IUD in this clinical scenario. *Prescribe levonorgestrel 1.5 mg single dose* - **Levonorgestrel** is primarily effective within **72 hours** of unprotected intercourse, rendering it largely ineffective at **96 hours** post-exposure. - Its mechanism of action to inhibit or delay ovulation is unlikely to be successful if ovulation has already occurred or is imminent, which is probable on day 16 of a regular cycle. *Prescribe double-dose levonorgestrel 3 mg due to elevated BMI* - Although a **double dose** (3 mg) of levonorgestrel is recommended for women with a **BMI >26 kg/m²** or weight >70 kg, it still must be administered within the **72-hour window** to be effective. - Clinical guidelines prioritize the **copper IUD** as the first-line recommendation for women with an **elevated BMI** due to the significantly reduced efficacy of oral emergency contraceptive pills. *Advise that emergency contraception is not effective beyond 72 hours* - This statement is incorrect as both **ulipristal acetate** and the **copper IUD** are effective and indicated for use up to **120 hours (5 days)** after unprotected intercourse. - Professional guidelines strongly recommend offering the **copper IUD** to all women presenting for emergency contraception beyond 72 hours to maximize the chances of preventing pregnancy.

Question 89: A 51-year-old woman commenced on transdermal estradiol 50 mcg patches twice weekly with cyclical dydrogesterone 10 mg (days 1-14) 10 months ago for menopausal symptoms. She now reports a 9-day episode of heavy vaginal bleeding that started 3 days after completing the progestogen phase. This is longer and heavier than her usual withdrawal bleeds. What is the most appropriate initial management?

A. Increase the progestogen dose to dydrogesterone 20 mg daily
B. Reassure that irregular bleeding is normal in the first year of HRT
C. Arrange urgent transvaginal ultrasound scan (Correct Answer)
D. Switch to continuous combined HRT preparation
E. Stop HRT and repeat pelvic examination in 4 weeks

Explanation: ***Arrange urgent transvaginal ultrasound scan*** - The patient is on **sequential HRT** and experiences **heavy, prolonged, irregular bleeding** 10 months into treatment, which is beyond the expected initial adaptation phase. - This requires urgent investigation to rule out **endometrial pathology**, such as **hyperplasia** or **carcinoma**, making a **transvaginal ultrasound** the appropriate initial diagnostic step to assess **endometrial thickness**. *Increase the progestogen dose to dydrogesterone 20 mg daily* - While increased progestogen might be considered for **insufficient endometrial protection**, it should only be done *after* excluding any underlying **pathology** through investigation. - Modifying the HRT regimen without proper investigation would dangerously delay the diagnosis of potential **endometrial cancer** or other significant issues. *Reassure that irregular bleeding is normal in the first year of HRT* - Although unscheduled bleeding is common in the first **3 to 6 months** of HRT, this patient is 10 months into treatment and her bleeding is **heavier and longer** than her usual withdrawal pattern. - This significant change in bleeding pattern after the initial stabilization period is a **red flag** and requires immediate investigation, not reassurance. *Switch to continuous combined HRT preparation* - **Continuous combined HRT** is generally reserved for women who are at least one year post-menopause or after successful sequential HRT, to avoid erratic bleeding. - Switching regimens at this point would obscure the clinical picture and fail to address the critical need for **endometrial assessment** of the current abnormal bleeding. *Stop HRT and repeat pelvic examination in 4 weeks* - Stopping HRT would not resolve the need to investigate a suspicious bleeding event that has already occurred and is abnormal for her HRT duration. - Delaying assessment by 4 weeks is inappropriate, as guidelines recommend **urgent evaluation** for abnormal uterine bleeding in women on HRT, particularly after the initial few months.

Question 90: According to current UK guidance, what is the minimum age at which the progesterone-only implant (etonogestrel) can be used without being classified as 'off-license' use?

A. 12 years
B. 16 years
C. There is no minimum age restriction
D. 13 years
E. 18 years (Correct Answer)

Explanation: ***18 years*** - According to the **Summary of Product Characteristics (SmPC)**, the etonogestrel implant (Nexplanon) is officially licensed for use in women aged **18 to 40 years** in the UK. - While it is frequently and safely used in clinical practice for younger adolescents, its use below the age of **18 years** is technically classified as **off-license** use. *12 years* - There is no clinical or regulatory guideline that specifies **12 years** as the minimum age for licensed use of the implant. - Although a child of this age could potentially receive it under **Fraser guidelines** if deemed competent, it would still be considered **off-license** in terms of product licensing. *16 years* - While **16 years** is often associated with the age of medical consent (competence), it does not align with the manufacturer's **licensing requirements** for this specific device. - Clinical data supporting the implant's efficacy and safety in the **under-18 population** was not primary to the original license application, leading to its current status. *There is no minimum age restriction* - While professional bodies like the **Faculty of Sexual and Reproductive Healthcare (FSRH)** state there are no medical prohibitions for use in younger girls, the **legal licensing status** of the product does have a specific age threshold. - Prescribing the implant to any person under **18 years** requires the clinician to acknowledge and document the **off-license** nature of the prescription. *13 years* - **13 years** is a significant age regarding safeguarding and **sexual activity reporting** protocols, but it is not the age specified for the medication's license. - Like other pediatric ages, use in a 13-year-old is supported by **clinical best practices** but remains outside the manufacturer's **official license**.

Question 91: A 54-year-old woman with a BMI of 33 kg/m² and a history of venous thromboembolism 3 years ago on the combined oral contraceptive pill presents with moderate vasomotor symptoms. She stopped HRT 2 months ago due to concerns about health risks after reading media reports. Her last menstrual period was 18 months ago. She requests non-hormonal management. What is the most appropriate first-line non-hormonal treatment?

A. Cognitive behavioural therapy (Correct Answer)
B. Paroxetine 20 mg daily
C. Venlafaxine 75 mg daily
D. Clonidine 50 mcg twice daily
E. Black cohosh supplement

Explanation: ***Cognitive behavioural therapy***- **NICE guidelines** recommend CBT as the first-line non-hormonal intervention for **vasomotor symptoms** and low mood associated with menopause.- It is highly appropriate for this patient who has a contraindication to HRT (**history of VTE**) and specifically requests a non-hormonal approach without pharmacological side effects.*Paroxetine 20 mg daily*- **SSRIs** like paroxetine are considered second-line options and are generally reserved if non-pharmacological methods like **CBT** are ineffective or declined.- They are associated with side effects such as **nausea**, insomnia, and **sexual dysfunction**, making them less desirable as an initial step.*Venlafaxine 75 mg daily*- This **SNRI** can reduce the severity of hot flushes but is not the first-line non-hormonal recommendation according to current clinical standards.- It carries a risk of side effects including **increased blood pressure** and significant **withdrawal symptoms** upon discontinuation.*Clonidine 50 mcg twice daily*- A centrally acting **alpha-2 agonist** that has limited efficacy in treating vasomotor symptoms compared to other available options.- Frequent side effects such as **dry mouth**, **drowsiness**, and hypotension often lead to poor patient compliance.*Black cohosh supplement*- **Herbal preparations** like black cohosh lack robust clinical evidence for efficacy and are not regulated with the same stringency as pharmaceuticals.- There are significant safety concerns regarding potential **hepatotoxicity** (liver damage) associated with its use.

Question 92: A 29-year-old woman who is currently breastfeeding her 8-week-old infant presents requesting contraception. She plans to continue breastfeeding for at least 6 months. She is fully breastfeeding and has not had a menstrual period since delivery. She does not wish to have another pregnancy in the near future. What is the most appropriate contraceptive advice?

A. Combined oral contraceptive pill can be safely started immediately
B. Lactational amenorrhoea method (LAM) provides adequate protection until 6 months postpartum
C. Progesterone-only pill should be started and can be commenced immediately (Correct Answer)
D. Copper IUD insertion should be delayed until 6 months postpartum
E. No contraception is needed until menstruation returns

Explanation: ***Progesterone-only pill should be started and can be commenced immediately***- The **progesterone-only pill (POP)** is highly suitable for breastfeeding women as it does not interfere with **milk production** or infant development.- It is categorized as **UKMEC 1** (no restrictions) and can be safely initiated at any time following delivery to provide reliable protection.*Combined oral contraceptive pill can be safely started immediately*- **Combined oral contraceptives (COCP)** are generally avoided in breastfeeding women before 6 weeks postpartum due to an increased risk of **venous thromboembolism** and potential reduction in **milk supply**.- It is classified as **UKMEC 4** (unacceptable health risk) before 6 weeks and **UKMEC 3** between 6 weeks and 6 months for breastfeeding mothers.*Lactational amenorrhoea method (LAM) provides adequate protection until 6 months postpartum*- While **LAM** is 98% effective, it requires strict adherence to three criteria: **exclusive breastfeeding**, remaining **amenorrhoeic**, and the infant being **under 6 months** old.- Because this patient explicitly desires to avoid pregnancy in the near future, relying solely on LAM may be riskier than using a **hormonal or barrier method** as a backup.*Copper IUD insertion should be delayed until 6 months postpartum*- A **Copper IUD** does not need to be delayed; it can be safely inserted starting from **4 weeks postpartum** (**UKMEC 1**).- It is an excellent **long-acting reversible contraceptive (LARC)** option that is hormone-free and does not affect breastfeeding.*No contraception is needed until menstruation returns*- This is a common misconception; **ovulation** can occur before the first postpartum menstrual period, leading to a risk of **unplanned pregnancy**.- Relying on the return of menses is unreliable compared to established methods like the **POP** or **LAM** criteria.

Question 93: A 48-year-old woman presents requesting HRT for troublesome menopausal symptoms. She has a history of a DVT 6 years ago during long-haul flight immobilisation, for which she was treated with anticoagulation for 3 months. Thrombophilia screening at the time was negative. She has had no further thrombotic events. Her BMI is 24 kg/m² and she is a non-smoker with no other medical conditions. What is the most appropriate initial HRT recommendation?

A. Standard oral continuous combined HRT
B. Transdermal estrogen with micronised progesterone (Correct Answer)
C. HRT is contraindicated due to VTE history
D. Tibolone
E. Selective serotonin reuptake inhibitor instead of HRT

Explanation: ***Transdermal estrogen with micronised progesterone*** - **Transdermal estrogen** is preferred in patients with a history of **venous thromboembolism (VTE)** as it avoids **first-pass hepatic metabolism** and does not increase the synthesis of clotting factors. - **Micronised progesterone** (Utrogestan) is used as the progestogenic component because it is considered **metabolically neutral** and carries a lower risk of VTE and breast cancer compared to synthetic progestogens. *Standard oral continuous combined HRT* - **Oral estrogen** significantly increases the risk of **VTE** by increasing levels of prothrombin and decreasing levels of antithrombin; this is avoided in patients with a history of DVT. - Although her DVT was **provoked** and occurred over 5 years ago, oral therapy remains a **UKMEC 3** risk (risks generally outweigh benefits), making it a poor initial choice. *HRT is contraindicated due to VTE history* - HRT is not **absolutely contraindicated** if the VTE was **provoked** (e.g., long-haul flight), the event was more than 5 years ago, and **thrombophilia screening** was negative. - Management involves a balanced discussion of risks, and the **transdermal route** provides a safe enough profile to manage severe menopausal symptoms in this patient group. *Tibolone* - **Tibolone** is a synthetic compound with estrogenic, progestogenic, and androgenic properties that still carries a **VTE risk** similar to that of oral HRT. - It is generally reserved for postmenopausal women who prefer a single-pill option but is not recommended for those specifically requiring an **ultra-low VTE risk** profile. *Selective serotonin reuptake inhibitor instead of HRT* - **SSRIs** are non-hormonal alternatives used to treat **vasomotor symptoms** but are significantly **less effective** than HRT for symptom control. - These should be considered second-line therapy for women who have a **contraindication** to HRT or those who actively choose to avoid hormone therapy.

Question 94: A 38-year-old woman attends for review 4 weeks after copper IUD insertion for emergency contraception. She reports that the IUD was inserted 4 days after unprotected sexual intercourse. She has had no bleeding since insertion and her pregnancy test today is positive. An ultrasound scan confirms an intrauterine pregnancy of 6 weeks gestation. The IUD threads are not visible at the cervical os. She wishes to continue with the pregnancy. What is the most appropriate management?

A. Prescribe prophylactic antibiotics and remove IUD at 12 weeks gestation
B. Attempt IUD removal under ultrasound guidance immediately
C. Arrange urgent hysteroscopy for IUD removal
D. Leave the IUD in situ and arrange close antenatal surveillance (Correct Answer)
E. Advise termination of pregnancy due to high risk of complications

Explanation: ***Leave the IUD in situ and arrange close antenatal surveillance*** - When **IUD threads are not visible** at the cervical os in a desired pregnancy, attempting removal by instrumentation within the uterine cavity significantly increases the risk of **miscarriage** or infection. - The most appropriate management is to leave the IUD in place and provide **close antenatal surveillance**, counseling the patient about the elevated risks of **preterm birth** and **second-trimester miscarriage**. *Prescribe prophylactic antibiotics and remove IUD at 12 weeks gestation* - There is no evidence to support the routine use of **prophylactic antibiotics** when an IUD is retained in a pregnancy without signs of infection. - Delaying removal to **12 weeks gestation** does not mitigate the risks associated with non-visible threads and instrumental removal, which should generally be avoided if threads are not easily accessible. *Attempt IUD removal under ultrasound guidance immediately* - Attempting to remove an IUD with **non-visible threads** by instrumentation under ultrasound guidance carries a substantial risk of disrupting the **gestational sac** or causing uterine trauma. - Guidelines advise against intrauterine exploration to retrieve an IUD when the strings are not visible, as this poses a higher risk of **miscarriage** than leaving it in situ. *Arrange urgent hysteroscopy for IUD removal* - **Hysteroscopy** is absolutely **contraindicated** in a desired ongoing pregnancy due to the high risk of **iatrogenic miscarriage** and potential harm to the fetus. - The procedure involves uterine distension and direct visualization, which is incompatible with the viability of an **early intrauterine pregnancy**. *Advise termination of pregnancy due to high risk of complications* - While a retained IUD increases the risks of **miscarriage** and **preterm delivery**, it is not an absolute medical indication for **termination of pregnancy**, especially when the patient wishes to continue. - Management should respect the patient's autonomy and desire to continue the pregnancy, focusing on **risk counseling** and vigilant monitoring rather than mandatory termination.

Question 95: A 56-year-old woman presents with persistent vulvovaginal atrophy symptoms despite 6 months of regular vaginal estrogen therapy. She has been using estradiol 10 mcg vaginal tablets twice weekly. She had a natural menopause at age 52 and is not on systemic HRT. Examination confirms vaginal atrophy with no concerning features. What is the most appropriate next step in management?

A. Discontinue vaginal estrogen and prescribe vaginal moisturisers only
B. Refer to gynaecology for further assessment
C. Switch to estriol 0.5 mg vaginal cream
D. Increase frequency of estradiol vaginal tablets to daily use (Correct Answer)
E. Add systemic HRT with continuous combined preparation

Explanation: ***Increase frequency of estradiol vaginal tablets to daily use*** - When standard twice-weekly dosing of **low-dose vaginal estrogen** fails to control symptoms, increasing to **daily administration** is an appropriate and safe next step in management. - Optimization of the current **topical estrogen** regimen is required before switching medications or considering more invasive specialist referrals. *Discontinue vaginal estrogen and prescribe vaginal moisturisers only* - **Vaginal moisturizers** are non-hormonal lubricants that treat dryness but do not address the underlying physiological **hypoestrogenic changes** of atrophy. - Discontinuing the primary curative treatment for a symptomatic patient with **confirmed atrophy** would result in a worsening of symptoms. *Refer to gynaecology for further assessment* - Referral is not indicated at this stage because **conservative optimization** of treatment in primary care has not yet been exhausted. - Specialist assessment is typically reserved for cases where there are **concerning features** (e.g., bleeding, masses) or if symptoms remain refractory after maximum topical therapy. *Switch to estriol 0.5 mg vaginal cream* - Switching between different low-dose estrogen formulations (tablets to creams) is unlikely to be more effective than **increasing the dose/frequency** of the current medication. - **Vaginal creams** are equivalent in efficacy to tablets; the issue here is the **dosing frequency** rather than the delivery vehicle. *Add systemic HRT with continuous combined preparation* - **Systemic HRT** is not the first-line treatment for isolated **genitourinary syndrome of menopause (GSM)** when vasomotor symptoms are absent. - Systemic therapy carries a higher **side-effect profile** and risks compared to targeted, low-dose **topical estrogen therapy**.

Question 96: A 32-year-old woman with type 1 diabetes mellitus and proliferative diabetic retinopathy presents requesting contraception. Her HbA1c is 58 mmol/mol (7.5%). She has no other vascular complications and her blood pressure is 125/78 mmHg. She has a BMI of 27 kg/m² and does not smoke. She would prefer a long-acting method. According to UKMEC, what is the contraceptive classification for the levonorgestrel intrauterine system in this patient?

A. UKMEC 1 - no restriction on use
B. UKMEC 2 - advantages generally outweigh risks (Correct Answer)
C. UKMEC 3 - risks generally outweigh advantages
D. UKMEC 4 - unacceptable health risk
E. UKMEC classification depends on duration of diabetes

Explanation: ***UKMEC 2 - advantages generally outweigh risks***- The **levonorgestrel intrauterine system (LNG-IUS)** is generally classified as **UKMEC 1** for women with diabetes without vascular complications.- However, the presence of **proliferative diabetic retinopathy**, a **microvascular complication**, elevates the classification to **UKMEC 2**. This means the benefits of effective contraception still generally outweigh the theoretical or proven risks, but careful consideration is required.*UKMEC 1 - no restriction on use*- This classification applies to women with **diabetes mellitus** who have **no evidence of vascular disease** (e.g., nephropathy, retinopathy, neuropathy).- The patient's **proliferative diabetic retinopathy** signifies established microvascular damage, thus precluding a UKMEC 1 classification for the LNG-IUS.*UKMEC 3 - risks generally outweigh advantages*- **UKMEC 3** for contraception in diabetic patients is typically reserved for methods with higher systemic hormonal impact, such as **combined hormonal contraceptives (CHCs)**, especially in the presence of vascular disease or diabetes duration >20 years.- The **LNG-IUS** delivers progestogen locally with minimal systemic absorption, making its impact on metabolic parameters and cardiovascular risk negligible compared to CHCs, thus it is not typically a UKMEC 3 for diabetes complications.*UKMEC 4 - unacceptable health risk*- A **UKMEC 4** classification indicates an unacceptable health risk and the method should not be used.- For the **LNG-IUS**, **diabetes mellitus**, even with **vascular complications** like retinopathy, does not constitute a **UKMEC 4** contraindication. Such classifications are usually for conditions like active pelvic inflammatory disease or certain uterine pathologies.*UKMEC classification depends on duration of diabetes*- While **duration of diabetes** (>20 years) can influence the UKMEC classification, particularly for **combined hormonal contraceptives**, it is not the primary determinant for the **LNG-IUS** in this patient.- The presence of **vascular complications** (like **proliferative retinopathy**) is the key factor that elevates the **LNG-IUS** classification from UKMEC 1 to UKMEC 2, regardless of diabetes duration.

Question 97: What is the primary reason for recommending that women who have undergone hysterectomy with ovarian conservation should be offered HRT at the time of natural menopause even if asymptomatic?

A. To prevent surgical menopause syndrome
B. To reduce the risk of premature ovarian insufficiency
C. To maintain bone density and reduce cardiovascular risk (Correct Answer)
D. To prevent postoperative adhesion formation
E. To reduce the risk of ovarian cancer

Explanation: ***To maintain bone density and reduce cardiovascular risk***- Women undergoing **natural menopause**, even with **ovarian conservation**, experience a decline in **estrogen**, which leads to an increased risk of **osteoporosis** and **cardiovascular disease**.- **Estrogen-only HRT** (feasible in women without a uterus) helps to mitigate these risks by supporting **bone mineral density** and improving **cardiovascular health**.*To prevent surgical menopause syndrome*- **Surgical menopause** is an acute, severe onset of menopausal symptoms caused by the abrupt loss of ovarian function after **bilateral oophorectomy**.- In women with **ovarian conservation**, menopause occurs naturally and gradually, leading to a typically milder and slower onset of symptoms, thus not fitting the definition of surgical menopause syndrome.*To reduce the risk of premature ovarian insufficiency*- **Hysterectomy** might slightly advance the age of natural menopause, but it does not directly cause **premature ovarian insufficiency (POI)**, which is the cessation of ovarian function before age 40.- HRT is a treatment for the symptoms and long-term consequences of POI, not a preventive measure against its occurrence.*To prevent postoperative adhesion formation*- **Postoperative adhesions** are fibrous bands that form between organs after surgery, caused by tissue injury and healing processes.- **Hormone replacement therapy** has no known mechanism or clinical evidence to prevent or reduce the formation of **postoperative adhesions**.*To reduce the risk of ovarian cancer*- **Ovarian conservation** means the ovaries are still present and functioning, maintaining the pre-existing risk of **ovarian cancer**.- HRT, particularly **estrogen-progestogen therapy**, may in fact slightly increase the risk of ovarian cancer, and it is not recommended for cancer prevention.

Question 98: A 45-year-old woman presents with a 12-month history of irregular menstrual cycles, hot flushes, and mood changes. She requests contraception as she remains sexually active. Her last menstrual period was 8 weeks ago. She has a BMI of 28 kg/m², blood pressure 135/85 mmHg, and no significant medical history. She smokes 5 cigarettes per day. What is the most appropriate management approach?

A. Advise that contraception is not needed as she is likely postmenopausal
B. Prescribe combined oral contraceptive pill for contraception and symptom control
C. Prescribe levonorgestrel intrauterine system with sequential HRT
D. Arrange FSH testing to confirm menopausal status before considering contraception
E. Prescribe progesterone-only pill and advise on smoking cessation (Correct Answer)

Explanation: ***Prescribe progesterone-only pill and advise on smoking cessation*** - Women over **45 years old** with perimenopausal symptoms still require **contraception** until they have been amenorrhoeic for **two years** (if under 50) or **one year** (if over 50). - The **Progesterone-Only Pill (POP)** is a safe choice (UKMEC 1) for this patient, unlike combined methods which are restricted due to her **age and smoking status**. *Advise that contraception is not needed as she is likely postmenopausal* - Postmenopause is only diagnosed clinically after **12 months of amenorrhoea** in a woman over 50, or **24 months** if under 50. - Ovulation can still occur during the **perimenopause**, meaning there is a persistent, albeit reduced, **risk of pregnancy**. *Prescribe combined oral contraceptive pill for contraception and symptom control* - The **Combined Oral Contraceptive Pill (COCP)** is generally avoided in women over **35 who smoke** (UKMEC 3) due to an increased risk of **venous thromboembolism** and stroke. - While it effective for symptom control, her smoking history makes the safety profile less favorable compared to **progestogen-only** methods. *Prescribe levonorgestrel intrauterine system with sequential HRT* - While the **LNG-IUS** is an excellent option for both contraception and the **progestogenic component of HRT**, it involves an invasive procedure that may not be her first choice. - **Sequential HRT** is used for symptom relief, but the initial priority is providing safe, simple **contraception** while managing lifestyle factors like smoking. *Arrange FSH testing to confirm menopausal status before considering contraception* - **FSH testing** is not routinely recommended to diagnose menopause or perimenopause in women over **45 years of age** based on clinical guidelines. - A single FSH level is unreliable due to **hormonal fluctuations** during the perimenopause and would not change the current need for **effective contraception**.

Question 99: A 34-year-old woman with well-controlled rheumatoid arthritis on methotrexate 15 mg weekly requests contraception. She is in a new relationship and wishes to avoid pregnancy while continuing her current treatment. She has no other medical conditions, does not smoke, and has a BMI of 23 kg/m². What is the most important counselling point regarding contraception for this patient?

A. She should use barrier methods only as all hormonal contraceptives are contraindicated with methotrexate
B. She requires highly effective contraception due to the teratogenic risk of methotrexate (Correct Answer)
C. She should discontinue methotrexate before starting any contraceptive method
D. Combined hormonal contraception is contraindicated due to increased risk of disease flare
E. The levonorgestrel intrauterine system is contraindicated due to immunosuppression risk

Explanation: ***She requires highly effective contraception due to the teratogenic risk of methotrexate*** - **Methotrexate** is a known **teratogen** that can cause severe birth defects and miscarriages due to its anti-folate mechanism. - Given this high risk, it is crucial for patients on methotrexate to use **highly effective contraception** to prevent pregnancy, continuing for at least **3 to 6 months** after discontinuing the drug. *She should use barrier methods only as all hormonal contraceptives are contraindicated with methotrexate* - **Hormonal contraceptives** are generally safe and **highly effective**, making them appropriate choices for women on methotrexate, unlike the false premise that they are contraindicated. - Relying solely on **barrier methods** is considered insufficient due to their higher failure rates, which poses an unacceptable risk given the **teratogenicity** of methotrexate. *She should discontinue methotrexate before starting any contraceptive method* - Discontinuing **methotrexate** is medically inadvisable as it could lead to a **flare** of her well-controlled **rheumatoid arthritis**, undermining her disease management. - Contraception should be initiated **prior to or concurrently** with methotrexate therapy to ensure continuous protection against pregnancy without interrupting essential treatment. *Combined hormonal contraception is contraindicated due to increased risk of disease flare* - There is **no evidence** to suggest that **combined hormonal contraception (CHC)** increases the risk of **rheumatoid arthritis flares**; some studies even suggest a potential stabilizing effect on disease activity. - Given her favorable profile (non-smoker, BMI 23), she is a good candidate for CHC, as her **cardiovascular risks** are low. *The levonorgestrel intrauterine system is contraindicated due to immunosuppression risk* - The **levonorgestrel intrauterine system (LNG-IUS)** is a **Long-Acting Reversible Contraceptive (LARC)** and is considered a safe and highly effective option for women on **immunosuppressive therapy** like methotrexate. - There is no increased risk of **infection** or **pelvic inflammatory disease (PID)** associated with LNG-IUS use in patients with well-controlled rheumatoid arthritis on methotrexate.

Question 100: A 52-year-old woman with a history of endometriosis presents with menopausal symptoms including severe hot flushes and night sweats for 6 months. She had a total hysterectomy without oophorectomy 8 years ago. Her FSH level is 67 IU/L. She is keen to start HRT but is concerned about symptom recurrence. Her BMI is 26 kg/m² and she is a non-smoker. What is the most appropriate initial HRT regimen?

A. Continuous combined estrogen and progestogen HRT
B. Sequential combined estrogen and progestogen HRT
C. Estrogen-only HRT with add-back progestogen
D. Estrogen-only HRT (Correct Answer)
E. Tibolone

Explanation: ***Estrogen-only HRT*** - In women who have undergone a **total hysterectomy**, the risk of **endometrial hyperplasia** is eliminated, making progesterone for endometrial protection unnecessary. - While the patient has a history of **endometriosis**, estrogen-only therapy remains the first-line choice because the risk of reactivating residual tissue is generally low and outweighed by managing severe **vasomotor symptoms**. *Continuous combined estrogen and progestogen HRT* - This regimen is typically reserved for women with an **intact uterus** to prevent endometrial cancer through continuous progestogen exposure. - Using progestogen in this patient unnecessarily increases the risk of side effects like **breast tenderness** and slightly higher **breast cancer** risk without clear benefit. *Sequential combined estrogen and progestogen HRT* - Typically used for **perimenopausal** women with a uterus to provide predictable withdrawal bleeds. - Since this patient has had a **hysterectomy**, there is no endometrium to shed, making this complex regimen inappropriate. *Estrogen-only HRT with add-back progestogen* - Add-back therapy is sometimes considered if there is known **extensive residual endometriosis**, but it is not the standard initial step post-hysterectomy. - It complicates the regimen and should only be initiated if symptoms of **endometriosis recurrence** (like pelvic pain) actually develop. *Tibolone* - Tibolone is a synthetic compound with **estrogenic, progestogenic, and androgenic** properties that can be used post-menopause. - While it is an option for women with a history of endometriosis to avoid estrogenic stimulation, standard **estrogen-only HRT** is more conventional for initial management of severe flashes.

Question 101: A 27-year-old woman presents requesting contraception. She has a history of multiple sclerosis diagnosed 3 years ago with limited mobility. She is currently wheelchair-bound and experiences frequent urinary tract infections. Her BMI is 24 kg/m². She does not smoke and has no other significant medical history. She is in a stable relationship and has completed her family. What is the most appropriate contraceptive method for this patient?

A. Combined oral contraceptive pill
B. Progesterone-only pill
C. Copper intrauterine device
D. Levonorgestrel intrauterine system (Correct Answer)
E. Etonogestrel subdermal implant

Explanation: ***Levonorgestrel intrauterine system*** - The **LNG-IUS** is ideal for this patient because it avoids the high **VTE risk** associated with immobility/wheelchair use in **multiple sclerosis** (UKMEC 3-4 for combined methods). - It provides highly effective **long-acting reversible contraception (LARC)** and offers the benefit of **reduced menstrual bleeding**, which simplifies hygiene for patients with **limited mobility**. *Combined oral contraceptive pill* - This is contraindicated (**UKMEC 4**) because the patient's **prolonged immobility** and wheelchair use significantly increase the risk of **venous thromboembolism (VTE)**. - Estrogen-containing methods are avoided in **multiple sclerosis** patients who are not fully ambulatory due to this synergistic **thrombotic risk**. *Progesterone-only pill* - While it is safe regarding **VTE risk**, it is less effective than **LARC** methods and requires strict daily adherence, which may be more difficult with chronic illness. - The **LNG-IUS** is preferred over the POP because it provides superior **menstrual suppression**, which is a significant quality-of-life benefit for this patient. *Copper intrauterine device* - Although it does not increase VTE risk, the **Copper IUD** is often associated with **heavier or more painful periods**, which is undesirable for someone with limited mobility. - The lack of hormonal benefits for **menstrual control** makes it a less optimal choice compared to the **Levonorgestrel intrauterine system**. *Etonogestrel subdermal implant* - The **implant** is a safe **LARC** option with no estrogen-related VTE risk, but it frequently causes **unpredictable bleeding** patterns. - In contrast, the **LNG-IUS** more consistently leads to **amenorrhea or oligomenorrhea**, which is clinically more beneficial for managing hygiene in a **wheelchair-bound** patient.

Question 102: A 40-year-old woman with well-controlled hypertension on ramipril presents requesting contraception. Her blood pressure today is 134/86 mmHg. She has been normotensive on treatment for the past year with no end-organ damage. Her BMI is 26 kg/m², and she is a non-smoker. She has regular periods and no other medical problems. She would prefer not to use an intrauterine device. According to UKMEC guidelines, which contraceptive method would be classified as category 2 (benefits generally outweigh risks) for this patient?

A. Combined oral contraceptive pill (Correct Answer)
B. Levonorgestrel intrauterine system
C. Etonogestrel contraceptive implant
D. Copper intrauterine device
E. Progestogen-only pill

Explanation: ***Combined oral contraceptive pill*** - For women with **adequately controlled hypertension** (consistently <140/90 mmHg), the **COCP** is classified as **UKMEC 2**, meaning benefits generally outweigh the risks. - While estrogen can slightly increase blood pressure, it is acceptable in this patient because she is a **non-smoker**, has a BMI <30, and no **target organ damage**. *Levonorgestrel intrauterine system* - All **intrauterine devices** (including hormonal systems like LNG-IUS) are classified as **UKMEC 1** for patients with hypertension. - Although a safe option, it is not the correct answer because the question specifically asks for a **UKMEC 2** classification and the patient prefers not to use an IUD. *Etonogestrel contraceptive implant* - The **contraceptive implant** is typically classified as **UKMEC 1** for patients with controlled or mildly elevated blood pressure. - It does not contain **estrogen**, which is the primary component restricted in hypertensive patients, thus having fewer restrictions than the COCP. *Copper intrauterine device* - The **Copper IUD** is a non-hormonal method and is classified as **UKMEC 1** for all degrees of hypertension. - This method has no effect on blood pressure or **cardiovascular risk**, but it was specifically declined by the patient. *Progestogen-only pill* - For patients with **adequately controlled hypertension**, the **POP** is classified as **UKMEC 1**. - It is only upgraded to **UKMEC 2** if the systolic blood pressure is 140–159 mmHg or the diastolic is 90–99 mmHg.

Question 103: A 53-year-old woman commenced on continuous combined HRT 3 months ago presents with bilateral breast tenderness and swelling. She had significant vasomotor symptoms which have improved on treatment. Her mother had breast cancer diagnosed at age 68. Examination reveals symmetrically enlarged, tender breasts with no discrete masses. What is the most appropriate initial management?

A. Stop HRT immediately and refer urgently to breast clinic under 2-week-wait pathway
B. Continue current HRT and arrange routine mammography
C. Reduce the estrogen dose of her current HRT preparation (Correct Answer)
D. Switch to tibolone which has less breast adverse effects
E. Add continuous progestogen to reduce breast symptoms

Explanation: ***Reduce the estrogen dose of her current HRT preparation*** - **Breast tenderness and swelling** are common side effects during the initial months of HRT due to **estrogen stimulation** of breast tissue. - Reducing the **estrogen dose** typically alleviates these symptoms while maintaining control of **vasomotor symptoms**, making it the most appropriate initial management step. *Stop HRT immediately and refer urgently to breast clinic under 2-week-wait pathway* - **Urgent referral** is not indicated as clinical findings are **bilateral and symmetrical** without discrete masses, which are typically benign features of HRT side effects. - Immediate cessation is unnecessary given the symptoms are expected **side effects** of recent treatment initiation rather than signs of malignancy; the family history of breast cancer at 68 is not an immediate red flag for this presentation. *Continue current HRT and arrange routine mammography* - While symptoms may settle over time, the patient is currently symptomatic; management should focus on **dose adjustment** rather than just observation. - Mammography should follow the **national screening program** guidelines, and there is no indication for diagnostic imaging of bilateral, symmetrical physiological tenderness outside of these guidelines. *Switch to tibolone which has less breast adverse effects* - **Tibolone** is an alternative, but it is premature to switch medication classes before attempting a simple **dose reduction** of the current effective regimen. - Dose titration is the standard first-line approach for managing **hormone-related side effects** within the first 3-6 months of HRT. *Add continuous progestogen to reduce breast symptoms* - The patient is already on **continuous combined HRT**, meaning she is already receiving daily progestogen to protect the endometrium. - Adding extra progestogen does not mitigate **estrogen-induced** breast swelling and may introduce additional side effects like mood changes or bloating.

Question 104: A 44-year-old woman with menorrhagia has been using a levonorgestrel intrauterine system for 18 months with good symptom control. She now presents with a 6-week history of deep dyspareunia and intermittent lower abdominal pain. Bimanual examination reveals a bulky, tender uterus with reduced mobility and tenderness in the posterior fornix. The IUS threads are visible. A transvaginal ultrasound shows a retroverted uterus, bulky adenomyotic uterus, and the LNG-IUS in the correct fundal position. What is the most likely cause of her symptoms?

A. IUS malposition causing pain
B. Pelvic inflammatory disease secondary to IUS
C. Progression of underlying adenomyosis (Correct Answer)
D. Development of endometrial cancer
E. IUS perforation into the pouch of Douglas

Explanation: ***Progression of underlying adenomyosis*** - The ultrasound and physical examination confirm a **bulky, tender uterus** and adenomyotic changes, which typically progress over time despite hormonal control of bleeding. - While the **LNG-IUS** effectively manages **menorrhagia**, it does not halt the structural progression of adenomyosis, leading to new-onset **deep dyspareunia** and pelvic pain. *IUS malposition causing pain* - The **transvaginal ultrasound** explicitly states that the LNG-IUS is in the **correct fundal position**. - Visible **IUS threads** during the clinical examination further support that the device has not displaced significantly from the uterine cavity. *Pelvic inflammatory disease secondary to IUS* - The risk of **PID** related to IUS insertion is highest within the first **20 days**; this patient has had the device for 18 months. - The absence of **fever**, abnormal discharge, and the specific ultrasound findings make a chronic infectious process less likely than a structural progression. *Development of endometrial cancer* - The **LNG-IUS** provides high levels of local progestogen, which offers significant **endometrial protection** against hyperplasia and malignancy. - Endometrial cancer usually presents with **postmenopausal** or abnormal bleeding rather than the **bulky, tender uterus** and dyspareunia seen here. *IUS perforation into the pouch of Douglas* - A **perforation** typically occurs during insertion, and the ultrasound clearly visualizes the device within the **fundal position** of the uterus. - If perforation had occurred, the **IUS threads** would likely be retracted and not visible on bimanual examination.

Question 105: A 25-year-old woman presents 36 hours after unprotected sexual intercourse requesting emergency contraception. She is on day 12 of her menstrual cycle with regular 28-day cycles. She takes no regular medications and has no medical contraindications. She does not wish to have an intrauterine device inserted. What is the most effective oral emergency contraception for this patient?

A. Levonorgestrel 1.5 mg as she is within 72 hours
B. Ulipristal acetate 30 mg as it is more effective around ovulation (Correct Answer)
C. Double dose levonorgestrel 3 mg due to timing in cycle
D. Either levonorgestrel or ulipristal acetate as they are equally effective
E. No emergency contraception needed as she is in the proliferative phase

Explanation: ***Ulipristal acetate 30 mg as it is more effective around ovulation*** - **Ulipristal acetate (UPA)** is the first-line oral choice for this patient because it is more effective than levonorgestrel in the **periovulatory period** (days 10–14 of a 28-day cycle), and she is on day 12. - UPA can delay or inhibit **ovulation** even after the **LH surge** has begun, providing a wider window of effectiveness closer to actual ovulation compared to levonorgestrel. *Levonorgestrel 1.5 mg as she is within 72 hours* - While **levonorgestrel (LNG)** is effective within 72 hours, its efficacy significantly decreases when taken close to **ovulation**, especially after the **LH surge** has started. - LNG primarily works by preventing or delaying ovulation *before* the LH surge, making it less effective than UPA in the patient's fertile window. *Double dose levonorgestrel 3 mg due to timing in cycle* - A **double dose** of levonorgestrel (3 mg) is not standard practice for increasing efficacy based on **menstrual cycle timing** alone. - This higher dose is typically considered only for patients with a **BMI >30 kg/m² or weight >75 kg**, or those on **enzyme-inducing medications**, none of which are mentioned here. *Either levonorgestrel or ulipristal acetate as they are equally effective* - This statement is incorrect; **ulipristal acetate** has been shown to be more effective than **levonorgestrel**, particularly when taken closer to ovulation and up to 120 hours post-coitus. - In the **periovulatory period**, UPA maintains higher efficacy in preventing pregnancy compared to LNG. *No emergency contraception needed as she is in the proliferative phase* - Day 12 of a regular 28-day cycle falls within the **fertile window** and is very close to the expected day of **ovulation** (typically day 14). - Given that **sperm** can survive for up to 5 days, unprotected intercourse on day 12 carries a high risk of conception, necessitating emergency contraception.

Question 106: A 57-year-old woman attends for review. She started estrogen-only HRT (transdermal 17β-estradiol 50 mcg) 2 years ago following total hysterectomy for fibroids. Her vasomotor symptoms are now well controlled. She asks about how long she should continue treatment and whether she needs any investigations. What is the most appropriate advice regarding duration and monitoring of her HRT?

A. Continue HRT indefinitely as benefits outweigh risks with estrogen-only therapy after hysterectomy
B. Stop HRT now as 2 years is the maximum recommended duration
C. Continue for up to 5 years total, then mandatory discontinuation
D. Continue while symptoms persist with annual review; no routine investigations needed (Correct Answer)
E. Continue only if mammography and bone density scans are normal

Explanation: ***Continue while symptoms persist with annual review; no routine investigations needed***- There is no **arbitrary time limit** for HRT use; it should be continued as long as the benefits outweigh the risks and symptoms persist.- Decision making involves an **annual review** of symptoms and risks, with no mandatory investigations required specifically for HRT monitoring.*Continue HRT indefinitely as benefits outweigh risks with estrogen-only therapy after hysterectomy*- While **estrogen-only HRT** has a more favorable risk profile than combined therapy, it should still be subject to **annual individual assessment** rather than an "indefinite" prescription.- This approach ignores the necessity of periodic trials of **dose reduction** or discontinuation to see if vasomotor symptoms have naturally resolved.*Stop HRT now as 2 years is the maximum recommended duration*- A two-year limit is medically unsupported; symptoms can last for many years, and **NICE guidelines** do not set a fixed maximum duration.- Stopping treatment prematurely can lead to a return of **vasomotor symptoms** and a loss of bone protective benefits.*Continue for up to 5 years total, then mandatory discontinuation*- The "5-year rule" is often cited regarding **combined HRT** and breast cancer risk, but it is not a mandatory cutoff for estrogen-only therapy.- Treatment duration should be **individualized** based on the patient's quality of life and clinical profile rather than a fixed number of years.*Continue only if mammography and bone density scans are normal*- Routine **bone density scans** are not indicated for monitoring HRT unless there are specific clinical risk factors for osteoporosis.- While **mammography** should continue as per the national screening program, it is not a prerequisite for the continuation of estrogen-only HRT.

Question 107: A 36-year-old woman with a history of venous thromboembolism 2 years ago following a long-haul flight requests contraception. She completed 6 months of anticoagulation and thrombophilia screening revealed no underlying abnormality. She is a non-smoker with BMI of 28 kg/m². She does not wish to become pregnant for at least 5 years. What is the most appropriate contraceptive method according to UKMEC classification?

A. Combined oral contraceptive pill as the VTE was provoked and she has no thrombophilia
B. Desogestrel progestogen-only pill
C. Etonogestrel contraceptive implant
D. Copper intrauterine device (Correct Answer)
E. Depot medroxyprogesterone acetate injection

Explanation: ***Copper intrauterine device*** - The copper IUD is classified as **UKMEC 1** (no restriction) for patients with a history of **venous thromboembolism (VTE)** because it is a non-hormonal method with no effect on coagulation. - It is highly appropriate for this patient as it provides effective **long-acting reversible contraception (LARC)** for 5 to 10 years, meeting her requirement for long-term pregnancy prevention. *Combined oral contraceptive pill as the VTE was provoked and she has no thrombophilia* - Any history of VTE, regardless of being provoked or having a negative thrombophilia screen, is classified as **UKMEC 4** (unacceptable health risk) for combined hormonal contraception. - The **estrogen component** significantly increases the risk of recurrent thrombosis, making it strictly contraindicated in this clinical scenario. *Desogestrel progestogen-only pill* - A history of VTE is categorized as **UKMEC 2** (benefits generally outweigh risks) for the progestogen-only pill (POP), although some guidelines previously considered it UKMEC 3 for active VTE. - While safer than combined methods, it requires daily compliance and is less ideal than the **UKMEC 1** copper IUD for a patient seeking long-term 5-year protection. *Etonogestrel contraceptive implant* - The contraceptive implant is categorized as **UKMEC 2** for patients with a history of VTE, indicating that the benefits generally outweigh the theoretical risks. - Although a valid LARC option, it only lasts for **3 years**, which does not fully meet the patient's request for at least **5 years** of contraception. *Depot medroxyprogesterone acetate injection* - Injectable progestogens like DMPA are classified as **UKMEC 2** for women with a previous history of VTE. - While it provides effective contraception, the **Copper IUD** is superior in this case due to its **UKMEC 1** status and its ability to provide protection for the full 5-year duration requested.

Question 108: A 52-year-old woman who has been taking sequential combined HRT for 14 months presents with a 10-day episode of vaginal bleeding that started on day 8 of her progestogen phase, which is earlier than her usual withdrawal bleed. The bleeding was heavier than normal. She has been compliant with her medication. Her last cervical screening 18 months ago was normal. Examination reveals a normal-sized, non-tender uterus. What is the most appropriate management?

A. Arrange transvaginal ultrasound to measure endometrial thickness
B. Stop HRT for 3 months and reassess bleeding pattern
C. Reassure and continue current HRT as breakthrough bleeding is common in the first year
D. Switch to continuous combined HRT to reduce bleeding
E. Arrange outpatient hysteroscopy and endometrial biopsy (Correct Answer)

Explanation: ***Arrange outpatient hysteroscopy and endometrial biopsy*** - In women on HRT for more than 6 months, any **unscheduled bleeding** or significant change in the withdrawal bleeding pattern requires urgent investigation to rule out **endometrial hyperplasia** or **malignancy**. - This patient’s bleeding is concerning because it is **heavier than normal**, lasted **10 days**, and occurred prematurely during the **progestogen phase** rather than after it. *Arrange transvaginal ultrasound to measure endometrial thickness* - While **transvaginal ultrasound** is a common first-line tool, it is less reliable for patients on HRT due to variations in **endometrial thickness** during the cycle. - **Hysteroscopy** and biopsy are preferred in this clinical scenario as they allow for **direct visualization** and histology, which is the gold standard for diagnosis. *Stop HRT for 3 months and reassess bleeding pattern* - Stopping HRT would delay the diagnosis of a potentially serious condition such as **endometrial cancer** and is not a recommended diagnostic strategy. - Management must focus on active investigation of the **abnormal bleeding** while the patient is still symptomatic. *Reassure and continue current HRT as breakthrough bleeding is common in the first year* - Breakthrough bleeding is common in the first **6 months**; however, this patient has been on HRT for **14 months**, making new bleeding patterns suspicious. - Reassurance is inappropriate because her bleeding started during the **progestogen phase**, which is not a normal physiological response to sequential HRT. *Switch to continuous combined HRT to reduce bleeding* - Switching to **continuous combined HRT** is only appropriate for women who are **postmenopausal** and have no suspicious bleeding symptoms. - Changing the formulation before excluding **endometrial pathology** is dangerous and could mask symptoms of an underlying malignancy.

Question 109: A 31-year-old woman with body mass index of 39 kg/m² attends for review 6 weeks after insertion of a copper intrauterine device. She reports the device is working well with no problems. She asks when she needs to have the device changed. What is the licensed duration of use for the copper IUD for contraception in this patient?

A. 5 years as per standard licensing for all copper IUDs
B. 10 years if the device contains ≥300 mm² copper (Correct Answer)
C. 10 years regardless of copper content
D. Indefinitely until menopause if inserted after age 40
E. 5 years due to her obesity reducing device efficacy

Explanation: ***10 years if the device contains ≥300 mm² copper*** - Copper IUDs with a **copper surface area of 300 mm² or more** (e.g., T-Safe 380A) are licensed for **10 years** of use due to their sustained contraceptive efficacy. - The higher copper content ensures a consistent spermicidal and anti-implantation effect over a longer period, making them highly effective long-acting reversible contraception (LARC). *5 years as per standard licensing for all copper IUDs* - While some copper IUDs are indeed licensed for **5 years**, many newer or higher-copper-content devices have an **extended license of 10 years**. - The licensed duration is dependent on the specific **model and copper surface area** of the device, not a universal standard of 5 years for all. *10 years regardless of copper content* - The **amount of copper** in the device is a critical determinant of its licensed duration, with devices containing less copper generally having a shorter (e.g., 5-year) license. - Copper works by causing a local inflammatory reaction in the uterus, and a sufficient **surface area** is required to maintain this effect for an extended period. *Indefinitely until menopause if inserted after age 40* - This rule applies to copper IUDs inserted when a woman is **40 years or older**, allowing them to be kept until menopause for contraception. - However, the patient in this scenario is **31 years old**, meaning the device must be removed or replaced at the end of its licensed duration. *5 years due to her obesity reducing device efficacy* - The **efficacy of copper IUDs** is not affected by a woman's **body mass index (BMI)** or obesity, unlike some hormonal contraceptive methods. - Therefore, there is no medical reason to reduce the licensed duration of a copper IUD based on the patient's **BMI of 39 kg/m²**.

Question 110: A 48-year-old woman presents with an 8-month history of increasingly irregular menstrual cycles, hot flushes, and mood swings. Her last period was 4 months ago. She requests hormone replacement therapy. Her BMI is 23 kg/m², blood pressure is 124/78 mmHg, and she is a non-smoker. She has no significant medical history. Pelvic examination is normal. What is the most appropriate initial HRT regimen for this woman?

A. Continuous combined HRT (estrogen and progestogen daily)
B. Sequential combined HRT (estrogen daily with cyclical progestogen) (Correct Answer)
C. Estrogen-only HRT with annual endometrial surveillance
D. Tibolone as first-line therapy
E. Progestogen-only preparation

Explanation: ***Sequential combined HRT (estrogen daily with cyclical progestogen)*** - This woman is **perimenopausal** (amenorrhea for less than 12 months) and has an **intact uterus**, thus requiring combined HRT to prevent **endometrial hyperplasia**. - The cyclical progestogen, administered for 10-14 days each month, ensures shedding of the uterine lining, leading to predictable **withdrawal bleeds** while managing symptoms. *Continuous combined HRT (estrogen and progestogen daily)* - This regimen is indicated for **postmenopausal women** who have been amenorrheic for at least **12 consecutive months**. - Initiating it during perimenopause often leads to high rates of **unscheduled or irregular breakthrough bleeding**, which is undesirable. *Estrogen-only HRT with annual endometrial surveillance* - **Estrogen-only HRT** is strictly reserved for women who have undergone a **hysterectomy**. - In a woman with an **intact uterus**, unopposed estrogen significantly increases the risk of developing **endometrial hyperplasia** and **endometrial carcinoma**. *Tibolone as first-line therapy* - **Tibolone** is a synthetic steroid with estrogenic, progestogenic, and androgenic properties, primarily used for **postmenopausal** symptoms and osteoporosis prevention. - Like continuous combined HRT, it is generally recommended only after **12 months of amenorrhea** to avoid unpredictable bleeding patterns. *Progestogen-only preparation* - **Progestogen-only** preparations are typically used for contraception or to manage heavy menstrual bleeding, not as primary therapy for **vasomotor symptoms**. - This regimen would not effectively alleviate the woman's **hot flushes** and other symptoms of estrogen deficiency.

Question 111: What is the maximum timeframe after the last menstrual period in a woman over 50 years of age during which ulipristal acetate can be used as emergency contraception?

A. 72 hours
B. 96 hours
C. 120 hours (Correct Answer)
D. 168 hours
E. 144 hours

Explanation: ***120 hours*** - **Ulipristal acetate (UPA)** is a selective progesterone receptor modulator licensed for emergency contraception up to **120 hours** (5 days) after unprotected intercourse. - The timeframe remains the same regardless of age; women over **50 years** are still considered at risk of pregnancy until they are documented as **postmenopausal** (two years of amenorrhea if under 50, or one year if over 50). *72 hours* - This is the licensed timeframe for **Levonorgestrel (LNG)** emergency contraception, which is less effective than UPA between 72 and 120 hours. - While LNG works best within the first 24 hours, **Ulipristal acetate** maintains its efficacy throughout the entire 120-hour window. *96 hours* - **Levonorgestrel** may be used off-license up to 96 hours after intercourse, but its efficacy is significantly reduced at this point. - Research indicates that **Ulipristal acetate** is the preferred oral choice when the timeframe exceeds 72 hours due to its superior **ovulation delay** capabilities. *168 hours* - There is currently no oral emergency contraceptive pill licensed for use up to **168 hours** (7 days); both LNG and UPA are ineffective at this stage. - If more than 120 hours have passed, clinical assessment for a **Copper IUD** (which can be used up to 5 days after the earliest predicted ovulation) is required. *144 hours* - This duration exceeds the maximum **5-day therapeutic window** established for both Ulipristal acetate and the Copper IUD (post-intercourse). - Oral emergency contraception relies on **inhibiting ovulation**, which is statistically unlikely to be successful if the delay between intercourse and treatment is this long.

Question 112: A 29-year-old woman presents requesting removal of her etonogestrel contraceptive implant which was inserted 2 years ago. She reports a 4-month history of persistent irregular bleeding and has decided she would like to try for pregnancy. On examination, the implant cannot be palpated in the expected location in the upper arm. What is the most appropriate next step in management?

A. Attempt removal under local anaesthetic using a small incision at the insertion site
B. Arrange plain radiograph of the arm to locate the implant
C. Arrange ultrasound scan of the arm to locate the implant (Correct Answer)
D. Refer urgently to radiology for chest X-ray to exclude migration
E. Reassure that the implant has dissolved and no further action is needed

Explanation: ***Arrange ultrasound scan of the arm to locate the implant***- **High-frequency ultrasound** (10-15 MHz) is the first-line investigation for a non-palpable **etonogestrel implant** as it is highly effective at identifying the device's location and depth.- Localization must be confirmed prior to any removal attempt to prevent **tissue damage** or a failed surgical procedure.*Attempt removal under local anaesthetic using a small incision at the insertion site*- **Blind exploration** is strictly contraindicated for non-palpable implants due to the risk of damaging underlying **nerves and vessels**.- It has a high failure rate and can lead to unnecessary **scarring** without guaranteeing the device is actually at that site.*Arrange plain radiograph of the arm to locate the implant*- Etonogestrel implants (Nexplanon/Implanon) are generally **not radio-opaque** enough for reliable detection on a standard **X-ray**.- Unlike the Jadelle system, these implants depend on **ultrasound or MRI** for visualization when they cannot be felt.*Refer urgently to radiology for chest X-ray to exclude migration*- **Migration** to the pulmonary vasculature is an extremely rare complication and is only considered if the implant is not found in the arm via **ultrasound or MRI**.- A **chest X-ray** is not the appropriate initial step for a patient presenting with an asymptomatic non-palpable device in the arm.*Reassure that the implant has dissolved and no further action is needed*- Contraceptive implants are made of **non-biodegradable** materials and do not dissolve in the body.- If the implant remains in situ, it may continue to release low levels of hormones, causing **irregular bleeding** and delaying the patient's desire for **pregnancy**.

Question 113: A 42-year-old nulliparous woman requests contraception. She has a history of focal epilepsy controlled on lamotrigine 200 mg daily. Her seizures have been well controlled for 3 years. She does not wish to become pregnant. What is the most important counselling point regarding combined oral contraceptive pill use in this patient?

A. The COCP will reduce the effectiveness of lamotrigine requiring dose adjustment
B. Lamotrigine will reduce the effectiveness of the COCP requiring additional contraception
C. The COCP may reduce lamotrigine levels increasing seizure risk (Correct Answer)
D. Both drugs interact causing increased risk of venous thromboembolism
E. No significant interaction occurs between lamotrigine and the COCP

Explanation: ***The COCP may reduce lamotrigine levels increasing seizure risk***- The **ethinylestradiol** component of the COCP induces the liver enzyme **UDP-glucuronosyltransferase (UGT1A4)**, which significantly increases the metabolism and clearance of **lamotrigine**.- This interaction can cause a **50% or greater reduction** in serum lamotrigine concentrations, potentially leading to a loss of **seizure control** and requiring dose adjustment.*The COCP will reduce the effectiveness of lamotrigine requiring dose adjustment*- While this statement acknowledges the effect on lamotrigine, it is slightly less precise than the correct option which directly links the level reduction to the **clinical risk of seizures**.- It is important to note that because of this interaction, the **UKMEC** category for COCP use with lamotrigine is **Category 3**, suggesting the risks usually outweigh the benefits.*Lamotrigine will reduce the effectiveness of the COCP requiring additional contraception*- Unlike enzyme-inducing antiepileptics (e.g., carbamazepine), **lamotrigine** does not significantly induce the cytochrome P450 system and does not reduce the **contraceptive efficacy** of the COCP.- Patients do not need to take extra precautions to prevent pregnancy specifically because they are on lamotrigine; the concern is exclusively the **anti-epileptic's efficacy**.*Both drugs interact causing increased risk of venous thromboembolism*- While the COCP itself carries a baseline increased risk of **venous thromboembolism (VTE)**, there is no evidence that lamotrigine synergistically increases this specific risk.- The interaction between these medications is **pharmacokinetic** (metabolism-based) rather than **pro-thrombotic**.*No significant interaction occurs between lamotrigine and the COCP*- This is incorrect as a major **bidirectional interaction** exists; lamotrigine levels can drop during the active pill weeks and rise to toxic levels during the **pill-free interval**.- Clinicians must be aware of this interaction to avoid **toxic side effects** or **breakthrough seizures**, making monitoring and counselling essential.

Question 114: A 54-year-old woman presents with severe vasomotor symptoms 18 months after her last menstrual period. She has a history of stage I endometrial cancer treated with total abdominal hysterectomy and bilateral salpingo-oophorectomy 3 years ago. She is currently disease-free on surveillance. She requests hormone replacement therapy as lifestyle measures have been ineffective. What is the most appropriate management?

A. Prescribe continuous combined HRT with progestogen protection
B. Offer cognitive behavioural therapy alone
C. Prescribe estrogen-only HRT as she has had a hysterectomy
D. Prescribe tibolone as it has weak estrogenic effects
E. Offer selective serotonin reuptake inhibitors as first-line treatment (Correct Answer)

Explanation: ***Offer selective serotonin reuptake inhibitors as first-line treatment***- In patients with a history of **estrogen-dependent cancers** like endometrial cancer, **Hormone Replacement Therapy (HRT)** is generally contraindicated due to the risk of disease recurrence.- **SSRIs** or **SNRIs** (e.g., venlafaxine) are the first-line pharmacological non-hormonal alternatives proven to effectively reduce the frequency and severity of **vasomotor symptoms**.*Prescribe continuous combined HRT with progestogen protection*- While progestogens can counteract estrogenic effects on the endometrium, any form of systemic **estrogen** is avoided in survivors of **endometrial cancer** to minimize recurrence risk.- Combined therapy is usually reserved for women with an intact uterus; since this patient had a **hysterectomy**, combined HRT is not standard practice even in healthy individuals.*Offer cognitive behavioural therapy alone*- Although **CBT** can help manage the impact of menopausal symptoms, it is often insufficient as **monotherapy** for patients complaining of "severe" vasomotor symptoms.- Guidelines suggest combining lifestyle or behavioral interventions with **non-hormonal pharmacological** agents when symptoms significantly impact quality of life.*Prescribe estrogen-only HRT as she has had a hysterectomy*- Estrogen-only HRT is the standard for women post-hysterectomy, but it is strictly **contraindicated** here because her cancer was **estrogen-dependent**.- Even with Stage I disease and successful surgical resection (**TAH-BSO**), the potential risk of stimulating residual micrometastatic cells outweighs the benefits.*Prescribe tibolone as it has weak estrogenic effects*- **Tibolone** is a synthetic compound with estrogenic, progestogenic, and androgenic activity, making it unsuitable for women with a history of **hormone-sensitive malignancies**.- Its use is specifically discouraged in survivors of **breast or endometrial cancer** due to its estrogen receptor-stimulating properties.

Question 115: A 35-year-old woman with type 2 diabetes mellitus and a BMI of 34 kg/m² requests contraception. She has regular periods and is a non-smoker. Her blood pressure is 118/76 mmHg. She has tried oral contraceptive pills previously but frequently forgot to take them. She is interested in long-acting reversible contraception and particularly asks about the copper intrauterine device. What is the primary advantage of the copper IUD over the levonorgestrel intrauterine system for this patient?

A. Lower risk of expulsion in obese women
B. Shorter duration of action allowing more flexible fertility planning
C. Non-hormonal method suitable for women with diabetes-related vascular complications (Correct Answer)
D. Reduced menstrual blood loss compared to baseline
E. Lower failure rate in overweight and obese women

Explanation: ***Non-hormonal method suitable for women with diabetes-related vascular complications***- The **copper intrauterine device (Cu-IUD)** is completely **non-hormonal**, making it an ideal choice for women with complex medical histories like diabetes where hormonal metabolic effects are a concern.- While progestogens are generally safe, a hormone-free method avoids any theoretical risk regarding **glucose metabolism** or **cardiovascular complications** associated with long-term steroid use.*Lower risk of expulsion in obese women*- There is no clinical evidence to suggest that the **Cu-IUD** has a lower **expulsion rate** compared to the **levonorgestrel intrauterine system (LNG-IUS)** based on BMI.- **Obesity** is generally not a risk factor for IUD expulsion; instead, factors like **age** and **parity** play a more significant role.*Shorter duration of action allowing more flexible fertility planning*- The **copper IUD** actually has a **longer duration of action** (approved for up to 10 years) compared to the LNG-IUS (approved for 5-8 years depending on the brand).- Both methods allow for an immediate **return to fertility** upon removal, so neither offers a specific advantage in planning flexibility.*Reduced menstrual blood loss compared to baseline*- This is incorrect as the **copper IUD** is well-known to potentially **increase menstrual blood loss** and cramping.- It is the **LNG-IUS**, not the copper IUD, that is the treatment of choice for reducing **menorrhagia** due to its local effect on the endometrium.*Lower failure rate in overweight and obese women*- Both the **Cu-IUD** and **LNG-IUS** are highly effective **Long-Acting Reversible Contraceptives (LARCs)** with failure rates of less than 1%.- Unlike some systemic hormonal methods (like the patch), the efficacy of **intrauterine devices** is not negatively impacted by a high **BMI**.

Question 116: A 55-year-old woman who experienced natural menopause at age 51 presents with vulvovaginal atrophy symptoms including severe vaginal dryness, dyspareunia, and urinary frequency. She declined systemic HRT 3 years ago due to concerns about breast cancer, as her sister was diagnosed with breast cancer at age 58. She has tried vaginal moisturisers with minimal benefit. What is the most appropriate management?

A. Prescribe systemic continuous combined HRT as benefits outweigh risks at 4 years postmenopause
B. Prescribe vaginal estradiol pessaries 10 mcg daily for 2 weeks then twice weekly maintenance (Correct Answer)
C. Prescribe vaginal conjugated equine estrogens cream with cyclical progestogen for endometrial protection
D. Prescribe ospemifene 60 mg daily as it is a selective estrogen receptor modulator
E. Prescribe prasterone vaginal DHEA suppositories with concurrent systemic progestogen

Explanation: ***Prescribe vaginal estradiol pessaries 10 mcg daily for 2 weeks then twice weekly maintenance***- **Low-dose vaginal estrogen** is the **first-line medical treatment** for **Genitourinary Syndrome of Menopause (GSM)** when non-hormonal moisturizers fail.- It has **minimal systemic absorption**, making it safe for women with a family history of breast cancer and eliminates the need for **progestogen-mediated endometrial protection**.*Prescribe systemic continuous combined HRT as benefits outweigh risks at 4 years postmenopause*- The patient specifically **declined systemic HRT** due to safety concerns and her primary symptoms are localized to the vulvovaginal area.- While the "window of opportunity" (within 10 years of menopause) makes her a candidate for systemic therapy, **local treatment** is safer and more targeted for isolated atrophy.*Prescribe vaginal conjugated equine estrogens cream with cyclical progestogen for endometrial protection*- **Low-dose local estrogens** (like 10 mcg estradiol) do not require a **progestogen** because they do not cause significant endometrial proliferation.- **Conjugated equine estrogen (CEE)** creams are older formulations with potentially higher systemic absorption compared to modern low-dose estradiol pessaries.*Prescribe ospemifene 60 mg daily as it is a selective estrogen receptor modulator*- **Ospemifene** is an oral SERM indicated for dyspareunia, but **local vaginal estrogens** are generally preferred as first-line therapy due to direct action.- It carries a risk profile similar to other SERMs, including potential **thromboembolic events** and hot flushes, which makes local therapy a more conservative choice.*Prescribe prasterone vaginal DHEA suppositories with concurrent systemic progestogen*- **Prasterone (Vaginal DHEA)** is used for vulvovaginal atrophy but, like other local therapies, it does **not require systemic progestogen**.- While effective, low-dose estradiol pessaries are more established as the standard first-line local hormonal intervention.

Question 117: A 26-year-old woman presents for routine review. She had the etonogestrel contraceptive implant inserted 18 months ago. Since insertion, she has experienced frequent irregular bleeding, occurring approximately every 2-3 weeks for 5-7 days. She is otherwise well and wishes to continue with the implant due to its high efficacy, but the bleeding pattern is affecting her quality of life. What is the most appropriate management strategy?

A. Remove the implant and insert a levonorgestrel intrauterine system
B. Prescribe a short course of combined oral contraceptive pill to regulate bleeding (Correct Answer)
C. Prescribe mefenamic acid to be taken during bleeding episodes
D. Reassure that bleeding will settle by 2 years and no intervention is needed
E. Remove the implant and insert a new one in the contralateral arm

Explanation: ***Prescribe a short course of combined oral contraceptive pill to regulate bleeding*** - A short course (usually 3 months) of the **combined oral contraceptive pill (COCP)** is a first-line management strategy to stabilize the **endometrium** and improve bleeding patterns in implant users. - This approach is suitable because the patient wishes to **retain the implant** for its high efficacy while needing a pharmacological intervention to improve her **quality of life**. *Remove the implant and insert a levonorgestrel intrauterine system* - While the **levonorgestrel intrauterine system (LNG-IUS)** typically results in lighter bleeding, the patient specifically stated a preference to **continue with the implant**. - Switching methods should be reserved for cases where **medical management** of bleeding fails or the patient no longer desires the current method. *Prescribe mefenamic acid to be taken during bleeding episodes* - **Mefenamic acid** (an NSAID) can reduce the volume and duration of bleeding episodes but is often less effective at **regulating the frequency** or unpredictability of bleeding compared to COCP. - It acts as a symptomatic treatment during active bleeding rather than **preventing future irregular episodes** by stabilizing the lining. *Reassure that bleeding will settle by 2 years and no intervention is needed* - While bleeding patterns can settle in early months, the patient has already had the implant for **18 months**, making spontaneous resolution unlikely at this stage. - Ignoring the patient's concerns about **quality of life** without offering an intervention increases the risk of **premature discontinuation** of a highly effective contraceptive. *Remove the implant and insert a new one in the contralateral arm* - Replacing the implant with a new one does not address the underlying **progestogen-induced endometrial changes** that cause the unscheduled bleeding. - This procedure is not an **evidence-based intervention** for managing irregular bleeding and would subject the patient to unnecessary minor surgery.

Question 118: A 51-year-old woman with a BMI of 29 kg/m² presents requesting HRT for moderate vasomotor symptoms. She smokes 10 cigarettes per day and has blood pressure of 145/92 mmHg measured on two occasions. She has no personal or family history of venous thromboembolism or breast cancer. Her mother had a myocardial infarction at age 68. What is the most appropriate initial management?

A. Prescribe transdermal estradiol with micronised progesterone as the cardiovascular risk is acceptable
B. Commence standard combined oral HRT as she is within 10 years of menopause and benefits outweigh risks
C. Offer lifestyle modification advice and smoking cessation support, then reassess her suitability for HRT (Correct Answer)
D. Prescribe tibolone as it has a more favourable cardiovascular profile than standard HRT
E. Advise that HRT is contraindicated due to her hypertension and smoking status and offer SSRI therapy

Explanation: ***Offer lifestyle modification advice and smoking cessation support, then reassess her suitability for HRT*** - This patient has significant **modifiable cardiovascular risk factors**, including **uncontrolled hypertension (145/92 mmHg)** and active **smoking**, which must be addressed before initiating hormonal therapy. - **NICE guidelines** emphasize that blood pressure should be controlled and lifestyle factors optimized to minimize the risk of **stroke** and **venous thromboembolism** associated with HRT. *Prescribe transdermal estradiol with micronised progesterone as the cardiovascular risk is acceptable* - Although **transdermal estradiol** and **micronised progesterone** have a better safety profile regarding VTE than oral options, they should not be started while blood pressure remains **uncontrolled**. - Initiating HRT without addressing the **smoking status** ignores the synergistically increased risk of **myocardial infarction** and **stroke** in this age group. *Commence standard combined oral HRT as she is within 10 years of menopause and benefits outweigh risks* - **Oral HRT** is specifically associated with a higher risk of **venous thromboembolism (VTE)** and is generally avoided in patients with a high **BMI** or those who smoke. - While she is in the "window of opportunity" (within 10 years of menopause), her **uncontrolled hypertension** and smoking make oral estrogen an inappropriate first-line choice. *Prescribe tibolone as it has a more favourable cardiovascular profile than standard HRT* - **Tibolone** is actually associated with an increased risk of **stroke** in women over 60 or those with established cardiovascular risk factors, and does not offer a superior cardiovascular safety profile for this patient. - Like other HRT forms, it should only be considered once **blood pressure** is stabilized and other **cardiovascular risks** are managed. *Advise that HRT is contraindicated due to her hypertension and smoking status and offer SSRI therapy* - Hypertension and smoking are **relative**, not absolute, contraindications for HRT; HRT can often be prescribed safely once blood pressure is **controlled below 140/90 mmHg** and smoking cessation achieved. - **SSRI therapy** is an alternative for vasomotor symptoms but is usually reserved for those with **absolute contraindications** or those who do not wish to take hormones, after lifestyle modifications have been attempted.

Question 119: A 40-year-old nulliparous woman has had the levonorgestrel intrauterine system in situ for 3 years for contraception and management of heavy menstrual bleeding. She has been amenorrhoeic for the past 18 months and is very satisfied. She asks how long the device can remain in place. What is the correct licensed duration for this device when used for contraception?

A. 3 years
B. 5 years (Correct Answer)
C. 6 years
D. 8 years
E. 10 years

Explanation: ***5 years*** - The **Mirena** (52 mg levonorgestrel-releasing IUS) is currently **licensed for 5 years** when used for **contraception** and management of **heavy menstrual bleeding**. - While recent FSRH guidance suggests some 52 mg systems can be used for up to 6 years off-label, the standard **licensed duration** remains 5 years for a 40-year-old patient. *3 years* - This is the licensed duration for the **Jaydess** (13.5 mg) IUS and the **Nexplanon** contraceptive implant, but not the 52 mg LNG-IUS. - Using a 52 mg LNG-IUS for only 3 years would result in premature replacement, as its hormone reservoir is designed for **longer efficacy**. *6 years* - Although some clinical evidence and updated UK guidelines (FSRH) support **off-license** contraceptive use of certain 52 mg IUS devices for 6 years, this is not currently the standard **product license**. - This duration does not apply to the **endometrial protection** component of HRT, which is typically licensed for 4 to 5 years. *8 years* - There is currently no levonorgestrel intrauterine system with a **primary license** for 8 years of use in the UK or major international markets. - Recent studies are investigating **extended use**, but any use beyond 5 or 6 years is currently considered **experimental/off-license**. *10 years* - This duration is typical for **non-hormonal copper IUDs** (such as the **Copper T380A**), which provide long-term protection without hormone release. - An LNG-IUS inserted **after age 45** may sometimes be used until menopause, but it is not licensed for a flat 10-year term for a 40-year-old.

Question 120: A 49-year-old woman presents with troublesome vasomotor symptoms affecting her sleep and quality of life. She had a deep vein thrombosis 8 years ago during pregnancy, which was treated with 6 months of anticoagulation. Thrombophilia screening at the time was negative. She has no other medical conditions. What is the most appropriate management of her menopausal symptoms?

A. Commence standard-dose transdermal estradiol HRT as more than 5 years have passed since her VTE
B. Offer selective serotonin reuptake inhibitor therapy as HRT is absolutely contraindicated (Correct Answer)
C. Commence low-dose oral estradiol HRT with close monitoring
D. Prescribe tibolone as it has lower VTE risk than standard HRT
E. Refer to haematology for assessment before considering any form of HRT

Explanation: ***Offer selective serotonin reuptake inhibitor therapy as HRT is absolutely contraindicated*** - A prior history of **venous thromboembolism (VTE)**, such as DVT, is considered an **absolute contraindication** to any form of Hormone Replacement Therapy (HRT) due to the increased risk of recurrence. - **Selective serotonin reuptake inhibitors (SSRIs)** or serotonin-norepinephrine reuptake inhibitors (SNRIs) are effective and safe **non-hormonal alternatives** for managing severe vasomotor symptoms. *Commence standard-dose transdermal estradiol HRT as more than 5 years have passed since her VTE* - While **transdermal HRT** carries a lower VTE risk than oral HRT, a history of DVT still represents a contraindication, as the risk is not entirely eliminated. - The passage of **5 years** since the DVT does not negate the fundamental increased risk associated with exogenous hormonal therapy in a patient with a thrombotic history. *Commence low-dose oral estradiol HRT with close monitoring* - **Oral estradiol** is associated with a significantly increased risk of VTE (2-3 fold) due to its effects on hepatic coagulation factors. - **Low-dose** oral HRT or **close monitoring** does not sufficiently mitigate this unacceptable risk in a patient with a confirmed history of DVT. *Prescribe tibolone as it has lower VTE risk than standard HRT* - **Tibolone** is a synthetic steroid with estrogenic properties that, despite some debate on its VTE risk compared to conventional HRT, is generally **contraindicated** in individuals with a history of thromboembolic disease. - It is not recommended as a safe alternative for patients with a known risk of **thrombosis**. *Refer to haematology for assessment before considering any form of HRT* - A **haematology referral** is typically not required to determine HRT suitability in this scenario, as the history of DVT is a well-established and clear **absolute contraindication**. - Even with a negative **thrombophilia screening**, the clinical history of the previous VTE remains the overriding factor precluding hormonal treatment.

Question 121: A 33-year-old woman with well-controlled HIV infection on antiretroviral therapy (efavirenz, tenofovir, and emtricitabine) attends for contraceptive counselling. Her CD4 count is 650 cells/mm³ and viral load is undetectable. She is in a stable relationship and requests effective contraception. Which contraceptive method is most appropriate?

A. Combined oral contraceptive pill as efavirenz does not affect its efficacy
B. Depot medroxyprogesterone acetate 150 mg intramuscularly every 12 weeks
C. Levonorgestrel intrauterine system 52 mg (Correct Answer)
D. Progesterone-only pill containing levonorgestrel 30 mcg
E. Etonogestrel implant with additional barrier contraception recommended

Explanation: ***Levonorgestrel intrauterine system 52 mg***- The **Levonorgestrel intrauterine system (LNG-IUS)** is highly effective and acts primarily locally, making it **unaffected by enzyme-inducing drugs** like efavirenz.- It is classified as **UKMEC 1** for patients with well-controlled HIV (CD4 >200 cells/mm³), providing long-acting reversible contraception without significant drug-drug interactions.*Combined oral contraceptive pill as efavirenz does not affect its efficacy*- **Efavirenz** is a potent **cytochrome P450 enzyme inducer** that significantly reduces the serum levels of ethinylestradiol and progestogens.- Due to the high risk of **contraceptive failure**, the combined pill is classified as **UKMEC 3** when used with efavirenz.*Depot medroxyprogesterone acetate 150 mg intramuscularly every 12 weeks*- While **DMPA** is not significantly affected by enzyme-inducing drugs and can be used, the **LNG-IUS** offers a more continuous and lower systemic hormonal exposure.- It is generally considered **UKMEC 1** or **UKMEC 2** for women with HIV, though long-term use can be associated with **bone mineral density loss**.*Progesterone-only pill containing levonorgestrel 30 mcg*- Standard-dose **progesterone-only pills (POP)** are highly susceptible to **hepatic enzyme induction**, leading to rapidly declining hormone levels and reduced efficacy.- This method is categorized as **UKMEC 3** because its reliability is compromised in patients taking **efavirenz**.*Etonogestrel implant with additional barrier contraception recommended*- The **etonogestrel implant** efficacy is significantly reduced by **enzyme inducers** like efavirenz, potentially leading to breakthrough ovulation and pregnancy.- It is managed as **UKMEC 2/3**; while it can be used with caution, it is less ideal than the **LNG-IUS** which requires no additional precautions due to its localized action.

Question 122: A 54-year-old woman who has been taking continuous combined HRT for 18 months presents with a single episode of vaginal bleeding. She had her last natural period 3 years ago. She is otherwise well and examination is normal. Transvaginal ultrasound shows an endometrial thickness of 6 mm with no focal lesions. What is the most appropriate management?

A. Reassure and review if bleeding recurs
B. Perform endometrial biopsy (Correct Answer)
C. Switch to sequential combined HRT
D. Increase the progestogen component of her HRT
E. Stop HRT and repeat ultrasound in 3 months

Explanation: ***Perform endometrial biopsy*** - Any **vaginal bleeding** that occurs after the first **6 months** of continuous combined **hormone replacement therapy (HRT)** in a postmenopausal woman must be investigated to rule out **endometrial malignancy**. - The **endometrial thickness of 6 mm** in this context exceeds the typical threshold (usually **4-5 mm**), necessitating an endometrial sample via **Pipelle biopsy** or hysteroscopy for histological assessment. *Reassure and review if bleeding recurs* - Reassurance is inappropriate because **unscheduled bleeding** after the 6-month adjustment period on HRT is a **red flag** for **endometrial hyperplasia** or cancer. - Waiting for recurrence could dangerously delay the diagnosis of a **potentially curable malignancy** in a postmenopausal woman. *Switch to sequential combined HRT* - **Sequential HRT** is intended for **perimenopausal women** to induce monthly bleeds, whereas this patient is **postmenopausal** and has been on continuous combined HRT. - Switching regimens does not address the urgent clinical need to investigate the **pathological cause** of her current bleeding episode. *Increase the progestogen component of her HRT* - While progestogen protects the endometrium, increasing the dose before obtaining a **histological diagnosis** is premature and potentially unsafe. - It is critical to first exclude **atypical hyperplasia** or **endometrial carcinoma** before making adjustments to the HRT composition. *Stop HRT and repeat ultrasound in 3 months* - Stopping HRT may temporarily halt the bleeding but does not provide a definitive diagnosis for the **thickened endometrium** observed. - **Delayed investigation** by three months is contrary to urgent **referral guidelines** for suspected postmenopausal gynecological cancers.

Question 123: A 28-year-old woman with body mass index of 36 kg/m² requests long-acting reversible contraception. She has no other medical conditions and is a non-smoker. She is particularly concerned about weight gain with contraception. Which of the following statements regarding contraceptive options and weight is most accurate?

A. The levonorgestrel intrauterine system is associated with significant weight gain in most users
B. Depot medroxyprogesterone acetate is the most suitable LARC option as it does not cause weight gain
C. The etonogestrel implant has the strongest evidence for causing clinically significant weight gain
D. The copper intrauterine device has no effect on weight and provides highly effective contraception (Correct Answer)
E. Combined hormonal contraceptives should be avoided solely due to obesity-related weight gain concerns

Explanation: ***The copper intrauterine device has no effect on weight and provides highly effective contraception*** - As a **non-hormonal** method, the copper IUD has no metabolic effect on body weight, making it an ideal choice for a patient with a **high BMI** concerned about weight gain. - It offers over **99% efficacy** and is classified as **UKMEC 1** for patients with obesity, indicating no restriction for use. *The levonorgestrel intrauterine system is associated with significant weight gain in most users* - The **LNG-IUS** acts primarily through local effects on the endometrium with **minimal systemic absorption**, and clinical trials do not show a significant link to weight gain in most users. - Any fluctuations in weight observed are generally comparable to those seen in aging populations not using hormonal contraception. *Depot medroxyprogesterone acetate is the most suitable LARC option as it does not cause weight gain* - **DMPA** is the only contraceptive method consistently linked with **clinically significant weight gain**, particularly in women who have a high BMI at the start of use. - It is classified as **UKMEC 2** (or UKMEC 3 if other factors exist) for obesity, and some users gain an average of **2-3 kg** over a year. *The etonogestrel implant has the strongest evidence for causing clinically significant weight gain* - While some studies show minimal fluctuations (average **<1 kg**), evidence for the implant causing major weight gain remains **inconsistent and weak** compared to DMPA. - Many women perceive weight gain with the implant, but large prospective studies fail to confirm a definitive causal link to significant adipose increase. *Combined hormonal contraceptives should be avoided solely due to obesity-related weight gain concerns* - The primary reason to avoid **combined hormonal contraceptives** in patients with a BMI ≥35 kg/m² is the significantly increased risk of **Venous Thromboembolism (VTE)**, not weight gain concerns. - For a patient with a BMI of 36 kg/m², these methods are categorized as **UKMEC 3** (risks generally outweigh benefits) due to cardiovascular safety profiles.

Question 124: A 50-year-old woman commenced on sequential combined HRT 4 months ago presents with withdrawal bleeding lasting 10 days, which is significantly heavier than her previous natural periods. Her cervical screening is up-to-date and normal. Abdominal and bimanual examination are unremarkable. What is the most appropriate initial investigation?

A. Pelvic MRI scan
B. Transvaginal ultrasound scan to assess endometrial thickness (Correct Answer)
C. Endometrial biopsy
D. Full blood count and serum ferritin
E. Hysteroscopy and endometrial biopsy

Explanation: ***Transvaginal ultrasound scan to assess endometrial thickness***- A **transvaginal ultrasound (TVUS)** is the recommended first-line investigation for persistent or abnormal bleeding, even when on **sequential combined HRT**, to assess the **endometrium** and rule out pathology.- It provides a non-invasive way to measure **endometrial thickness**; a thickness of **<4 mm** in women on HRT (or postmenopausal bleeding) has a high negative predictive value for **endometrial cancer**.*Endometrial biopsy*- This is an invasive procedure typically reserved for cases where the **endometrial thickness** is significantly increased on **ultrasound** or if other suspicious features are identified.- It is not the primary initial step in evaluating abnormal bleeding in a woman on HRT unless **ultrasound** findings warrant it.*Full blood count and serum ferritin*- These tests assess for **iron deficiency anemia** resulting from heavy bleeding but do not identify the **underlying cause** of the abnormal uterine bleeding.- While important for managing the consequences of blood loss, they are not diagnostic investigations for **endometrial pathology** itself.*Pelvic MRI scan*- **MRI** is not a first-line diagnostic tool for evaluating **abnormal uterine bleeding** as it is expensive, less accessible, and provides less specific information for endometrial assessment than TVUS.- It is generally used for further characterization of **complex pelvic pathology** or staging known **malignancies** rather than initial screening for bleeding.*Hysteroscopy and endometrial biopsy*- This combination is considered the **gold standard** for diagnosing endometrial issues, allowing direct visualization and targeted biopsy, but is usually a **second-line** investigation after **TVUS**.- It is indicated if the **ultrasound** shows focal abnormalities (like **polyps**) or if bleeding persists despite normal initial scans and continued clinical concern.

Question 125: A 37-year-old woman with a BMI of 32 kg/m² presents requesting contraception. She has a history of migraine without aura occurring approximately twice monthly, well-controlled hypertension on ramipril 5 mg daily (blood pressure today 128/82 mmHg), and type 2 diabetes diagnosed 2 years ago managed with metformin (HbA1c 48 mmol/mol with no microvascular complications). She is a non-smoker. According to UK Medical Eligibility Criteria, which contraceptive method is classified as UKMEC 1 (no restriction) for this patient?

A. Combined oral contraceptive pill
B. Copper intrauterine device (Correct Answer)
C. Progestogen-only injectable (depot medroxyprogesterone acetate)
D. Vaginal contraceptive ring
E. Combined transdermal patch

Explanation: ***Copper intrauterine device*** - The copper IUD is classified as **UKMEC 1** for this patient because it is a **non-hormonal** method, making it safe and unaffected by her medical history of hypertension, diabetes, or migraine. - It provides highly effective **long-acting reversible contraception (LARC)** without increasing the risk of cardiovascular events or interfering with glucose metabolism. *Combined oral contraceptive pill* - This method is categorized as **UKMEC 3** (risks outweigh benefits) due to the patient's **controlled hypertension** and **multiple cardiovascular risk factors**, including diabetes and obesity. - Estrogen-containing methods increase the risk of **venous thromboembolism (VTE)** and arterial disease, making them unsuitable for patients with such a risk profile. *Progestogen-only injectable (depot medroxyprogesterone acetate)* - Classified as **UKMEC 3** for patients with multiple risk factors for **cardiovascular disease** and those with a **BMI ≥30 kg/m²** due to potential metabolic effects. - There are additional concerns regarding its effect on **lipid metabolism** and glucose tolerance in patients already at higher metabolic risk. *Vaginal contraceptive ring* - Like the combined pill, this is a **combined hormonal contraceptive** and is classified as **UKMEC 3** because of her **hypertension** and significant metabolic risk factors (diabetes, obesity). - The **estrogen component** carries the same systemic **cardiovascular contraindications** as other combined hormonal methods, regardless of the route of administration. *Combined transdermal patch* - This method is also classified as **UKMEC 3** because it is a **combined hormonal contraceptive** containing estrogen, which is restricted in individuals with **hypertension** and multiple metabolic risk factors. - The patient's **BMI of 32 kg/m²** and **Type 2 Diabetes** further increase the absolute risk for thrombotic events when using estrogen-containing contraception.

Question 126: What is the minimum duration that women over the age of 50 years should continue using contraception after their last menstrual period to prevent pregnancy?

A. 6 months
B. 1 year (Correct Answer)
C. 2 years
D. 5 years
E. Until FSH levels are consistently elevated above 30 IU/L

Explanation: ***1 year*** - According to **FSRH guidelines**, women **over the age of 50** are advised to continue contraception for **12 months** (1 year) after their last menstrual period (LMP). - This duration is sufficient because **fertility significantly declines** after age 50, making spontaneous ovulation and pregnancy highly unlikely after one year of amenorrhea. *6 months* - Six months is an **insufficient duration** to confirm the permanent cessation of ovarian function in women over 50. - Using this shorter timeframe increases the risk of **unintended pregnancy** due to potential sporadic ovulation during the perimenopausal transition. *2 years* - Continuance for **2 years** after the LMP is the specific recommendation for women **under the age of 50**. - Younger women have a higher **residual follicular reserve**, necessitating a longer period of amenorrhea to confirm menopause compared to those over 50. *5 years* - There is **no clinical evidence** to support a recommendation for 5 years of contraception post-LMP regardless of age. - Most women over 50 reach **sterility** naturally long before this timeframe; contraception is generally stopped by **age 55** regardless of menstrual history. *Until FSH levels are consistently elevated above 30 IU/L* - **FSH levels** are unreliable for determining when to stop contraception because they involve **significant fluctuations** during the perimenopausal period. - Clinical guidelines prioritize the **duration of amenorrhea** or the attainment of **age 55** over biochemical markers to guide contraceptive cessation.

Question 127: A 52-year-old woman who underwent total abdominal hysterectomy and bilateral salpingo-oophorectomy 8 weeks ago for endometriosis presents with severe vasomotor symptoms affecting her quality of life and work performance. She has no personal or family history of venous thromboembolism or breast cancer. What is the most appropriate initial hormone replacement therapy regimen?

A. Continuous combined HRT with estradiol 2 mg and norethisterone 1 mg
B. Estradiol 2 mg oral tablet daily (Correct Answer)
C. Sequential combined HRT with estradiol and dydrogesterone
D. Transdermal estradiol 50 mcg patch twice weekly with micronised progesterone 200 mg daily
E. Tibolone 2.5 mg daily

Explanation: ***Estradiol 2 mg oral tablet daily*** - In a patient who has undergone a **total abdominal hysterectomy** (removal of the uterus), the primary concern of endometrial hyperplasia due to unopposed estrogen is eliminated. Therefore, **estrogen-only HRT** is the most appropriate regimen for managing severe vasomotor symptoms. - The patient's history of **endometriosis** does not typically contraindicate estrogen-only HRT post-hysterectomy and oophorectomy, as the risk of **malignant transformation** or recurrence from residual implants is generally very low and does not routinely warrant progestogen. *Continuous combined HRT with estradiol 2 mg and norethisterone 1 mg* - This regimen includes a **progestogen** (norethisterone), which is primarily indicated for women with an **intact uterus** to counteract the proliferative effect of estrogen on the endometrium and prevent hyperplasia or cancer. - Since the patient has undergone a **hysterectomy**, the uterus is absent, rendering the progestogen component unnecessary and potentially increasing risks like **breast cancer** without providing endometrial protection. *Sequential combined HRT with estradiol and dydrogesterone* - **Sequential combined HRT** is designed for perimenopausal or recently menopausal women with an **intact uterus** to induce regular, predictable withdrawal bleeding by adding progestogen cyclically. - This patient is post-hysterectomy and **surgically menopausal**, meaning there is no uterus to bleed from, and the sequential progestogen is therefore inappropriate and redundant. *Transdermal estradiol 50 mcg patch twice weekly with micronised progesterone 200 mg daily* - While **transdermal estradiol** is a suitable estrogen delivery method, the inclusion of **micronised progesterone** is unwarranted for a patient without a uterus. - Progesterone is added to protect the **endometrium**, which is absent here. It would only be considered in rare cases of extensive residual endometriosis, not as a standard initial choice. *Tibolone 2.5 mg daily* - **Tibolone** is a synthetic steroid with estrogenic, progestogenic, and weak androgenic properties used to alleviate menopausal symptoms and prevent osteoporosis. - While it can be used post-hysterectomy, **estrogen-only HRT** (like estradiol) is generally considered the **first-line** and simpler approach for managing severe vasomotor symptoms in women without a uterus.

Question 128: A 46-year-old perimenopausal woman presents with increasing menstrual irregularity and requests contraception. She has a 6-month history of menstrual cycles ranging from 21 to 45 days. Her FSH level measured on day 3 of her cycle is 18 IU/L. She is a non-smoker with BMI 27 kg/m² and no significant medical history. Which contraceptive method would provide both reliable contraception and symptom relief for her perimenopausal symptoms?

A. Combined oral contraceptive pill containing ethinylestradiol 30 mcg and levonorgestrel 150 mcg (Correct Answer)
B. Levonorgestrel intrauterine system 52 mg
C. Progesterone-only pill containing desogestrel 75 mcg
D. Etonogestrel subdermal implant 68 mg
E. Copper intrauterine device

Explanation: ***Combined oral contraceptive pill containing ethinylestradiol 30 mcg and levonorgestrel 150 mcg***- The **combined oral contraceptive (COC)** is ideal for perimenopausal women under 50 because it provides both **reliable contraception** and **symptom relief** for vasomotor symptoms and irregular cycles.- In a healthy, non-smoking woman with a BMI under 30, the COC effectively stabilizes hormone levels and manages **menstrual irregularity** associated with an elevated **FSH** level.*Levonorgestrel intrauterine system 52 mg*- While excellent for **long-acting reversible contraception** and treating heavy menstrual bleeding, it does not provide systemic estrogen required to relieve **perimenopausal vasomotor symptoms**.- It would manage local uterine symptoms but would not address the systemic hormonal fluctuations indicated by the patient's **irregular cycle lengths**.*Progesterone-only pill containing desogestrel 75 mcg*- This method provides effective contraception but often causes **irregular bleeding patterns**, which can complicate the clinical assessment of perimenopausal bleeding.- Since it lacks an **estrogen component**, it offers no therapeutic benefit for the vasomotor symptoms or the underlying hormonal decline of **perimenopause**.*Etonogestrel subdermal implant 68 mg*- The implant is a highly effective contraceptive, but like other progestogen-only methods, it frequently leads to **unpredictable spotting** or amenorrhea.- It does not contain the **ethinylestradiol** necessary to regulate the menstrual cycle or alleviate symptoms caused by **estrogen deficiency**.*Copper intrauterine device*- This is a hormone-free contraceptive that provides no relief for **menstrual irregularity** and may actually **increase menstrual flow** and cramping.- It has no impact on **perimenopausal symptoms** or the hormonal fluctuations indicated by the rising **Day 3 FSH** levels.

Question 129: A 23-year-old woman attends the sexual health clinic 48 hours after unprotected sexual intercourse. She is on day 18 of her regular 28-day menstrual cycle. Her BMI is 23 kg/m². She has no significant medical history and takes no regular medications. She requests emergency contraception. What is the most appropriate management?

A. Prescribe levonorgestrel 1.5 mg single dose
B. Prescribe ulipristal acetate 30 mg single dose
C. Insert copper intrauterine device (Correct Answer)
D. Prescribe two doses of levonorgestrel 750 mcg 12 hours apart
E. Reassure that emergency contraception is not required as conception is unlikely

Explanation: ***Insert copper intrauterine device*** - The **copper intrauterine device (Cu-IUD)** is the most effective form of emergency contraception, boasting a failure rate of less than **0.1%**. - It can be inserted up to **5 days (120 hours)** after unprotected sexual intercourse or up to 5 days after the earliest predicted ovulation, making it the **gold standard** regardless of the menstrual cycle day. *Prescribe levonorgestrel 1.5 mg single dose* - This medication is licensed for use up to **72 hours** post-intercourse but is significantly **less effective** than the Cu-IUD, especially in the fertile window or if ovulation has occurred. - Its efficacy decreases as the time from intercourse increases, and its primary mechanism of delaying ovulation may be less effective on day 18, which is typically post-ovulatory. *Prescribe ulipristal acetate 30 mg single dose* - While **ulipristal acetate** is more effective than levonorgestrel, particularly later in the fertile window, it still carries a higher failure rate compared to the **Cu-IUD**. - It can be used up to **120 hours** post-intercourse, but the Cu-IUD is generally recommended first due to its superior efficacy. *Prescribe two doses of levonorgestrel 750 mcg 12 hours apart* - This split-dose regimen of levonorgestrel is considered **obsolete** and has been largely replaced by the more convenient and equally effective **1.5 mg single dose**. - Current guidelines for emergency contraception no longer recommend this older practice. *Reassure that emergency contraception is not required as conception is unlikely* - Although ovulation typically occurs around day 14 in a 28-day cycle, unprotected sexual intercourse on day 18 still carries a **risk of pregnancy** due to variations in individual cycle lengths and potential for delayed ovulation. - It is medically inappropriate to dismiss a patient's request for emergency contraception, as any unprotected intercourse carries a risk, and patient autonomy in reproductive health decisions is paramount.

Question 130: A 39-year-old woman presents 76 hours after unprotected sexual intercourse requesting emergency contraception. She has a regular 28-day cycle and her last menstrual period started 12 days ago. She weighs 68 kg with BMI 25 kg/m². She takes no regular medications and has no significant medical history. She declines intrauterine contraception. Which pharmacological emergency contraception option is most appropriate?

A. Levonorgestrel 1.5 mg single dose as she is within the 96-hour window
B. Ulipristal acetate 30 mg as she is within the 120-hour window and likely near ovulation (Correct Answer)
C. Levonorgestrel 3 mg double dose to increase efficacy
D. No emergency contraception needed as she is not in her fertile window
E. Combined oral contraceptive (Yuzpe regimen) as she is beyond the 72-hour window for levonorgestrel

Explanation: ***Ulipristal acetate 30 mg as she is within the 120-hour window and likely near ovulation*** - **Ulipristal acetate (UPA)** is the most effective oral emergency contraceptive when administered between **72 and 120 hours** after unprotected intercourse, making it suitable for this patient at 76 hours. - UPA can effectively delay ovulation even after the **LH surge** has commenced, which is crucial as the patient is on day 12 of a 28-day cycle, indicating she is likely in her **fertile window** approaching ovulation. *Levonorgestrel 1.5 mg single dose as she is within the 96-hour window* - The efficacy of **levonorgestrel** significantly diminishes when taken more than **72 hours** after unprotected intercourse, and this patient is at 76 hours. - Levonorgestrel primarily acts by inhibiting the **LH surge** and preventing ovulation, but it is less effective once the LH surge has already begun, which is probable on day 12 of a 28-day cycle. *Levonorgestrel 3 mg double dose to increase efficacy* - A **double dose** (3 mg) of levonorgestrel is generally considered for individuals with a **BMI > 26 kg/m²** or those on **enzyme-inducing medications**. - This patient has a **BMI of 25 kg/m²** and no relevant medication use, so a standard or double dose of levonorgestrel is not preferred over ulipristal acetate in this specific time frame and cycle phase. *No emergency contraception needed as she is not in her fertile window* - For a **regular 28-day cycle**, the **fertile window** typically encompasses the 5 days before ovulation and the day of ovulation, which is usually around day 14. - As her last menstrual period was **12 days ago**, she is precisely within her fertile window and at a high risk of conception, therefore emergency contraception is strongly indicated. *Combined oral contraceptive (Yuzpe regimen) as she is beyond the 72-hour window for levonorgestrel* - The **Yuzpe regimen** involves multiple high doses of combined oral contraceptives and is considered a **less effective** and **older method** compared to levonorgestrel or ulipristal acetate. - This regimen is associated with a much higher incidence of **side effects**, particularly severe nausea and vomiting, making it a less desirable option for emergency contraception.

Question 131: A 54-year-old woman who had a hysterectomy for benign disease 10 years ago has been using oestrogen-only HRT (transdermal oestradiol 50 mcg patches) for 5 years. She reports well-controlled vasomotor symptoms but has recently read about risks of HRT and is concerned. She has no personal or family history of breast cancer or cardiovascular disease. Her BMI is 26 kg/m² and blood pressure is 128/78 mmHg. Which statement about continuing HRT represents the most accurate assessment of her risk-benefit profile?

A. She should stop HRT immediately as the risks outweigh benefits after 5 years of use
B. Oestrogen-only HRT after hysterectomy is associated with increased breast cancer risk similar to combined HRT
C. She can continue HRT as oestrogen-only HRT in women post-hysterectomy has a favourable risk profile with no increased breast cancer risk demonstrated (Correct Answer)
D. She should switch to tibolone which has a lower risk profile than oestrogen-only HRT
E. She should have annual mammography while continuing HRT due to significantly increased breast cancer risk

Explanation: ***She can continue HRT as oestrogen-only HRT in women post-hysterectomy has a favourable risk profile with no increased breast cancer risk demonstrated*** - Evidence, notably from the **Women's Health Initiative (WHI) study**, indicates that **oestrogen-only HRT** in women post-hysterectomy does not increase the risk of **breast cancer**. - This patient has well-controlled symptoms, no contraindications, and a favorable risk profile, supporting continued individualized use without a fixed time limit. *She should stop HRT immediately as the risks outweigh benefits after 5 years of use* - There is no **arbitrary time limit** for HRT use; continuation depends on persistent symptoms and a favorable risk-benefit assessment, not solely on duration. - Abruptly stopping HRT could lead to a recurrence of her **vasomotor symptoms**, negatively impacting her quality of life unnecessarily. *Oestrogen-only HRT after hysterectomy is associated with increased breast cancer risk similar to combined HRT* - **Combined HRT** (oestrogen plus progestogen) is associated with a slightly increased risk of **breast cancer**, primarily due to the progestogen component. - In contrast, **oestrogen-only HRT** in women without a uterus has not shown a similar increase in breast cancer risk and may even have a protective effect. *She should switch to tibolone which has a lower risk profile than oestrogen-only HRT* - **Tibolone** is a synthetic steroid that has a different risk profile and is not inherently safer than **transdermal oestradiol** for all women; it can carry its own risks including potential increased breast cancer recurrence or incidence in certain populations. - Given she is well-controlled on her current **oestrogen-only HRT** with a favorable risk profile, there is no clinical indication to switch. *She should have annual mammography while continuing HRT due to significantly increased breast cancer risk* - Current guidelines recommend that women on **oestrogen-only HRT** follow **standard national breast screening protocols**, not necessarily annual mammography, as their breast cancer risk is not significantly increased. - The absence of increased breast cancer risk with **oestrogen-only HRT** means that more intensive surveillance beyond routine screening is unwarranted.

Question 132: A 25-year-old woman attends for removal and replacement of her etonogestrel contraceptive implant, which was inserted 3 years ago. She is very satisfied with the method. On examination, the implant is palpable but lies deeper than expected in the subcutaneous tissue of the upper arm. You make an attempt at removal but cannot visualise the implant clearly through the initial incision. What is the most appropriate immediate management?

A. Continue with deeper dissection until the implant is located and removed
B. Insert a new implant in the contralateral arm and arrange specialist removal of the original implant
C. Apply pressure to the distal end of the implant to make it more superficial, then attempt removal again
D. Extend the incision and use forceps to grasp deeper tissue to locate the implant
E. Abandon the procedure, apply pressure dressing, and refer for ultrasound localisation and specialist removal (Correct Answer)

Explanation: ***Abandon the procedure, apply pressure dressing, and refer for ultrasound localisation and specialist removal*** - When an **etonogestrel implant** cannot be easily visualised or removed through a small incision, further blind manipulation increases the risk of **neurovascular injury** to the median nerve or brachial artery. - **FSRH guidelines** recommend abandoning the procedure and referring to a specialist service where **ultrasound guidance** can be used to precisely locate and remove the deep implant. *Continue with deeper dissection until the implant is located and removed* - **Deep dissection** in the primary care setting is contraindicated as it lacks appropriate imaging and increases the risk of **permanent scarring** and tissue trauma. - Searching blindly for a non-visible implant can lead to further **displacement** of the device into deeper muscular compartments. *Insert a new implant in the contralateral arm and arrange specialist removal of the original implant* - Inserting a second implant before the first is removed would lead to an **excessive progestogen dose**, which is clinically inappropriate. - Specialist removal of the **expired implant** should be prioritised before a replacement is provided to ensure hormonal stability and patient safety. *Apply pressure to the distal end of the implant to make it more superficial, then attempt removal again* - This technique is generally used for **palpable, superficial implants**; if initial attempts failed, the implant is likely deeper than initially assessed. - Repeated pressure and manipulation of a **deeply placed implant** can cause it to migrate further or cause pain to the patient. *Extend the incision and use forceps to grasp deeper tissue to locate the implant* - Grasping deeper tissues blindly with **forceps** is dangerous due to the proximity of the **medial epicondyle** and associated nerves and vessels. - **Specialist tools** and imaging are required to ensure the implant is grasped specifically without damaging surrounding anatomical structures.

Question 133: A 51-year-old woman with a history of breast cancer treated 7 years ago presents requesting treatment for severe vasomotor symptoms affecting her quality of life and work. She is reluctant to use non-hormonal options. Examination is unremarkable. Recent mammography shows no evidence of recurrence. Which non-hormonal pharmacological treatment has the strongest evidence base for managing vasomotor symptoms in women with contraindications to HRT?

A. Evening primrose oil 1000 mg twice daily
B. Black cohosh 40 mg daily
C. Venlafaxine 75 mg daily (Correct Answer)
D. Gabapentin 900 mg daily in divided doses
E. Vitamin E 800 IU daily

Explanation: ***Venlafaxine 75 mg daily***- **SNRIs** and **SSRIs** like venlafaxine have the strongest evidence base for reducing **vasomotor symptoms** (up to 60%) in women where **HRT** is contraindicated due to breast cancer.- It is effective in titration and does not have the significant **CYP2D6 inhibition** concerns that medications like paroxetine have when used alongside **tamoxifen**.*Evening primrose oil 1000 mg twice daily*- This is a complementary therapy that lacks robust clinical evidence for the management of **menopausal flushing**.- **NICE guidelines** do not recommend its use due to inconsistent results in systematic reviews.*Black cohosh 40 mg daily*- While widely used, there is limited and inconsistent evidence regarding the efficacy and long-term safety of **black cohosh** for **hot flushes**.- Concerns exist regarding potential **hepatotoxicity** and its unknown impact on **breast tissue** in cancer survivors.*Gabapentin 900 mg daily in divided doses*- Although **gabapentin** is an effective alternative to HRT, it is generally considered **second-line** to SNRIs/SSRIs.- Its use is often limited by a higher side-effect profile, including **somnolence** and **dizziness**, and the inconvenience of **three-times-daily dosing**.*Vitamin E 800 IU daily*- **Vitamin E** has shown only a marginal benefit in clinical trials, often no better than **placebo** for severe vasomotor symptoms.- High doses are not recommended for routine use as they do not provide the clinical relief required for **severe symptoms**.

Question 134: A 30-year-old woman with systemic lupus erythematosus (SLE) requests contraception. Her disease is well-controlled on hydroxychloroquine. She has no history of thrombosis, her antiphospholipid antibodies are negative, and her renal function is normal. She is a non-smoker with BMI 23 kg/m² and blood pressure 122/76 mmHg. According to UKMEC criteria, which statement regarding contraceptive options is correct?

A. Combined oral contraceptive is UKMEC 2 (advantages generally outweigh risks) as her SLE is stable without organ involvement (Correct Answer)
B. All combined hormonal contraceptives are absolutely contraindicated in SLE regardless of disease activity or antibody status
C. Progesterone-only methods are UKMEC 3 (risks usually outweigh advantages) in SLE
D. Copper intrauterine device is contraindicated due to increased infection risk in SLE
E. Depot medroxyprogesterone acetate should be avoided due to concerns about bone density in women with SLE on corticosteroids

Explanation: ***Combined oral contraceptive is UKMEC 2 (advantages generally outweigh risks) as her SLE is stable without organ involvement*** - For women with **Systemic Lupus Erythematosus (SLE)**, combined hormonal contraception (CHC) is classified as **UKMEC 2** if their disease is stable and **antiphospholipid antibodies** are negative. - This classification reflects that the **advantages of preventing pregnancy** generally outweigh the potential risks, especially when there are no risk factors for **thromboembolism** like positive antiphospholipid antibodies or active disease. *All combined hormonal contraceptives are absolutely contraindicated in SLE regardless of disease activity or antibody status* - Combined hormonal contraceptives are classified as **UKMEC 4** (absolute contraindication) only in SLE patients with **positive antiphospholipid antibodies** or those with severe active lupus. - For women with stable, well-controlled SLE and negative antiphospholipid antibodies, CHCs are not absolutely contraindicated, as evidenced by the **UKMEC 2** categorization. *Progesterone-only methods are UKMEC 3 (risks usually outweigh advantages) in SLE* - Most **progesterone-only methods (POPs, implants, injectables)** are categorized as **UKMEC 1** for women with SLE, indicating no restrictions on their use. - Even in the presence of **positive antiphospholipid antibodies**, progesterone-only methods are generally considered **UKMEC 2**, making them a safer option for contraception in most SLE patients. *Copper intrauterine device is contraindicated due to increased infection risk in SLE* - The **Copper IUD** is classified as **UKMEC 1** for women with SLE, meaning it can be used without restriction and does not worsen disease activity or increase flare risk. - There is no increased risk of **pelvic inflammatory disease** in women with stable SLE using IUDs, even if on low-dose immunosuppression, contrary to this statement. *Depot medroxyprogesterone acetate should be avoided due to concerns about bone density in women with SLE on corticosteroids* - **Depot medroxyprogesterone acetate (DMPA)** is categorized as **UKMEC 2** for women with SLE, suggesting that advantages generally outweigh risks. - While DMPA can cause a **reversible reduction in bone mineral density**, it is not strictly contraindicated, especially in patients like this one who are on **hydroxychloroquine** and not long-term **corticosteroids**, which are more detrimental to bone health.

Question 135: A 49-year-old woman commenced continuous combined HRT 6 weeks ago for troublesome vasomotor symptoms. She now reports diffuse breast tenderness and bloating. Her symptoms are well-controlled otherwise. Examination reveals bilateral diffuse breast tenderness with no discrete masses. What is the most appropriate management approach?

A. Reassure that symptoms commonly resolve within 3 months and review at 3 months (Correct Answer)
B. Switch to sequential combined HRT to reduce progestogen exposure
C. Discontinue HRT immediately and arrange urgent breast imaging
D. Add danazol to reduce mastalgia while continuing current HRT
E. Switch to transdermal oestrogen with cyclical progestogen

Explanation: ***Reassure that symptoms commonly resolve within 3 months and review at 3 months*** - Side effects such as **breast tenderness** and **bloating** are common during the first 3 months of **HRT initiation** as the body adjusts to the hormones. - Since her clinical examination is **reassuring** (no masses) and **vasomotor symptoms** are well-controlled, monitoring for the standard 3-month window is the first-line approach. *Switch to sequential combined HRT to reduce progestogen exposure* - Switching to **sequential HRT** is generally indicated if progestogen-related side effects persist beyond the initial 3-month trial period or if the patient is **perimenopausal**. - Changing the regimen too early prevents the assessment of whether the body would have tolerated the **continuous combined** regimen, which offers better **endometrial protection**. *Discontinue HRT immediately and arrange urgent breast imaging* - **Urgent imaging** is not indicated as there are no **red flags** such as discrete masses, skin changes, or nipple discharge; her tenderness is bilateral and diffuse. - Discontinuing HRT would lead to the immediate recurrence of her distressing **vasomotor symptoms** unnecessarily. *Add danazol to reduce mastalgia while continuing current HRT* - **Danazol** is not an appropriate or licensed treatment for HRT-induced breast tenderness and carries significant **androgenic side effects**. - Management of HRT side effects should focus on **dose adjustment** or route changes of the HRT itself rather than adding secondary systemic medications. *Switch to transdermal oestrogen with cyclical progestogen* - While **transdermal preparations** or changing the progestogen type can help with tenderness, these adjustments should only be considered if symptoms persist for more than **3 months**. - Initiating a **cyclical progestogen** would also induce **withdrawal bleeds**, which the patient may prefer to avoid if she is already established on a continuous regimen.

Question 136: A 36-year-old woman with a history of recurrent major depressive disorder, currently stable on sertraline 100 mg daily, requests contraceptive advice. She reports that her mood significantly deteriorates in the week before menstruation. She has no other medical history, is a non-smoker with BMI 25 kg/m² and blood pressure 116/72 mmHg. Which contraceptive method would be most beneficial for managing both contraception and her premenstrual mood symptoms?

A. Cyclical combined oral contraceptive pill with 4-day hormone-free interval
B. Continuous combined oral contraceptive pill regimen without breaks (Correct Answer)
C. Etonogestrel subdermal implant
D. Depot medroxyprogesterone acetate injection
E. Copper intrauterine device

Explanation: ***Continuous combined oral contraceptive pill regimen without breaks*** - This regimen provides a **stable hormonal environment** by continuously delivering **estrogen and progestogen**, effectively suppressing **ovulation** and preventing the cyclical hormonal fluctuations that trigger **premenstrual mood symptoms**. - By eliminating the **hormone-free interval**, it avoids the abrupt **hormone withdrawal** that is often associated with the worsening of mood symptoms in the luteal phase and before menstruation, making it ideal for **Premenstrual Dysphoric Disorder (PMDD)** or severe **PMS**. *Cyclical combined oral contraceptive pill with 4-day hormone-free interval* - Even with a shorter 4-day hormone-free interval, there is still a significant **hormone drop** that can induce **withdrawal symptoms** and exacerbate **mood instability** in individuals sensitive to hormonal changes. - This method does not fully address the need for **continuous hormonal suppression** to prevent the cyclical mood symptoms experienced by the patient, unlike a continuous regimen. *Etonogestrel subdermal implant* - The **etonogestrel implant** is a **progestogen-only method** that often results in **irregular bleeding patterns** and can sometimes worsen or cause **mood changes** due to continuous progestogen exposure without the balancing effect of estrogen. - It may not reliably suppress the **hypothalamic-pituitary-ovarian axis** sufficiently to prevent all cyclical hormonal fluctuations, making it less effective for managing premenstrual mood symptoms compared to continuous combined hormonal contraception. *Depot medroxyprogesterone acetate injection* - **DMPA** is a **progestogen-only method** known for potential side effects including **weight gain** and **depressive mood changes**, especially in individuals with a history of depression. - While it can lead to amenorrhea, the **lack of estrogen** and the potential for **adverse mood effects** make it less suitable than continuous combined oral contraception for directly managing premenstrual mood exacerbations. *Copper intrauterine device* - The **copper IUD** is a **non-hormonal contraceptive method**, meaning it has no effect on the patient's **hormonal fluctuations** or **premenstrual mood symptoms**. - It often leads to **heavier and more painful periods**, which could potentially worsen the patient's overall experience and does not provide any therapeutic benefit for her chief complaint of premenstrual mood deterioration.

Question 137: A 44-year-old woman presents with increasingly irregular menstrual cycles over the past 8 months, with cycle length varying from 21 to 50 days. She reports mild hot flushes and sleep disturbance. She is sexually active and uses condoms for contraception but is concerned about contraceptive reliability due to irregular cycles. Her BMI is 24 kg/m² and blood pressure is 124/78 mmHg. She has no significant medical history. What is the most appropriate contraceptive recommendation?

A. Continue condoms as she is likely perimenopausal and fertility is low
B. Commence combined oral contraceptive pill which will also regulate her cycles and help vasomotor symptoms
C. Recommend levonorgestrel intrauterine system for contraception and cycle control (Correct Answer)
D. Advise that no contraception is needed once amenorrhoeic for 6 months given her age
E. Measure FSH and LH levels to assess if contraception is still required

Explanation: ***Recommend levonorgestrel intrauterine system for contraception and cycle control*** - This woman is experiencing symptoms consistent with **perimenopause**, including irregular cycles, hot flushes, and sleep disturbance. The **levonorgestrel intrauterine system (LNG-IUS)** provides highly effective contraception (>99% efficacy). - The LNG-IUS is also highly effective at managing **irregular and heavy menstrual bleeding**, which is common in perimenopause, and can serve as the progestogen component for future hormone replacement therapy (HRT). *Continue condoms as she is likely perimenopausal and fertility is low* - While fertility declines with age, **ovulation can still occur unpredictably** during perimenopause, making reliable contraception necessary until menopause is confirmed. - **Condoms** have a higher typical-use failure rate (13-18%) compared to long-acting reversible contraceptives and do not address her irregular cycles or vasomotor symptoms. *Commence combined oral contraceptive pill which will also regulate her cycles and help vasomotor symptoms* - While **combined oral contraceptive (COC)** pills can regulate cycles and help vasomotor symptoms, they carry increased **thromboembolic risks** and cardiovascular risks in women over 35. - The LNG-IUS is generally preferred in perimenopausal women as it avoids the systemic side effects of estrogen while providing superior **endometrial protection** and contraception. *Advise that no contraception is needed once amenorrhoeic for 6 months given her age* - Clinical guidelines state that women aged under 50 require contraception for **24 months** after their last menstrual period to ensure the cessation of fertility. - Amenorrhea for only 6 months is **insufficient** to confirm the permanent cessation of ovarian function and the end of fertile potential in a 44-year-old. *Measure FSH and LH levels to assess if contraception is still required* - **Follicle-stimulating hormone (FSH)** levels fluctuate significantly during the perimenopause and are not a reliable indicator of contraceptive need or fertility status. - The diagnosis of the menopausal transition and the need for contraception are primarily **clinical** based on age and symptom profile; hormonal testing does not alter management in this context.

Question 138: According to the UK Medical Eligibility Criteria for Contraceptive Use (UKMEC), which of the following conditions is classified as UKMEC category 4 (unacceptable health risk) for the combined oral contraceptive pill?

A. History of venous thromboembolism while pregnant
B. Migraine without aura in a 38-year-old woman
C. Current breast cancer (Correct Answer)
D. Controlled hypertension with blood pressure 138/88 mmHg
E. Breastfeeding between 6 weeks and 6 months postpartum

Explanation: ***Current breast cancer*** - **Current breast cancer** is classified as **UKMEC 4** (unacceptable health risk) because it is a **hormone-sensitive malignancy** that can be promoted by exogenous oestrogen from the **combined oral contraceptive pill (COCP)**. - Using COCP in this situation significantly increases the risk of **disease progression** or recurrence, making it an absolute contraindication. *History of venous thromboembolism while pregnant* - A **personal history of VTE** that was associated with a **transient risk factor** (like pregnancy or surgery) is classified as **UKMEC 3** for the COCP. - This means the risks generally outweigh the benefits, but it is not an absolute contraindication (UKMEC 4). *Migraine without aura in a 38-year-old woman* - **Migraine without aura** at any age is classified as **UKMEC 2** for the COCP, meaning the advantages generally outweigh the risks. - It is **migraine with aura** that is classified as **UKMEC 4** due to the significantly increased risk of **ischaemic stroke** with oestrogen-containing contraceptives. *Controlled hypertension with blood pressure 138/88 mmHg* - **Controlled hypertension** with a blood pressure reading between **140-159/90-99 mmHg** (and therefore 138/88 mmHg) is classified as **UKMEC 3** for the COCP. - Hypertension is only classified as **UKMEC 4** if the blood pressure is **≥160/100 mmHg** or if there is associated **vascular disease**. *Breastfeeding between 6 weeks and 6 months postpartum* - **Breastfeeding** during the period of **6 weeks to 6 months postpartum** is classified as **UKMEC 3** for the COCP. - This is due to theoretical concerns regarding the impact of oestrogen on **milk volume** and potential effects on infant growth, but it is not an absolute contraindication.

Question 139: A 53-year-old woman who underwent bilateral salpingo-oophorectomy at age 48 for endometriosis has been taking oestrogen-only HRT since surgery. She now presents requesting to stop HRT as she believes she has 'gone through the menopause naturally'. Her current symptoms are well-controlled on transdermal oestradiol 50 mcg patches. What is the most appropriate advice regarding HRT continuation?

A. She can stop HRT immediately as she is now past the average age of menopause
B. She should continue HRT until at least age 55 to cover the physiological age of menopause (Correct Answer)
C. She should have FSH levels checked to determine if she can stop HRT
D. She should reduce to the lowest dose and stop within the next year
E. She should continue HRT until age 51, which is the average age of natural menopause

Explanation: ***She should continue HRT until at least age 55 to cover the physiological age of menopause*** - For women who experience **iatrogenic menopause** (surgical removal of ovaries) before the natural age, it is recommended to continue HRT until at least **age 55**. - This continuation mitigates long-term health risks such as **osteoporosis**, **cardiovascular disease**, and **cognitive decline** associated with prolonged oestrogen deficiency after early surgical menopause. *She can stop HRT immediately as she is now past the average age of menopause* - While 51 is the average age, the physiological age range for natural menopause extends up to **age 55 and beyond**. - Stopping abruptly at 53, especially after surgical menopause, can lead to a resurgence of **vasomotor symptoms** and a loss of protective benefits. *She should have FSH levels checked to determine if she can stop HRT* - **FSH levels** are not a reliable indicator in women who are currently on HRT, as exogenous oestrogen suppresses the **pituitary gland's production** of gonadotropins. - Clinical decisions regarding HRT continuation should be based on **age**, symptoms, and individual risk factors, rather than biochemical markers while on treatment. *She should reduce to the lowest dose and stop within the next year* - While gradual tapering can be considered, stopping HRT by age 54 (within the next year) would still be **premature** relative to the recommended continuation until at least 55 for those with iatrogenic menopause. - A transdermal oestradiol 50 mcg patch is a standard dose, and reducing it further or stopping early could compromise **bone mineral density** and cardiovascular protection. *She should continue HRT until age 51, which is the average age of natural menopause* - Continuing only until age 51, the average age of menopause, does not adequately cover the **natural physiological range** which extends to at least 55. - The aim for women with early surgical menopause is to replace oestrogen for the full duration their ovaries would have naturally produced it, typically until **age 55**.

Question 140: A 41-year-old woman with a BMI of 38 kg/m² attends for insertion of a levonorgestrel intrauterine system for contraception and management of heavy menstrual bleeding. The procedure is technically difficult and after multiple attempts, you are unable to sound the uterus beyond 4 cm or pass the IUS through the internal os. The patient tolerates the procedure but finds it uncomfortable. What is the most appropriate next step in management?

A. Attempt insertion again after administering misoprostol to soften the cervix
B. Refer for insertion under ultrasound guidance
C. Prescribe tranexamic acid and arrange hysteroscopy to assess uterine cavity
D. Arrange pelvic ultrasound and consider alternative contraceptive methods (Correct Answer)
E. Book for insertion under general anaesthesia

Explanation: ***Arrange pelvic ultrasound and consider alternative contraceptive methods***- When the uterus cannot be sounded beyond **4 cm** (normal is 6-9 cm), it is essential to perform a **pelvic ultrasound** to exclude anatomical abnormalities like **fibroids**, **uterine anomalies**, or **cervical stenosis**.- While awaiting investigation, discussing **alternative contraception** (e.g., implant or depot) is crucial to prevent pregnancy and manage her **heavy menstrual bleeding**.*Attempt insertion again after administering misoprostol to soften the cervix*- **Misoprostol** for cervical priming is generally not recommended for routine use and should not be used after a failed attempt without first identifying the **underlying anatomical cause** of the difficulty.- Re-attempting blindly increases the risk of **uterine perforation** or significant patient distress if the cause is not simple cervical resistance.*Refer for insertion under ultrasound guidance*- **Ultrasound-guided insertion** is a valid technique but is typically utilized only after a diagnostic ultrasound has confirmed the uterine anatomy is suitable for an **IUS**.- It is premature to refer for this procedure until structural issues like a **submucous fibroid** or **congenital anomaly** have been assessed.*Prescribe tranexamic acid and arrange hysteroscopy to assess uterine cavity*- While **tranexamic acid** manages bleeding, **hysteroscopy** is an invasive second-line investigation that should only follow a **non-invasive pelvic ultrasound**.- This approach neglects the immediate need for **effective contraception**, which is the patient's primary reason for the visit.*Book for insertion under general anaesthesia*- **General anaesthesia** may overcome patient discomfort but does not address the potential anatomical barrier that prevented sounding beyond **4 cm**.- Moving directly to surgery carries unnecessary **anaesthetic risks**, especially in a patient with a high **BMI of 38 kg/m²**, before basic imaging is performed.

Question 141: A 50-year-old woman presents with vaginal dryness and dyspareunia 18 months after her last menstrual period. She has no systemic menopausal symptoms. She has a history of oestrogen receptor-positive breast cancer treated with wide local excision and radiotherapy 3 years ago. She is currently taking tamoxifen. What is the most appropriate initial management for her genitourinary symptoms?

A. Systemic continuous combined HRT
B. Vaginal oestrogen therapy
C. Vaginal lubricants and moisturisers (Correct Answer)
D. Tibolone
E. Topical testosterone cream

Explanation: ***Vaginal lubricants and moisturisers*** - These are the **first-line therapy** for managing **genitourinary syndrome of menopause (GSM)** in patients with a history of **oestrogen receptor-positive breast cancer**. - They provide symptomatic relief without **systemic absorption**, avoiding the risk of stimulating residual breast cancer cells or interfering with **tamoxifen** therapy. *Systemic continuous combined HRT* - This is **contraindicated** in women with a history of **hormone-sensitive breast cancer** as it significantly increases the risk of recurrence. - The patient also lacks **vasomotor symptoms** (e.g., hot flushes), making systemic therapy unnecessary and inappropriate. *Vaginal oestrogen therapy* - While effective for **atrophic vaginitis**, it is reserved as a second-line option in breast cancer survivors only if **non-hormonal treatments** fail. - There is a theoretical concern regarding **systemic absorption** of oestrogen, which requires a multidisciplinary discussion with an **oncologist** before initiation. *Tibolone* - Tibolone is a synthetic steroid with **oestrogenic, progestogenic, and androgenic** properties, which is contraindicated in survivors of breast cancer. - Evidence suggests it is associated with an increased risk of **breast cancer recurrence**. *Topical testosterone cream* - This is primarily used for **hypoactive sexual desire disorder (HSDD)** in postmenopausal women, not as a standard treatment for vaginal dryness. - It is not indicated as an initial management strategy for **vulvovaginal atrophy** in this clinical context.

Question 142: A 27-year-old woman presents requesting contraception. She mentions that she sometimes forgets to take daily medication. She has no significant medical history and takes no regular medications. Her BMI is 32 kg/m² and blood pressure is 118/76 mmHg. She is in a stable relationship and would like to have children in approximately 3 years. Which contraceptive method would be most appropriate to recommend?

A. Combined oral contraceptive pill
B. Progesterone-only pill
C. Etonogestrel subdermal implant (Correct Answer)
D. Depot medroxyprogesterone acetate injection
E. Levonorgestrel intrauterine system

Explanation: ***Etonogestrel subdermal implant*** - The implant is a **Long-Acting Reversible Contraceptive (LARC)**, effective for up to **3 years**, which perfectly aligns with the patient's stated desire to conceive in approximately 3 years. - It eliminates the issue of **medication adherence** (forgetting daily pills) and offers a **rapid return to fertility** immediately upon removal. *Combined oral contraceptive pill* - This method requires **daily adherence**, which is unsuitable for a patient who mentions she **sometimes forgets daily medication**, increasing the risk of **user failure**. - Her **BMI of 32 kg/m²** (obesity) is a relative contraindication for combined hormonal contraceptives due to a slightly increased risk of **venous thromboembolism (VTE)**. *Progesterone-only pill* - Similar to the combined oral contraceptive, the progesterone-only pill demands **strict daily timing** for effectiveness, making it a poor choice for someone with a history of **poor medication adherence**. - Missing the tablet even by a few hours can compromise its efficacy, necessitating backup contraception or abstinence. *Depot medroxyprogesterone acetate injection* - While highly effective, this method requires injections every **12-13 weeks**, still necessitating regular clinic visits. It is also associated with **weight gain**, which may be a concern for a patient with a BMI of 32. - It commonly causes a **delayed return to fertility**, potentially up to 12 months, which may conflict with her plan to have children in approximately 3 years. *Levonorgestrel intrauterine system* - This is an **effective LARC** but typically provides contraception for **5 years or more**, which is longer than her stated desire to conceive in approximately 3 years. - It is an **invasive procedure** requiring insertion by a trained clinician and is often preferred for managing heavy menstrual bleeding, which is not a stated concern here.

Question 143: A 34-year-old woman attends for contraceptive counselling. She smokes 15 cigarettes per day and has a blood pressure of 158/98 mmHg on two separate occasions. Her BMI is 28 kg/m². She has no other medical history. Blood tests including renal function and lipid profile are normal. What is the most appropriate contraceptive method for this patient?

A. Combined oral contraceptive pill
B. Copper intrauterine device
C. Vaginal contraceptive ring
D. Progesterone-only pill (Correct Answer)
E. Combined transdermal patch

Explanation: ***Progesterone-only pill*** - The patient's **hypertension** (158/98 mmHg) and **smoking** are significant cardiovascular risk factors, making estrogen-containing contraceptives unsafe. The **progesterone-only pill (POP)** does not increase **thromboembolic** or **vascular risk** and is a **UKMEC 1** or **2** choice for her. - It is the most appropriate hormonal oral contraceptive option for patients with contraindications to estrogen, such as **uncontrolled hypertension** and being a **smoker** over 35 or with other risk factors. *Combined oral contraceptive pill* - The **estrogen component** of combined oral contraceptives significantly increases the risk of **stroke** and **myocardial infarction** in patients with **uncontrolled hypertension** and smoking. - This method is classified as **UKMEC 4** (unacceptable risk) for patients with blood pressure consistently above 140/90 mmHg, especially with other risk factors like smoking. *Copper intrauterine device* - While the **copper IUD** is a highly effective and medically safe **long-acting reversible contraceptive (LARC)** (UKMEC 1), the question asks for the most appropriate *contraceptive method* in general counselling. - The progesterone-only pill is often considered a standard first-line oral alternative when combined hormonal methods are contraindicated, addressing the patient's immediate need for a safe oral option. *Vaginal contraceptive ring* - The vaginal ring, like other combined hormonal methods, delivers **systemic estrogen**, making it subject to the same contraindications as the combined oral pill due to the patient's **hypertension** and smoking. - Its use is classified as **UKMEC 4** for individuals with blood pressure above **160/100 mmHg** or those with multiple vascular risk factors. *Combined transdermal patch* - The **combined transdermal patch** contains **estrogen** and carries similar cardiovascular risks to other combined hormonal contraceptives, including an increased risk of **venous thromboembolism** and arterial disease in hypertensive patients. - The **transdermal route of administration** does not mitigate the contraindications posed by the patient's **hypertension** and **smoking status**.

Question 144: A 43-year-old woman attends for contraceptive advice. She is currently using condoms. She smokes 25 cigarettes per day and has a BMI of 33 kg/m². Her blood pressure is 142/90 mmHg on two separate occasions. She has regular menstrual cycles and wishes to continue menstruating. She has no other medical history. After counseling about smoking cessation and lifestyle modification, which contraceptive method would be most appropriate while addressing her cardiovascular risk profile?

A. Combined oral contraceptive pill
B. Progesterone-only pill (desogestrel) (Correct Answer)
C. Depot medroxyprogesterone acetate
D. Etonogestrel subdermal implant
E. Copper intrauterine device

Explanation: ***Progesterone-only pill (desogestrel)***- This method is safe (typically **UKMEC 1 or 2**) for women with multiple cardiovascular risk factors like **smoking**, **obesity**, and **hypertension**, as it does not contain estrogen.- It provides a suitable balance for a patient who **wishes to continue menstruating**, as it often allows for more predictable cycles compared to long-acting reversible contraceptives (LARCs) while avoiding the risks of combined pills.*Combined oral contraceptive pill*- This is strictly contraindicated (**UKMEC 4**) in this patient because she is over 35 years old and **smokes more than 15 cigarettes per day**.- The estrogen component significantly increases the risk of **myocardial infarction**, **stroke**, and **venous thromboembolism** in patients with pre-existing hypertension and cardiovascular risk factors.*Depot medroxyprogesterone acetate*- The injectable contraceptive is generally avoided (**UKMEC 3**) in patients with multiple cardiovascular risk factors due to potential adverse effects on **lipid profiles** and **weight gain**.- It is also associated with a high incidence of **amenorrhea** or persistent irregular spotting, which may not align with her preference to maintain a regular cycle.*Etonogestrel subdermal implant*- While safe from a cardiovascular standpoint, the implant frequently causes **amenorrhea** or highly irregular bleeding, which contradicts the patient's wish to continue menstruating.- It is a highly effective **LARC**, but user preference regarding menstrual patterns is a key factor in selecting the most "appropriate" method in this clinical scenario.*Copper intrauterine device*- Although the copper IUD is the safest option cardiovascularly (**UKMEC 1**), it is known to **increase menstrual blood loss** and cause heavier periods.- While it allows for natural menstruation, the potential for **menorrhagia** (heavy bleeding) often makes it less desirable for patients simply wishing to maintain their normal cycle without exacerbation.

Question 145: A 57-year-old woman with type 2 diabetes mellitus presents requesting HRT for moderate vasomotor symptoms that are affecting her sleep. Her last menstrual period was 3 years ago. Her HbA1c is 58 mmol/mol (7.5%), BMI is 29 kg/m², and blood pressure is 136/84 mmHg. She has background diabetic retinopathy but no other diabetic complications. She takes metformin and gliclazide. What factor would represent the greatest relative contraindication to HRT in this patient?

A. Type 2 diabetes mellitus
B. Her age of 57 years
C. Blood pressure of 136/84 mmHg (Correct Answer)
D. BMI of 29 kg/m²
E. Current glycaemic control

Explanation: ***Blood pressure of 136/84 mmHg*** - While not an absolute contraindication, **blood pressure** must be carefully managed as oral estrogen can potentially increase blood pressure and the risk of **stroke**. - In patients with **Diabetes Mellitus**, blood pressure targets are often stricter, and this reading approaches the threshold where **hypertension** needs to be stabilized before starting treatment. *Type 2 diabetes mellitus* - Diabetes is classified as **UKMEC 2**, meaning the benefits of HRT generally outweigh the risks, and it is not a direct contraindication. - HRT can actually have positive effects on **glucose metabolism** and insulin sensitivity in many menopausal women. *Her age of 57 years* - Commencing HRT at age 57 is generally safe, as it falls within the **"window of opportunity"** (under age 60 or within 10 years of menopause onset). - At this age, the **cardiovascular benefit-to-risk ratio** remains favorable for treating symptomatic women. *BMI of 29 kg/m²* - A BMI in the overweight range is a **UKMEC 2** factor; while it increases baseline **venous thromboembolism (VTE)** risk, it does not preclude HRT use. - For women with higher BMIs, **transdermal HRT** is preferred as it avoids the increased VTE risk associated with oral preparations. *Current glycaemic control* - An HbA1c of 58 mmol/mol (7.5%) indicates suboptimal control, but it is not a **relative contraindication** to hormone therapy. - HRT does not typically worsen **glycaemic control** and is safe to use alongside metformin and sulfonylureas like **gliclazide**.

Question 146: A 33-year-old woman with a 6-month history of migraine with aura has been using combined oral contraceptive pills for 4 years. She presents for a routine contraceptive review. Her migraines have increased in frequency from once every 3 months to 2-3 times per month over the past 6 months. She has no other medical history and her blood pressure is 122/78 mmHg. What is the most appropriate management of her contraception?

A. Continue combined oral contraceptive as migraines are well-controlled
B. Switch to progesterone-only pill (Correct Answer)
C. Reduce the estrogen dose in her combined oral contraceptive
D. Switch to tricycling regimen to reduce pill-free intervals
E. Continue current pill but add prophylactic migraine treatment

Explanation: ***Switch to progesterone-only pill***- Combined hormonal contraception (CHC) is a **UKMEC 4** (unacceptable health risk) contraindication in patients with **migraine with aura** due to an increased risk of **ischemic stroke**.- Progesterone-only methods, such as the **progesterone-only pill (POP)**, do not contain estrogen and are considered safe (**UKMEC 2**) for women who experience migraines with aura.*Continue combined oral contraceptive as migraines are well-controlled*- Regardless of frequency or control, the presence of **aura** makes estrogen-containing pills strictly contraindicated because of the **cardiovascular risk profile**.- These migraines are actually increasing in frequency (2-3 times per month), which further contraindicates the use of high-risk hormonal medications.*Reduce the estrogen dose in her combined oral contraceptive*- Lowering the **estradiol dose** does not eliminate the contraindication; any amount of estrogen in the context of aura significantly elevates **stroke risk**.- **UKMEC 4** guidelines apply to all forms of combined contraception, including low-dose pills, patches, and vaginal rings.*Switch to tricycling regimen to reduce pill-free intervals*- **Tricycling** (taking three packs back-to-back) is used to manage **estrogen-withdrawal migraines** (migraine without aura), but it is unsafe here.- Because this patient experiences **aura**, the primary concern is the safe use of estrogen itself, not just the fluctuations during the **pill-free interval**.*Continue current pill but add prophylactic migraine treatment*- Prophylactic treatment for migraines does not mitigate the **thromboembolic and stroke risks** associated with using CHC in patients with aura.- The priority in clinical management is to **discontinue the estrogen component** immediately to ensure the patient's long-term safety.

Question 147: A 56-year-old woman who has been on continuous combined HRT for 3 years presents for review. She remains asymptomatic with good control of vasomotor symptoms. She asks about when she should stop HRT. She has no history of premature ovarian insufficiency, cardiovascular disease, or osteoporosis risk factors. What is the most appropriate advice regarding continuation of HRT?

A. HRT should be stopped immediately as she has been on it for more than 2 years
B. HRT can be continued if benefits outweigh risks, with annual review (Correct Answer)
C. HRT should be stopped at age 60 regardless of symptoms
D. HRT should be continued until age 65 to protect against osteoporosis
E. HRT should be gradually reduced and stopped within 6 months

Explanation: ***HRT can be continued if benefits outweigh risks, with annual review***- Current guidelines emphasize an **individualized assessment** for HRT duration, with **no arbitrary time limit**.- The decision to continue should be based on ongoing **symptom control**, quality of life, and a personal risk-benefit analysis during an **annual review**.*HRT should be stopped immediately as she has been on it for more than 2 years*- There is no medical requirement or guideline to stop HRT after a **fixed two-year period**; symptom duration varies greatly.- Immediate cessation is not indicated unless there's a **new contraindication** or significant adverse effects.*HRT should be stopped at age 60 regardless of symptoms*- While risks can increase with age, **age 60 is not an absolute cutoff** for HRT, especially if symptoms are well-controlled.- Stopping HRT regardless of symptoms ignores the patient's **symptomatic relief** and potential recurrence of vasomotor symptoms.*HRT should be continued until age 65 to protect against osteoporosis*- Although HRT is effective for **osteoporosis prevention**, it is generally not recommended as a first-line long-term treatment solely for this purpose in women without high fracture risk.- The duration of HRT should primarily be driven by **symptomatic need** and quality of life, not a specific target age like 65 for bone protection.*HRT should be gradually reduced and stopped within 6 months*- While some women may choose to **taper the dose** to assess symptom recurrence, there is no mandatory requirement to stop within a 6-month timeframe.- Forcing a reduction and stop in an **asymptomatic patient** benefiting from HRT contradicts the principle of individualized, patient-centered care.

Question 148: A 38-year-old woman with body mass index of 42 kg/m² requests contraception. She has a history of previous deep vein thrombosis 2 years ago associated with long-haul flight. Thrombophilia screening was negative. She has essential hypertension controlled on ramipril with blood pressure today of 138/88 mmHg. She is a non-smoker. Which contraceptive method would be most suitable?

A. Levonorgestrel intrauterine system (Correct Answer)
B. Vaginal contraceptive ring
C. Depot medroxyprogesterone acetate
D. Combined oral contraceptive pill
E. Transdermal contraceptive patch

Explanation: ***Levonorgestrel intrauterine system*** - The **LNG-IUS** is classified as **UKMEC 1** for patients with a history of **venous thromboembolism (VTE)** because it is a progestogen-only method with minimal systemic absorption, not increasing the risk of recurrence. - It is highly suitable for this patient as it is not affected by her **BMI of 42 kg/m²** or her controlled **hypertension**, offering superior efficacy and the additional benefit of reduced menstrual bleeding. *Vaginal contraceptive ring* - This is a **combined hormonal contraceptive (CHC)**, containing estrogen, and is therefore categorized as **UKMEC 4** (absolute contraindication) due to the patient's history of **deep vein thrombosis (DVT)**. - CHCs significantly increase the synthesis of clotting factors, substantially elevating the risk of recurrent **thromboembolic events**. *Depot medroxyprogesterone acetate* - Although **depot medroxyprogesterone acetate (DMPA)** is a progestogen-only method and does not increase VTE risk, it is often avoided in morbidly obese patients (**BMI >40 kg/m²**) due to its association with significant **weight gain**. - While classified as **UKMEC 2** in this context, the potential for further weight gain makes it less ideal than the IUS given her existing BMI and cardiovascular risk factors. *Combined oral contraceptive pill* - The **COCP** is strictly contraindicated (**UKMEC 4**) in any woman with a previous history of **VTE**, regardless of whether the event was provoked or unprovoked, due to its **estrogen** component. - Her **BMI >35 kg/m²** and controlled **hypertension** are also independent **UKMEC 3** criteria, making this method unsafe and highly unsuitable for her. *Transdermal contraceptive patch* - Similar to the pill and ring, the **transdermal patch** contains **estrogen**, which is absolutely contraindicated (**UKMEC 4**) in patients with a history of **DVT**. - The efficacy of the **transdermal patch** may also be reduced in women weighing more than 90 kg, which is highly probable given her **BMI of 42 kg/m²**.

Question 149: A 49-year-old woman on sequential combined HRT presents with a 3-day episode of vaginal bleeding on day 18 of her cycle. She started this HRT regimen 10 months ago for vasomotor symptoms. She takes 2 mg estradiol daily with 10 mg dydrogesterone on days 15-28 of each 28-day cycle. Her previous bleeding pattern showed withdrawal bleeds on days 22-26. What is the most appropriate next step in management?

A. Switch to continuous combined HRT
B. Continue current regimen and review in 3 months
C. Arrange transvaginal ultrasound scan (Correct Answer)
D. Increase the progestogen dose
E. Refer for urgent endometrial biopsy

Explanation: ***Arrange transvaginal ultrasound scan*** - In women on **sequential combined HRT**, bleeding that occurs outside the expected withdrawal period or a **change in an established bleeding pattern** requires investigation to rule out endometrial pathology. - A **transvaginal ultrasound (TVUS)** is the first-line investigation to assess **endometrial thickness** and check for structural issues like polyps before considering invasive biopsies. *Switch to continuous combined HRT* - This patient began HRT only 10 months ago and is likely **perimenopausal**; switching to continuous combined HRT is usually reserved for women who are **postmenopausal** for at least one year. - Switching regimens would be inappropriate before investigating the cause of the **unscheduled bleeding** to ensure a malignancy is not being masked. *Continue current regimen and review in 3 months* - While **breakthrough bleeding** is common in the first 6 months of HRT, this patient has been on her regimen for 10 months and has a **new change** in her bleeding pattern. - Expectant management is inappropriate when a stable bleeding pattern changes, as it delays the diagnosis of potential **endometrial hyperplasia** or cancer. *Increase the progestogen dose* - Increasing the **progestogen dose** is a strategy to manage breakthrough bleeding, but it should only be done after **pathology** has been excluded via imaging. - Adjusting doses without investigation risks providing a false sense of security while an underlying **endometrial abnormality** persists. *Refer for urgent endometrial biopsy* - While an **endometrial biopsy** may eventually be needed, it is typically indicated if the **TVUS** shows an endometrial thickness >7mm or other irregularities. - An **urgent 2-week wait referral** is generally reserved for true **postmenopausal bleeding (PMB)** or persistent unscheduled bleeding where malignancy is highly suspected.

Question 150: A 24-year-old woman requests emergency contraception. She had unprotected sexual intercourse 60 hours ago and again 12 hours ago. Her last menstrual period started 10 days ago and she has regular 28-day cycles. Her BMI is 32 kg/m². She takes no regular medications. What is the most effective emergency contraception option for this patient?

A. Levonorgestrel 1.5 mg single dose
B. Ulipristal acetate 30 mg single dose
C. Copper intrauterine device (Correct Answer)
D. Levonorgestrel 3 mg single dose
E. Combined oral contraceptive (Yuzpe method)

Explanation: ***Copper intrauterine device***- The **copper IUD** is the most effective method of emergency contraception with a **failure rate of <0.1%** and remains the gold standard regardless of body mass index.- It can be inserted up to **5 days (120 hours)** after unprotected intercourse or up to 5 days after the **earliest estimated date of ovulation**, making it highly suitable for this patient.*Levonorgestrel 1.5 mg single dose*- This hormonal method is primarily effective up to **72 hours** after intercourse and its efficacy is significantly reduced in patients with a **BMI over 26 kg/m²**.- Given this patient's **BMI of 32 kg/m²**, this standard dose is considered significantly less effective than other available options.*Ulipristal acetate 30 mg single dose*- While more effective than levonorgestrel and capable of delaying ovulation closer to the **LH surge**, it is still less effective than the **copper IUD**.- Its efficacy may also be reduced in women with a **BMI >30 kg/m²**, although it remains a better oral choice than standard-dose levonorgestrel.*Levonorgestrel 3 mg single dose*- **Double-dosing** levonorgestrel is sometimes recommended for women with a **BMI >30 kg/m²** or weight >70kg if the IUD is not an option.- However, even at a higher dose, it does not reach the near-100% efficacy provided by the **copper intrauterine device**.*Combined oral contraceptive (Yuzpe method)**- This historical method involves taking high doses of **ethinylestradiol and levonorgestrel** but is the **least effective** modern option for emergency contraception.- It is associated with a much higher incidence of side effects like **nausea and vomiting** compared to single-hormone or IUD methods.

Question 151: A 46-year-old woman presents with worsening hot flushes and night sweats over the past 4 months. Her periods have become irregular, occurring every 6-8 weeks. She has a history of breast cancer treated with wide local excision and radiotherapy 3 years ago, now in remission. She is currently taking tamoxifen. She requests HRT for symptom control. What is the most appropriate management?

A. Prescribe standard dose continuous combined HRT
B. Recommend cognitive behavioural therapy and lifestyle modifications (Correct Answer)
C. Prescribe tibolone
D. Prescribe low-dose oestrogen-only HRT
E. Stop tamoxifen and commence HRT

Explanation: ***Recommend cognitive behavioural therapy and lifestyle modifications*** - Systemic **HRT is contraindicated** in patients with a history of **breast cancer** (UKMEC 4) due to the risk of stimulating residual malignant cells and increasing **recurrence risk**. - **Cognitive Behavioural Therapy (CBT)** and lifestyle changes are the evidence-based first-line non-hormonal management strategies for **vasomotor symptoms** in cancer survivors. *Prescribe standard dose continuous combined HRT* - Oestrogen-containing therapy poses an **unacceptable health risk** for women with a history of oestrogen-sensitive malignancies like breast cancer. - Combined HRT is also only appropriate for patients who have been **amenorrhoeic for at least 12 months** to avoid irregular breakthrough bleeding, and this patient still has irregular periods. *Prescribe tibolone* - **Tibolone** is a synthetic steroid with oestrogenic, progestogenic, and androgenic properties that is specifically **contraindicated** in breast cancer survivors. - Clinical trials (like the **LIBERATE study**) demonstrated that tibolone significantly increases the risk of **breast cancer recurrence**. *Prescribe low-dose oestrogen-only HRT* - **Oestrogen-only HRT** is contraindicated in women with an **intact uterus** as it leads to endometrial hyperplasia and increases the risk of **endometrial cancer**. - Regardless of dose, systemic oestrogen should be avoided in this patient due to her **breast cancer history**. *Stop tamoxifen and commence HRT* - **Tamoxifen** is a vital **selective estrogen receptor modulator (SERM)** used to prevent recurrence in breast cancer and should not be discontinued for symptom management. - Tamoxifen itself can worsen **vasomotor symptoms**, but these should be managed with non-hormonal alternatives rather than stopping **life-saving oncology treatment**.

Question 152: A 31-year-old woman with Crohn's disease had the etonogestrel implant inserted 10 months ago. She presents with a 4-month history of frequent irregular bleeding, occurring every 10-14 days and lasting 5-7 days. She reports no abdominal pain and her Crohn's disease is well controlled. She wishes to continue with the implant. What is the most appropriate management to address the bleeding pattern?

A. Prescribe mefenamic acid during bleeding episodes (Correct Answer)
B. Prescribe tranexamic acid during bleeding episodes
C. Reassure that bleeding will settle spontaneously
D. Remove the implant and insert a new one
E. Prescribe combined oral contraceptive pill for 3 months

Explanation: ***Prescribe mefenamic acid during bleeding episodes***- **Mefenamic acid** is a first-line medical intervention for managing irregular bleeding associated with the **etonogestrel implant** by reducing prostaglandin levels in the endometrium.- It is a suitable option for this patient because her **Crohn's disease** (even if well-controlled) may represent a relative contraindication or increased risk for estrogen-based therapies.*Prescribe tranexamic acid during bleeding episodes*- **Tranexamic acid** is primarily indicated for **heavy menstrual bleeding** (menorrhagia) rather than the frequent, irregular spotting typical of hormonal implants.- While it can be used, evidence suggests it is generally less effective than **NSAIDs** like mefenamic acid for implant-related bleeding disturbances.*Reassure that bleeding will settle spontaneously*- Bleeding patterns with the implant usually stabilize within the first **3 to 6 months**; since she is at 10 months, spontaneous improvement is unlikely.- **Active management** is required here because the patient is seeking help for a persistent problem that has lasted 4 months.*Remove the implant and insert a new one*- **Early replacement** of the etonogestrel implant does not resolve bleeding issues, as the bleeding is a physiological side effect of the **progestogen-only** delivery.- This approach is not evidence-based and would unnecessarily expose the patient to surgical procedures and **medical costs**.*Prescribe combined oral contraceptive pill for 3 months*- Although a **COCP** is often used to stabilize the endometrium, it contains **estrogen**, which increases the risk of **venous thromboembolism (VTE)**.- This is specifically avoided in patients with **Crohn's disease** due to the associated baseline increase in **prothrombotic risk**, making mefenamic acid a safer choice.

Question 153: A 51-year-old woman commenced on continuous combined HRT 8 months ago presents with light vaginal bleeding for 3 days. She reports good control of her menopausal symptoms. Her last natural menstrual period was 14 months ago. On examination, her blood pressure is 128/82 mmHg and abdominal and pelvic examination are unremarkable. What is the most appropriate next step in management?

A. Reassure her that irregular bleeding is common in the first year of continuous combined HRT
B. Arrange urgent transvaginal ultrasound and refer to gynecology (Correct Answer)
C. Switch to sequential combined HRT
D. Arrange pelvic ultrasound within 2 weeks
E. Increase the progestogen component of her HRT

Explanation: ***Arrange urgent transvaginal ultrasound and refer to gynecology*** - The patient has been on continuous combined HRT for **8 months**, which exceeds the **initial 6-month period** during which irregular bleeding is often considered acceptable. - Any unscheduled or persistent vaginal bleeding in a postmenopausal woman on HRT after 6 months must be urgently investigated to rule out **endometrial pathology**, including **endometrial cancer**, typically via a **transvaginal ultrasound** and **gynecological referral**. *Reassure her that irregular bleeding is common in the first year of continuous combined HRT* - While irregular bleeding can be common during the initial adjustment to continuous combined HRT, this typically applies only to the **first 3-6 months**. - Beyond this timeframe, unscheduled bleeding in a postmenopausal woman requires investigation as it is considered **postmenopausal bleeding (PMB)** and carries a risk of underlying **endometrial pathology**. *Switch to sequential combined HRT* - **Sequential combined HRT** is generally used for perimenopausal women or those who prefer cyclical bleeding, and switching to it would not address the urgent need to investigate the current **unscheduled bleeding**. - Adjusting the HRT type without first excluding serious **endometrial conditions** or malignancy is clinically inappropriate and may delay critical diagnosis. *Arrange pelvic ultrasound within 2 weeks* - While a **pelvic ultrasound** (specifically transvaginal) is a necessary diagnostic tool, the situation demands an **urgent referral** to gynecology, often within a **2-week wait pathway**, for comprehensive evaluation. - Simply arranging an ultrasound without the accompanying specialist referral for suspected **postmenopausal bleeding** does not fully meet the standard of care. *Increase the progestogen component of her HRT* - Increasing the **progestogen** component may be considered for managing benign breakthrough bleeding, but only **after** serious endometrial pathology, such as **endometrial hyperplasia** or cancer, has been definitively ruled out. - Without prior investigation, adjusting the hormonal dose risks masking symptoms of a significant underlying condition and delaying appropriate management.

Question 154: A 29-year-old woman with factor V Leiden mutation attends for contraceptive counseling. She is in a stable relationship and wishes to avoid pregnancy for the next 3 years. Her BMI is 23 kg/m², blood pressure is 116/74 mmHg, and she is a non-smoker. She has regular menstrual cycles and no dysmenorrhea. Which contraceptive method is most appropriate for her?

A. Combined oral contraceptive pill
B. Copper intrauterine device (Correct Answer)
C. Vaginal contraceptive ring
D. Transdermal contraceptive patch
E. Progesterone-only pill (desogestrel)

Explanation: ***Copper intrauterine device*** - The **copper intrauterine device (Cu-IUD)** contains no hormones and carries no increased risk of **venous thromboembolism (VTE)**, making it ideal for patients with **Factor V Leiden mutation**. - It is a highly effective **long-acting reversible contraceptive (LARC)** that provides protection for up to 10 years, satisfying her desire to avoid pregnancy for 3 years.*Combined oral contraceptive pill* - The **oestrogen** component in combined pills significantly increases the risk of **VTE**, which is synergistically elevated in patients with **thrombophilias** like **Factor V Leiden**. - It is classified as **UKMEC 4** (unacceptable health risk) for women with known thrombogenic mutations.*Vaginal contraceptive ring* - Like the combined pill, the vaginal ring contains **oestrogen** and is contraindicated in women with an increased baseline risk of **thrombosis**. - It carries a similar **thrombotic risk profile** to other combined hormonal delivery systems, regardless of the route of administration.*Transdermal contraceptive patch* - The patch delivers **ethinylestradiol** systemically, which leads to an increased production of **clotting factors** by the liver. - It is strictly **contraindicated** in this patient due to her underlying **coagulopathy** and the risk of life-threatening thromboembolic events.*Progesterone-only pill (desogestrel)* - While the **progesterone-only pill (POP)** is safe in Factor V Leiden as it does not increase **VTE risk**, it is generally less effective in typical use compared to **LARCs**. - The **copper IUD** is often preferred over the POP for long-term planning (3 years) as it eliminates the need for daily adherence and offers superior **contraceptive efficacy**.

Question 155: A 54-year-old woman who underwent hysterectomy for fibroids 5 years ago presents with severe vasomotor symptoms affecting her quality of life. She has no personal or family history of breast cancer or venous thromboembolism. Her BMI is 28 kg/m² and blood pressure is 132/84 mmHg. What is the most appropriate hormone replacement therapy regimen for this patient?

A. Continuous combined oestrogen and progesterone therapy
B. Sequential combined oestrogen and progesterone therapy
C. Oestrogen-only therapy (Correct Answer)
D. Progesterone-only therapy
E. Tibolone

Explanation: ***Oestrogen-only therapy*** - In women who have undergone a **hysterectomy**, there is no **endometrium** to protect from the stimulatory effects of oestrogen, making progestogens unnecessary. - **Oestrogen-only HRT** is the most effective treatment for **vasomotor symptoms** (hot flashes and night sweats) and has a lower risk profile regarding breast cancer compared to combined therapy. *Continuous combined oestrogen and progesterone therapy* - This regimen is indicated for postmenopausal women with an **intact uterus** to prevent **endometrial hyperplasia** and cancer. - Adding **progesterone** in this patient would provide no clinical benefit and would unnecessarily increase the risk of certain side effects like **breast cancer**. *Sequential combined oestrogen and progesterone therapy* - This approach is typically used for perimenopausal women with an **intact uterus** to provide regular **withdrawal bleeds**. - Since this patient has no uterus, there is no need for **endometrial protection** or a induced bleeding cycle. *Progesterone-only therapy* - **Progesterone-only** options are not the standard of care or first-line choice for treating **vasomotor symptoms** in the absence of a uterus. - Its primary use in hormone therapy is to counteract the effects of oestrogen on the **endometrium**, which is not required here. *Tibolone* - **Tibolone** is a synthetic compound with oestrogenic, progestogenic, and androgenic properties that can be used post-hysterectomy. - However, **oestrogen-only therapy** is generally preferred as the first-line treatment for severe vasomotor symptoms due to more robust efficacy data and a favorable risk-benefit profile.

Question 156: A 47-year-old woman presents with a 3-month history of irregular menstrual cycles, previously regular 28-day cycles. She reports occasional hot flushes. Her last menstrual period was 6 weeks ago. She requests hormonal contraception. Her BMI is 26 kg/m² and blood pressure is 124/78 mmHg. She is a non-smoker with no significant medical history. What is the most appropriate initial contraceptive advice?

A. She should use barrier methods only until menopause is confirmed
B. Combined hormonal contraception is contraindicated due to her age
C. She can use combined hormonal contraception and should continue until age 50 (Correct Answer)
D. Progesterone-only methods are the only suitable options at her age
E. She no longer needs contraception as she is perimenopausal

Explanation: ***She can use combined hormonal contraception and should continue until age 50***- Per **FSRH guidelines**, healthy non-smoking women with a BMI <35 kg/m² and no other risk factors can safely use **combined oral contraception (COC)** up to the age of 50.- In this perimenopausal patient, **combined hormonal contraception** not only provides effective birth control but also helps manage symptoms such as **hot flushes** and **irregular menstrual cycles**.*She should use barrier methods only until menopause is confirmed*- Barrier methods are an option, but they are not the only choice for a healthy woman under 50; they have a higher **failure rate** compared to hormonal methods.- Resting on barrier methods alone ignores the beneficial effects of hormonal treatments on **vasomotor symptoms** and bone health during the perimenopause.*Combined hormonal contraception is contraindicated due to her age*- Age alone is not a contraindication; **UKMEC 1** or 2 criteria often apply to women over 40 long as they are non-smokers and lack significant cardiovascular risk.- Modern low-dose **estrogen** formulations have significantly reduced the risks historically associated with COC use in older reproductive-age women.*Progesterone-only methods are the only suitable options at her age*- While **progestogen-only pills (POP)** or implants are excellent choices, they are not the *only* choice as combined methods are permissible until age 50.- Progestogen-only methods do not consistently provide the **estrogenic support** needed to control perimenopausal symptoms like hot flushes.*She no longer needs contraception as she is perimenopausal*- Women are considered potentially fertile until they have been **amenorrheic** for at least two years if under 50, or one year if over 50.- Although fertility declines with age, **spontaneous pregnancy** is still possible during the perimenopause, making reliable contraception essential.

Question 157: A 22-year-old woman requests contraception. She has no significant medical history and is a non-smoker. Her BMI is 24 kg/m². She mentions she sometimes forgets to take medications regularly. On examination, her blood pressure is 118/76 mmHg. Which contraceptive method would provide the longest duration of action with a single administration?

A. Copper intrauterine device (Correct Answer)
B. Levonorgestrel intrauterine system (52mg)
C. Etonogestrel subdermal implant
D. Depot medroxyprogesterone acetate injection
E. Combined oral contraceptive pill

Explanation: ***Copper intrauterine device***- The **copper IUD** (Cu-IUD) provides the longest duration of action among the options, with many devices licensed for up to **10 years** of continuous use.- It is a highly effective **Long-Acting Reversible Contraceptive (LARC)** that eliminates the need for daily adherence, making it ideal for patients who forget medications.*Levonorgestrel intrauterine system (52mg)*- The 52mg **LNG-IUS** (e.g., Mirena) is typically licensed for **5 to 6 years** for contraception, which is shorter than the 10-year copper IUD.- While it provides secondary benefits like **reduced menstrual bleeding**, it does not meet the criteria for the longest possible single-administration duration.*Etonogestrel subdermal implant*- The **subdermal implant** (e.g., Nexplanon) is a LARC that provides highly effective contraception for a duration of **3 years**.- Although it has the **lowest failure rate** of all methods, it requires replacement much sooner than the copper IUD or the 52mg LNG-IUS.*Depot medroxyprogesterone acetate injection*- This method requires a repeat intramuscular or subcutaneous injection every **12 to 13 weeks** to maintain efficacy.- It is not considered a true "set and forget" method for years and is associated with a **delay in the return of fertility**.*Combined oral contraceptive pill*- This method requires **daily administration** at approximately the same time, making it the least suitable for a patient who mentions forgetting medications.- It is a **short-acting** method and has a significantly higher typical-use failure rate compared to LARC methods like the IUD or implant.

Question 158: A 53-year-old woman on continuous combined HRT for 2 years presents with bilateral breast tenderness and reports feeling a lump in her right breast. Examination reveals diffuse nodularity bilaterally and a 2 cm smooth, mobile lump in the upper outer quadrant of the right breast. She is up to date with breast screening; her last mammogram 10 months ago showed dense breast tissue with no abnormalities. What is the most appropriate management?

A. Refer urgently via two-week wait pathway for triple assessment (Correct Answer)
B. Stop HRT for 6 weeks and review; if lump persists, refer for imaging
C. Arrange ultrasound of the breast lump in the next few weeks
D. Reduce HRT dose and prescribe evening primrose oil for breast tenderness
E. Reassure and arrange routine follow-up in 6 months as recent mammogram was normal

Explanation: ***Refer urgently via two-week wait pathway for triple assessment*** - NICE guidelines mandate an urgent **two-week wait (2WW) referral** for any woman aged 30 or older presenting with an **unexplained, new discrete breast lump**. - A normal mammogram within the last year does not exclude malignancy, as **dense breast tissue** (noted here) can frequently mask small or developing cancers. *Stop HRT for 6 weeks and review; if lump persists, refer for imaging* - Delaying referral to observe the effects of stopping **hormone replacement therapy (HRT)** is dangerous and deviates from standard **cancer referral pathways**. - While HRT can cause generalized **nodularity** and tenderness, a **discrete 2 cm lump** must be investigated immediately to ensure it is not malignant. *Arrange ultrasound of the breast lump in the next few weeks* - Standard primary care investigations like a simple ultrasound are insufficient for a **new palpable lump**; the patient requires a specialist **triple assessment** (clinical examination, imaging, and potential biopsy). - Ordering tests outside of the **2WW pathway** leads to clinical delay and does not meet the necessary standard of care for suspected malignancy. *Reduce HRT dose and prescribe evening primrose oil for breast tenderness* - Reducing the dose and using **evening primrose oil** may address the **bilateral tenderness**, but it clinically ignores the presence of the **discrete mobile lump**. - Symptomatic relief of mastalgia should only be prioritized after a **malignant process** has been formally excluded by specialist referral. *Reassure and arrange routine follow-up in 6 months as recent mammogram was normal* - Reassurance is inappropriate because a **palpable clinical finding** takes precedence over a previous imaging report, especially when the tissue is **dense**. - Approximately **10-15% of breast cancers** are mammographically occult, making clinical progression the primary indicator for a new urgent referral.

Question 159: A 35-year-old woman with well-controlled type 1 diabetes requests contraception. She has no diabetic complications, her last HbA1c was 52 mmol/mol (6.9%), and her blood pressure is 124/78 mmHg. She has two children and has no plans for further pregnancies in the foreseeable future. She prefers not to take daily medication. Which contraceptive method is most appropriate?

A. Combined oral contraceptive pill
B. Etonogestrel subdermal implant (Correct Answer)
C. Copper intrauterine device
D. Depot medroxyprogesterone acetate injection
E. Progesterone-only pill

Explanation: ***Etonogestrel subdermal implant*** - The **etonogestrel implant** is a **Long-Acting Reversible Contraceptive (LARC)**, which fits the patient's preference to avoid **daily medication** and offers high efficacy (>99%). - It is categorized as **UKMEC 1** for women with diabetes regardless of complications, as it has no significant impact on **carbohydrate metabolism** or **thrombotic risk**. *Combined oral contraceptive pill* - While it is **UKMEC 2** (benefits outweigh risks) for women with uncomplicated diabetes, it requires **daily administration**, which the patient specifically wants to avoid. - It carries a slightly higher **venous thromboembolism (VTE)** risk compared to progestogen-only or non-hormonal methods. *Copper intrauterine device* - The **copper IUD** is a highly effective **non-hormonal LARC** and is **UKMEC 1** for diabetic patients. - However, it may cause **heavier or more painful menstruation**, making the hormonal implant a more favourable option for cycle control in many women. *Depot medroxyprogesterone acetate injection* - This injection is **UKMEC 2** for diabetes but is associated with **weight gain**, which can complicate glycemic control in **Type 1 diabetes**. - There are also concerns regarding its impact on **lipid profiles** and a potential reduction in **bone mineral density** with long-term use. *Progesterone-only pill* - The **progesterone-only pill (POP)** is safe and **UKMEC 1** for this patient, but it does not meet her requirement for avoiding **daily medication**. - It is generally less effective than LARCs like the implant due to the risk of **user error** and missed doses.

Question 160: A 50-year-old woman on sequential combined HRT for 18 months reports a 7-day episode of heavy vaginal bleeding occurring 10 days after her expected withdrawal bleed. She has no pain or other symptoms. Her last cervical screening 18 months ago was normal. Abdominal examination is unremarkable. What is the most appropriate initial investigation?

A. Transvaginal ultrasound to assess endometrial thickness (Correct Answer)
B. Outpatient hysteroscopy and endometrial biopsy
C. Repeat cervical cytology and HPV testing
D. Serum CA-125 and pelvic ultrasound
E. Switch to continuous combined HRT and review in 3 months

Explanation: ***Transvaginal ultrasound to assess endometrial thickness*** - In a woman on **sequential HRT** for more than 6 months, **unscheduled bleeding** (bleeding outside the expected withdrawal phase) requires investigation to rule out **endometrial hyperplasia** or **carcinoma**. - **Transvaginal ultrasound (TVUS)** is the gold-standard initial non-invasive tool; a thickness **>4 mm** or **>5 mm** (depending on local guidelines) necessitates further invasive testing. *Outpatient hysteroscopy and endometrial biopsy* - This is the definitive investigation for **histological diagnosis** but is considered the **second-line** step if the ultrasound shows an increased endometrial thickness or irregularity. - While accurate, it is more invasive and is typically reserved for cases where **TVUS** findings are abnormal or if symptoms persist despite a normal scan. *Repeat cervical cytology and HPV testing* - The patient’s symptoms are consistent with **uterine pathology** rather than cervical pathology, especially given the timing relative to her HRT cycle. - She had a **normal cervical screening** only 18 months ago, making a primary cervical cause less likely as the initial diagnostic focus. *Serum CA-125 and pelvic ultrasound* - **CA-125** is a biomarker used primarily for the evaluation of **ovarian cancer**, which typically presents with bloating, pelvic pain, or early satiety, rather than isolated heavy vaginal bleeding. - A standard **pelvic ultrasound** is less effective than a **transvaginal** approach for measuring the fine details of the **endometrial stripe**. *Switch to continuous combined HRT and review in 3 months* - **Unscheduled bleeding** in a patient who has been stable on HRT for 18 months must be investigated promptly and should not be managed by simply adjusting the medication. - Delaying investigation by 3 months to "review" risks missing a diagnosis of **endometrial malignancy** during a critical window.

Question 161: A 42-year-old woman using a copper IUD for contraception presents with increasingly heavy and painful periods over the past 6 months. Her periods now last 8 days with flooding and clots. She has mild dysmenorrhea. Examination reveals a bulky uterus and the IUD threads are visible. Pelvic ultrasound shows a uniformly enlarged uterus measuring 14 cm with multiple small intramural fibroids and the IUD is in normal position. Haemoglobin is 96 g/L. She has completed her family and wants effective contraception. What is the most appropriate management?

A. Continue copper IUD with tranexamic acid and mefenamic acid for symptom control
B. Remove copper IUD and fit levonorgestrel intrauterine system (Correct Answer)
C. Remove copper IUD and commence combined oral contraceptive pill
D. Remove copper IUD and arrange uterine artery embolization
E. Remove copper IUD and refer for hysterectomy

Explanation: ***Remove copper IUD and fit levonorgestrel intrauterine system***- The **levonorgestrel intrauterine system (LNG-IUS)** is the first-line treatment for **heavy menstrual bleeding (HMB)** as it reduces blood loss by up to 95% and provides highly effective contraception.- It is appropriate for this patient as her **small intramural fibroids** do not distort the uterine cavity, and the uterus size (14 cm) is within the manageable range for insertion.*Continue copper IUD with tranexamic acid and mefenamic acid for symptom control*- The **copper IUD** is known to worsen **menorrhagia**, and continuing its use in an already **anemic (Hb 96 g/L)** patient is suboptimal.- Medical management with **tranexamic acid** is less effective than the LNG-IUS for long-term control of heavy bleeding associated with fibroids.*Remove copper IUD and commence combined oral contraceptive pill*- The **combined oral contraceptive (COCP)** is generally less effective than the **LNG-IUS** for reducing menstrual volume in cases of HMB.- Given the patient's age (42), there may be increased risks or **contraindications** compared to the localized hormonal effect of the IUS.*Remove copper IUD and arrange uterine artery embolization*- **Uterine artery embolization (UAE)** is a more invasive interventional radiology procedure typically reserved for larger, symptomatic fibroids.- It is not first-line when conservative, **medical-hormonal treatments** like the LNG-IUS have not yet been trialed.*Remove copper IUD and refer for hysterectomy*- **Hysterectomy** is a major surgical procedure and should only be considered when **conservative measures** have failed or are unsuitable.- Although the patient has completed her family, it is preferred to trial less invasive options for **symptom control** before proceeding to surgery.

Question 162: What is the mechanism of action of ulipristal acetate when used as emergency contraception?

A. Inhibition of ovulation by delaying the LH surge through progesterone receptor modulation (Correct Answer)
B. Direct toxic effect on the fertilized ovum
C. Disruption of corpus luteum function leading to progesterone withdrawal
D. Prevention of implantation by causing endometrial shedding
E. Thickening of cervical mucus to prevent sperm penetration

Explanation: ***Inhibition of ovulation by delaying the LH surge through progesterone receptor modulation*** - **Ulipristal acetate** is a **selective progesterone receptor modulator (SPRM)** that inhibits or delays **follicular rupture** for at least 5 days, exceeding the lifespan of sperm. - Unlike levonorgestrel, it remains effective in delaying **ovulation** even when taken immediately before the **LH surge** begins, providing a wider window of efficacy. *Direct toxic effect on the fertilized ovum* - There is no medical evidence that ulipristal acetate acts as an **embryotoxic** agent or affects the viability of a **fertilized ovum**. - Its primary function occurs **pre-fertilization** by preventing the release of an egg from the ovary. *Disruption of corpus luteum function leading to progesterone withdrawal* - Ulipristal acetate does not primarily target the **corpus luteum**; its mechanism is focused on the **follicular phase** to prevent ovulation. - **Progesterone withdrawal** is typically a mechanism associated with medications used for medical termination of pregnancy, not the primary action of this emergency contraceptive. *Prevention of implantation by causing endometrial shedding* - Studies indicate that clinical doses used for emergency contraception do not significantly alter the **endometrium** enough to prevent **implantation**. - It is not an **abortifacient** and will not disrupt an existing pregnancy or cause the shedding of the uterine lining post-fertilization. *Thickening of cervical mucus to prevent sperm penetration* - While **progestin-only** daily contraceptives use **cervical mucus thickening** as a primary mechanism, this is not the mechanism for ulipristal acetate. - The drug is designed as a single-dose emergency intervention to counteract the high risk of pregnancy by specifically targeting the **ovulatory cycle**.

Question 163: A 58-year-old woman with premature ovarian insufficiency diagnosed at age 38 has been on HRT continuously since diagnosis. She is now concerned about continuing treatment and asks about stopping. She has no vasomotor symptoms currently and her last period was 20 years ago. She has no other medical history and no family history of breast cancer. What is the most appropriate advice?

A. Stop HRT immediately as she has exceeded safe duration of use
B. Continue HRT until at least age 51 (average age of natural menopause) then review (Correct Answer)
C. Stop HRT but commence bisphosphonate therapy for bone protection
D. Switch to lower-dose HRT preparation and continue for 2 more years
E. Continue current HRT indefinitely as premature ovarian insufficiency requires lifelong treatment

Explanation: ***Continue HRT until at least age 51 (average age of natural menopause) then review***- In patients with **Premature Ovarian Insufficiency (POI)**, Hormone Replacement Therapy (HRT) acts as physiological replacement for endogenous estrogen, and the standard practice is to continue therapy until reaching the **average age of natural menopause** (approximately 51 years).- HRT is essential in these women to reduce the long-term risks of **osteoporosis**, **cardiovascular disease**, and cognitive decline associated with early estrogen deficiency; the risks (like breast cancer) are not significantly increased before age 51.*Stop HRT immediately as she has exceeded safe duration of use*- There is no specific "safe duration" limit for HRT in POI; stopping prematurely before the natural menopausal age increases the risk of **bone density loss** and **cardiovascular events**.- Decision-making at age 58 should be based on a **risk-benefit discussion** regarding current symptoms and long-term health, rather than an arbitrary immediate cessation.*Stop HRT but commence bisphosphonate therapy for bone protection*- **HRT** is considered the first-line treatment for bone protection in women with POI as it also addresses other metabolic and symptomatic needs that **bisphosphonates** do not.- Bisphosphonates are generally reserved for older, post-menopausal women or those with specific contraindications to hormonal therapy.*Switch to lower-dose HRT preparation and continue for 2 more years*- While tapering or switching to a **lower dose** can be done during a review, there is no clinical evidence supporting a mandatory "2-year" limit after reaching age 51.- Treatment should be **individualized** based on the patient's symptoms and health goals rather than following a rigid two-year extension period.*Continue current HRT indefinitely as premature ovarian insufficiency requires lifelong treatment*- While some women may choose to continue HRT longer for symptom control, it is not strictly required **indefinitely**; treatment should be reviewed periodically after the age of natural menopause.- Lifelong treatment carries different risk profiles (such as **breast cancer risk**) as the patient ages, shifting the balance from physiological replacement to pharmacological supplementation.

Question 164: A 26-year-old woman with epilepsy controlled on carbamazepine 400 mg twice daily requests contraception. She is in a stable relationship and prefers a highly effective long-acting method. Her BMI is 23 kg/m² and she has no other medical history. Which contraceptive method would provide the most reliable contraception for this patient?

A. Levonorgestrel intrauterine system 52 mg
B. Etonogestrel subdermal implant 68 mg
C. Depot medroxyprogesterone acetate injection
D. Combined oral contraceptive pill with 30 mcg ethinylestradiol
E. Copper intrauterine device (Correct Answer)

Explanation: ***Copper intrauterine device***- **Carbamazepine** is a potent **liver enzyme inducer** that speeds up the metabolism of hormonal contraceptives, but it has no effect on the **copper intrauterine device (Cu-IUD)** because it is **non-hormonal**.- The **Cu-IUD** provides the most reliable contraception in this scenario, as it is a **Long-Acting Reversible Contraceptive (LARC)** with a failure rate of less than 1% regardless of medication interactions.*Levonorgestrel intrauterine system 52 mg*- While the **LNG-IUS** acts primarily locally, there is a theoretical risk that **enzyme-inducing drugs** could reduce its efficacy through systemic absorption, making it less ideal than the **Cu-IUD**.- Although it is often classified as **UKMEC 2** (benefits outweigh risks), the **Cu-IUD** remains the **gold standard** for reliability when drug interactions are a concern.*Etonogestrel subdermal implant 68 mg*- The **etonogestrel implant** is highly sensitive to **enzyme induction**, which significantly lowers progestogen levels and increases the risk of **contraceptive failure**.- It is classified as **UKMEC 3** (risks usually outweigh benefits) for women taking **carbamazepine**, making it an unsuitable choice for this patient.*Depot medroxyprogesterone acetate injection*- **DMPA** is less affected by **enzyme inducers** than oral methods, but some guidelines suggest the **dosing interval** might need to be shortened to maintain efficacy.- While it can be used (**UKMEC 2**), it is not as reliable as the **Cu-IUD** which removes the risk of metabolic interaction entirely.*Combined oral contraceptive pill with 30 mcg ethinylestradiol*- **Carbamazepine** induces the **CYP3A4 enzyme system**, leading to rapid breakdown of **ethinylestradiol** and increasing the risk of breakthrough ovulation.- Even higher doses of estrogen (at least **50 mcg**) are often insufficient to overcome this interaction, making **COCPs** a poor choice for those taking **enzyme-inducing antiepileptics**.

Question 165: A 48-year-old woman presents with a 6-month history of hot flushes and night sweats significantly affecting her quality of life. Her periods are irregular but ongoing. She has a BMI of 28 kg/m², blood pressure 132/84 mmHg, and no significant medical history. What initial investigations should be performed before considering HRT?

A. Follicle-stimulating hormone, luteinizing hormone, and estradiol levels
B. Full blood count, thyroid function tests, and lipid profile
C. Transvaginal ultrasound and endometrial biopsy
D. Mammography and bone density scan
E. Blood pressure measurement and assessment of cardiovascular risk only (Correct Answer)

Explanation: ***Blood pressure measurement and assessment of cardiovascular risk only*** - In women over **45 years** with typical symptoms like hot flushes and irregular periods, the diagnosis of perimenopause is primarily **clinical** and does not require routine hormonal blood tests. - Essential pre-HRT screening focuses on identifying **contraindications** such as uncontrolled **hypertension** or high **cardiovascular risk** to ensure the safest HRT regimen and delivery method. *Follicle-stimulating hormone, luteinizing hormone, and estradiol levels* - **FSH** and **estradiol** levels fluctuate significantly during the **perimenopause**, making them unreliable and unnecessary for diagnosis in women over age 45. - NICE guidelines specifically advise against using these tests to diagnose menopause in this age group as they do not change clinical management. *Full blood count, thyroid function tests, and lipid profile* - These tests are not routinely required unless the patient presents with specific symptoms suggestive of **anemia**, **thyroid dysfunction**, or metabolic disorders. - While **thyroid disease** can mimic menopausal symptoms, it is not a standard initial investigation for a classic clinical presentation of perimenopause. *Transvaginal ultrasound and endometrial biopsy* - These are invasive investigations reserved for **abnormal uterine bleeding** or a thickened **endometrial stripe**, rather than routine menopause screening. - Perimenopausal irregular periods are expected, and these tests are only indicated if there is **intermenstrual bleeding** or postmenopausal bleeding. *Mammography and bone density scan* - Routine **mammography** is not required before HRT unless the patient is due for her standard national breast screening program or has a suspicious breast lump. - **DEXA scans** are not routine pre-HRT investigations unless the patient has specific risk factors for **osteoporosis** or high fracture risk scores.

Question 166: A 32-year-old woman attends for review of her levonorgestrel intrauterine system, which was fitted 18 months ago. She reports complete amenorrhea for the past 8 months and is concerned she might be pregnant. A urine pregnancy test is negative. She is otherwise well with no abdominal pain or abnormal discharge. On examination, the IUS threads are visible at the cervix. What is the most appropriate management?

A. Arrange pelvic ultrasound to confirm IUS position and exclude pregnancy
B. Perform serum beta-hCG to definitively exclude pregnancy
C. Remove and replace the IUS as amenorrhea suggests device failure
D. Reassure that amenorrhea is a common and expected side effect of the levonorgestrel IUS (Correct Answer)
E. Arrange hysteroscopy to assess endometrial changes

Explanation: ***Reassure that amenorrhea is a common and expected side effect of the levonorgestrel IUS*** - **Amenorrhea** is a common and expected side effect of the **levonorgestrel intrauterine system (LNG-IUS)**, occurring in approximately 20% of users by one year due to **endometrial suppression**. - Since the **urine pregnancy test is negative** and the **IUS threads are visible**, no further investigations are required for a patient who is otherwise asymptomatic. *Arrange pelvic ultrasound to confirm IUS position and exclude pregnancy* - **Pelvic ultrasound** is not indicated because the **IUS threads are visible** during examination, confirming the device is in the correct position. - Ultrasound to exclude pregnancy is unnecessary as the **urine pregnancy test** is already negative and the patient is asymptomatic. *Perform serum beta-hCG to definitively exclude pregnancy* - Modern **urine pregnancy tests** are highly sensitive; a negative result 8 months into amenorrhea is sufficient to exclude pregnancy. - **Serum beta-hCG** is typically reserved for cases where an **ectopic pregnancy** is suspected or when urine tests are inconclusive. *Remove and replace the IUS as amenorrhea suggests device failure* - **Amenorrhea** is a sign of effective **local progestogen action** on the endometrium, not a sign of device failure or loss of contraceptive efficacy. - Routine removal is inappropriate unless the device is **expired**, **displaced**, or the patient requests removal due to side effects. *Arrange hysteroscopy to assess endometrial changes* - **Hysteroscopy** is an invasive procedure not indicated for managing **expected side effects** of hormonal contraception like amenorrhea. - It is generally reserved for investigating **abnormal uterine bleeding**, postmenopausal bleeding, or when an IUS is "lost" and cannot be found via ultrasound.

Question 167: A 55-year-old woman has been taking continuous combined HRT for 4 years for menopausal symptoms. She is concerned about breast cancer risk and asks about stopping treatment. Her vasomotor symptoms are now minimal. She had a total abdominal hysterectomy for fibroids at age 42. What is the most appropriate advice regarding her HRT?

A. Stop HRT immediately as the recommended maximum duration of 5 years is approaching
B. Switch from combined HRT to estrogen-only HRT and continue (Correct Answer)
C. Continue current combined HRT as benefits outweigh risks given minimal symptoms
D. Gradually taper the HRT dose over 3-6 months before stopping
E. Stop combined HRT and commence progesterone-only pill for symptom control

Explanation: ***Switch from combined HRT to estrogen-only HRT and continue*** - The patient has undergone a **total abdominal hysterectomy**, meaning she no longer has a uterus and therefore does not require **progestogen** for endometrial protection; switching to **estrogen-only HRT** is the appropriate clinical step. - **Estrogen-only HRT** is associated with a **lower risk of breast cancer** compared to combined HRT, which directly addresses the patient's primary concern while effectively managing her minimal menopausal symptoms. *Stop HRT immediately as the recommended maximum duration of 5 years is approaching* - There is no fixed **maximum duration** for HRT; treatment duration should be individualized based on the balance of ongoing **menopausal symptoms**, risks, and benefits, with regular review. - Abrupt cessation of HRT can lead to a **recurrence of vasomotor symptoms**, and decisions to stop should be a shared discussion rather than based on an arbitrary time limit. *Continue current combined HRT as benefits outweigh risks given minimal symptoms* - Continuing **progestogen** in a woman who has had a hysterectomy provides no clinical benefit as there is no endometrium to protect, and it unnecessarily increases the risk of **breast cancer** and venous thromboembolism. - Given the patient's specific concern about **breast cancer risk**, maintaining an unnecessary combined formulation is not appropriate and could exacerbate her anxiety. *Gradually taper the HRT dose over 3-6 months before stopping* - While **gradual tapering** can be considered to reduce the likelihood of symptom recurrence, it is not a mandatory safety measure, and clinical evidence does not consistently demonstrate its superiority over abrupt cessation for preventing relapse. - This option still fails to address the fundamental issue of continuing **progestogen** in a patient without a uterus, which is the primary inappropriate aspect of her current regimen. *Stop combined HRT and commence progesterone-only pill for symptom control* - The **progesterone-only pill (POP)** is primarily a contraceptive method and is not an effective treatment for **menopausal vasomotor symptoms** as it does not address **estrogen deficiency**. - Commencing a **progestogen-only** preparation without estrogen would be inappropriate for managing menopausal symptoms and would not mitigate the risks associated with the previous combined HRT effectively.

Question 168: A 45-year-old woman with irregular periods presents requesting contraception. She reports cycle lengths varying from 21 to 60 days over the past year. She has vasomotor symptoms occasionally. Her BMI is 24 kg/m², blood pressure 118/76 mmHg, and she is a non-smoker. She would like a method that might also help with her symptoms. What is the most appropriate contraceptive option?

A. Progesterone-only pill
B. Combined oral contraceptive pill (Correct Answer)
C. Levonorgestrel intrauterine system
D. Copper intrauterine device
E. Progesterone-only implant

Explanation: ***Combined oral contraceptive pill*** - For women under **age 50** who are non-smokers and have no contraindications, the **Combined oral contraceptive pill (COCP)** is ideal for providing contraception and regulating **irregular menstrual cycles**.- The **estrogen component** also effectively alleviates **vasomotor symptoms** and helps maintain **bone mineral density**, addressing the patient's desire for symptom management. *Progesterone-only pill* - While a safe contraceptive option for women over 40, the **progesterone-only pill (POP)** does not contain estrogen, therefore it cannot relieve **vasomotor symptoms**.- It may also lead to **irregular bleeding** or unscheduled spotting, which would not improve the patient's existing cycle irregularities. *Levonorgestrel intrauterine system* - The **LNG-IUS** is highly effective for contraception and managing **heavy menstrual bleeding**, but it does not contain estrogen and therefore cannot alleviate **vasomotor symptoms**.- Although it can be used as the progestogen component of **HRT**, the patient would still require separate estrogen therapy to treat her hot flushes. *Copper intrauterine device* - The **copper IUD** provides highly effective non-hormonal contraception but offers **no relief** for **perimenopausal symptoms** such as irregular periods or vasomotor symptoms.- It is known to potentially cause **heavier or more painful periods**, which could exacerbate the patient's existing menstrual irregularities. *Progesterone-only implant* - The **etonogestrel implant** provides long-acting reversible contraception but, as a progesterone-only method, it does not contain estrogen to suppress **vasomotor symptoms**.- It frequently causes **unpredictable bleeding patterns**, which would not provide the cycle regularity and symptom relief that this patient desires.

Question 169: A 19-year-old woman requests emergency contraception. She had unprotected sexual intercourse 36 hours ago, on day 11 of her regular 28-day cycle. She weighs 58 kg with a BMI of 22 kg/m². She has no significant medical history and takes no regular medications. What is the most effective emergency contraception method to offer?

A. Levonorgestrel 1.5 mg single dose
B. Ulipristal acetate 30 mg single dose
C. Copper intrauterine device insertion (Correct Answer)
D. Combined oral contraceptive pill (Yuzpe regimen)
E. Levonorgestrel 3 mg double dose

Explanation: ***Copper intrauterine device insertion*** - The **copper intrauterine device (Cu-IUD)** is the most effective method of emergency contraception, with a failure rate of approximately **0.1%**. - It can be inserted up to **5 days (120 hours)** after unprotected intercourse or within 5 days of the **earliest predicted ovulation**, significantly outperforming oral options in high-risk windows. *Levonorgestrel 1.5 mg single dose* - This method is only licensed for use up to **72 hours** after intercourse and its efficacy decreases as the time from intercourse increases. - It works by **delaying ovulation** and is less effective than both the Cu-IUD and ulipristal acetate, especially when taken close to the LH surge. *Ulipristal acetate 30 mg single dose* - While more effective than levonorgestrel and usable up to **120 hours**, it remains statistically inferior to the **Cu-IUD**. - It acts as a **progesterone receptor modulator** to delay ovulation but does not prevent implantation if fertilization has already occurred. *Combined oral contraceptive pill (Yuzpe regimen)* - This involves high doses of **ethinylestradiol and levonorgestrel** but is considered an outdated method due to lower efficacy and higher rates of side effects like nausea. - It is significantly **less effective** than modern single-dose hormonal regimens or mechanical methods. *Levonorgestrel 3 mg double dose* - A double dose of levonorgestrel is only indicated for patients with a **BMI > 26 kg/m²** or those taking **enzyme-inducing medications**. - Since this patient has a normal **BMI of 22 kg/m²**, a double dose is not clinically indicated and would not exceed the efficacy of a Cu-IUD.

Question 170: A 52-year-old woman presents with hot flushes, night sweats, and mood disturbance for 8 months. Her last menstrual period was 14 months ago. She has a history of breast cancer treated with wide local excision and radiotherapy 3 years ago, currently on tamoxifen. She requests hormone replacement therapy for symptom control. What is the most appropriate initial management?

A. Advise venlafaxine or another selective serotonin reuptake inhibitor (Correct Answer)
B. Prescribe tibolone as it has fewer breast cancer risks
C. Prescribe low-dose combined HRT preparation
D. Discontinue tamoxifen and commence HRT after appropriate washout period
E. Prescribe vaginal estrogen pessaries for symptom control

Explanation: ***Advise venlafaxine or another selective serotonin reuptake inhibitor*** - **Hormone replacement therapy (HRT)** is contraindicated in patients with a history of **breast cancer** due to the risk of stimulating tumor recurrence. - **Venlafaxine** (an SNRI) or certain SSRIs are first-line non-hormonal options for managing **vasomotor symptoms** (hot flushes) and mood disturbance in breast cancer survivors. *Prescribe tibolone as it has fewer breast cancer risks* - **Tibolone** is a synthetic steroid with estrogenic properties and is specifically contraindicated in women with a history of breast cancer due to increased **recurrence risk**. - While it may be used for osteoporosis or menopause in some populations, it does not provide a safe profile for **hormone-sensitive malignancies**. *Prescribe low-dose combined HRT preparation* - **Systemic HRT** is consistently avoided in breast cancer patients as it directly counteracts the therapeutic purpose of drugs like **Tamoxifen**. - Even low doses pose a significant theoretical and clinical risk for promoting the growth of latent **estrogen-receptor-positive** cells. *Discontinue tamoxifen and commence HRT after appropriate washout period* - Tamoxifen is a vital **adjuvant therapy** that reduces the risk of cancer recurrence; discontinuing it would compromise the patient's **oncological prognosis**. - Managing symptoms should never involve stopping life-prolonging **cancer treatment** when non-hormonal alternatives exist. *Prescribe vaginal estrogen pessaries for symptom control* - **Vaginal estrogen** is primarily indicated for **genitourinary syndrome of menopause** (vaginal dryness) rather than systemic symptoms like hot flushes or night sweats. - Although systemic absorption is low, it remains a second-line option after **non-hormonal lubricants** for breast cancer patients and does not treat mood disturbances.

Question 171: A 28-year-old nulliparous woman attends for contraceptive advice. She has a BMI of 34 kg/m² and smokes 15 cigarettes daily. Her blood pressure is 138/88 mmHg. She has no past medical history and takes no regular medications. She requests the combined oral contraceptive pill as she finds it convenient. What is the most appropriate management?

A. Prescribe combined oral contraceptive pill with advice about smoking cessation
B. Repeat blood pressure measurement and consider combined oral contraceptive pill if consistently below 140/90 mmHg
C. Advise that combined oral contraceptive pill is contraindicated and recommend progesterone-only pill (Correct Answer)
D. Prescribe combined oral contraceptive pill with low-dose aspirin for cardiovascular protection
E. Refer to specialist contraception clinic for further assessment

Explanation: ***Advise that combined oral contraceptive pill is contraindicated and recommend progesterone-only pill*** - The **combined oral contraceptive pill (COCP)** is generally avoided in patients with multiple risk factors; while she is under 35, her heavy smoking (≥15/day) and **obesity (BMI 34)** increase cardiovascular risks significantly. - The **progestogen-only pill (POP)** is a safer alternative as it does not carry the same **venous thromboembolism (VTE)** or stroke risks associated with the estrogen component of the COCP. *Prescribe combined oral contraceptive pill with advice about smoking cessation* - Prescribing the COCP despite multiple risk factors is unsafe; smoking ≥15 cigarettes/day and obesity are **UKMEC 3** criteria which means risks usually outweigh benefits. - Smoking cessation advice is essential but does not immediately mitigate the acute **cardiovascular and thrombotic risks** posed by current heavy smoking and high BMI. *Repeat blood pressure measurement and consider combined oral contraceptive pill if consistently below 140/90 mmHg* - Although her BP of 138/88 is borderline, even a normal BP would not resolve the contraindications posed by her **smoking status and BMI**. - Relying solely on BP monitoring ignores the additive risk of **arterial disease** and VTE inherent in her clinical profile. *Prescribe combined oral contraceptive pill with low-dose aspirin for cardiovascular protection* - **Aspirin** is not indicated or effective as a primary mitigation strategy for the specific thromboembolic risks introduced by the **estrogen** in COCP. - Adding aspirin does not change the **UKMEC category** of the COCP from unsafe to safe for use in this high-risk patient. *Refer to specialist contraception clinic for further assessment* - A specialist referral is unnecessary as the **UKMEC guidelines** provide clear criteria for primary care to manage this case. - The decision to switch to a **progestogen-only method** or a LARC (long-acting reversible contraceptive) can and should be made by the primary clinician based on existing evidence.

Practice by Chapter

Contraception

Practice Questions

Menopause management

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free

Reproductive Health — MCQs

Reproductive Health — MCQs

On this page